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ABSTRACT 
 
The oral route of drug administration is convenient since it is acceptable to most patients and 
the manufacturing processes used to produce tablets and capsules are relatively simple when 
compared to those used to manufacture other types of dosage forms. Metronidazole (MTZ) 
and Ranitidine (RTD) have been used in combination, as part of triple therapy for the 
treatment of ulcers. However the use of large numbers of tablets and long duration of therapy 
makes adherence to drug treatment challenging for patients. Therefore the formulation of a 
fixed dose combination (FDC) of MTZ and RTD may improve patient adherence to therapy 
and consequently may reduce morbidity and mortality due to ulcers.   
 
A stability indicating HPLC method for the simultaneous analysis of MTZ and RTD was 
developed and validated according to the International Conference on Harmonization (ICH) 
guidelines. The method was sensitive, selective, precise, accurate and linear. 
 
Preformulation studies were performed on the active pharmaceutical ingredients (API) alone 
and in combination with potential excipients. Differential scanning calorimetry (DSC) studies 
revealed a potential interaction between MTZ and RTD, however the interaction was not 
apparent following IR analysis of the same samples. DSC analyses of the API in combination 
with potential excipients revealed that the compounds were compatible with most materials 
with the exception of a binary mixture of RTD and Dibasic calcium phosphate (DCP) that 
exhibited a potential interaction. Thermal gravimetric analysis (TGA) of MTZ and RTD 
revealed that both compounds exhibited thermal stability. The Carrs Index (CI) and Hausner 
Ratio (HR) values of MTZ and RTD indicated that both compounds exhibited poor flow and 
compressibility properties, whereas the CI and HR values for (Microcrystalline cellulose) 
MCC and DCP indicated better flowability and compressibility characteristics. 
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Direct compression and wet granulation processes were assessed to identify a suitable method 
of manufacture of FDC tablets of MTZ and RTD. The blends were evaluated using bulk and 
tapped density and the resultant tablets were evaluated for weight uniformity, crushing 
strength, tensile strength and disintegration time. The wet granulation method of manufacture 
produced tablets that showed acceptable pharmacotechnical properties: this approach was 
therefore used as the method of manufacture of FDC tablets of MTZ and RTD. 
 
Tablet formulations comprised of API, viz. MTZ and RTD and different compositions of 
MCC, DCP, Sodium starch glycolate (SSG) and Croscarmellose sodium (CCS), were 
manufactured in order to screen for an appropriate diluent and disintegrant composition for 
use in response surface studies. Assays of tablet content and in vitro drug release were 
undertaken using the validated HPLC method. Tablets in which MCC and CCS were used 
appeared to produce better assay and dissolution results as compared to those manufactured 
using DCP and SSG. Consequently a formulation comprised of MCC and CCS was selected 
and used in studies in which the effect(s) of level two formulation and composition changes 
as described in the Scale and Post Approval Changes for Immediate Release (SUPAC-IR) 
Guidelines on tablet disintegration and in vitro release were assessed.  A Box-Behnken 
statistical design was used for the investigation of the effect of input factors, viz. CCS, 
(Polyvinyl pyrollidone K30) PVP-K30 and magnesium stearate on measured responses, viz. 
disintegration time and percent drug release in 10 minutes (Q10). CCS appeared to have an 
inverse linear relationship on disintegration time and a linear relationship with the Q10 for 
MTZ and RTD, whereas PVP-K30 and magnesium stearate appeared to have an antagonistic 
effect on the measured responses. Furthermore CCS and magnesium stearate exhibited an 
interaction that had an agonistic effect on the Q10 value for RTD. A numerical optimization 
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approach was used to predict a formulation composition that would produce tablets that 
exhibited a disintegration time and Q10 values for MTZ and RTD that fell within the 
constraints set in our laboratory. The resultant model was found to be accurate and had a 
percent prediction error of < 5% for all measured response variables. 
 
FDC tablets of MTZ and RTD have been successfully produced. The disintegration of the 
tablet and dissolution of the API were within compendial specifications and the tablets are of 
suitable quality and have the potential to be further investigated to reduce the pill burden in 
the treatment of ulcers. 
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STUDY OBJECTIVES 
 
Metronidazole (MTZ) and ranitidine (RTD) are used as part of triple therapy in the 
management of ulcers.  The desired clinical outcome when treating uncomplicated ulcers is 
dependent on patient adherence to pharmacotherapy. However drug therapy in the treatment 
of ulcers may require the administration of a large number of tablets and is dependent on the 
severity of the condition. Treatment may be as short as seven days or as long as one month 
and consequently adherence to drug therapy becomes challenging. RTD is used as an 
alternative to proton pump inhibitors for the treatment of ulcer in patients that cannot tolerate 
proton pump inhibitors and is also used as a second line treatment of ulcers. Therefore the 
development of a FDC tablet of MTZ and RTD may improve patient adherence to therapy 
and consequently reduce morbidity and mortality due to ulcers. 
 
The objectives of this study were therefore: 
i. To develop and validate a sensitive high performance liquid chromatographic method 
to quantitate MTZ and RTD in pharmaceutical dosage forms. 
ii. To conduct preformulation studies to determine the compatibility of excipients and 
API in FDC tablet formulations. 
iii. To develop and optimize a suitable method of manufacture of FDC tablets of MTZ 
and RTD.  
iv. To conduct preliminary formulation studies to identify a suitable formulation 
composition(s) that could be used for response surface studies. 
v. To determine the impact of formulation and composition changes as described in 
SUPAC-IR Guidelines on the disintegration time and in vitro release characteristics of 
MTZ and RTD FDC tablets. 
vi.  To use RSM to optimize the disintegration time and in vitro release characteristics of 
MTZ and RTD from the tablets.  
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 CHAPTER ONE 
A REVIEW OF RANITIDINE AND METRONIDAZOLE  
 
1.1 INTRODUCTION 
 
Gastric and duodenal ulcers are conditions in which the mucosal membranes of the stomach 
and duodenum become ulcerated as a result of excessive gastric acid secretion and in which 
the degree of mucus protection provided to the mucosa is limited [1]. The exact aetiology of 
the disease is not known, however it has been reported that infection with Helicobacter 
pylori, chronic use of non-steroidal anti-inflammatory drugs, cigarette smoking, alcohol 
abuse and stress are contributing factors [2-4]. 
 
Two types of ulcers are known to exist viz. acute and chronic. Acute ulceration is easily 
managed and usually does not give rise to serious complications. However, chronic ulceration  
is more serious, due to the persistence of the ulcer, potential for haemorrhage, perforation or 
stenosis formation and/or the potential for malignant changes to the membrane structure of 
the gut [1]. As with any other disease, early diagnosis and treatment may significantly reduce 
morbidity and consequently mortality. 
 
The management of ulcers depends on the degree of ulceration and associated complications. 
Pharmacotherapy is usually sufficient for the treatment of acute and mild cases of ulcers, 
however surgery may be considered if a patient fails to respond to treatment, or if there is  
malignancy or if bleeding occurs frequently [5]. The current approach to the management of 
ulcerous conditions aims at relieving the pain and discomfort associated with the condition, 
and to prevent the recurrence and complications of the disease. In South Africa the treatment 
for ulcers consists of administration of a proton pump inhibitor and one antibiotic which 
could be clarithromycin 500 mg twice daily or amoxicillin 1000 mg per day in combination 
with metronidazole (MTZ) as a 400 mg twice daily dose for a period of seven days [6]. If a 
proton pump inhibitor is contraindicated for any reason, an alternative regimen that includes 
the use of ranitidine (RTD) 300 mg daily for seven days in addition to administration of 
bismuth subcitrate in doses of 120 mg six hourly for seven days and one of the 
aforementioned antibiotics in combination with MTZ [6]. In the latter regimen a patient will 
have to take nine to eleven tablets per day for the duration of therapy which may vary 
between seven days and a month depending on severity of the condition. Since 
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pharmacotherapy entails taking a large number of tablets, patient adherence to therapy is 
often compromised with the result that morbidity and mortality may increase. 
 
In comparison to combination therapy, fixed-dose combination (FDC) therapy has been 
shown to improve patient adherence [7]. The formulation of a fixed-dose combination tablet 
of RTD and MTZ for the management of ulcers may therefore improve patient adherence 
since the number of tablets that have to be taken on a daily basis may be reduced from eleven 
to seven or nine depending on the course of antibiotic that is taken. 
 
1.2 PHYSICOCHEMICAL PROPERTIES OF RANITIDINE AND 
METRONIDAZOLE 
 
1.2.1 RANITIDINE 
 
1.2.1.1 Description 
 
RTD hydrochloride is a white to yellowish crystalline powder with little or no odour [8]. It 
exists in two major polymorphic forms, viz. Forms 1 and  2 in addition to a series of pseudo 
polymorphic forms [9]. The chemical name for RTD is (N-(2[({5-[(dimethylamino) methyl]-
2-furanyl}methyl)thio]ethyl}-N′-methyl-2-nitro-1,1-ethenediamine hydrochloride) and the 
chemical structure is depicted in Figure 1.1. 
 
Me
Me Me
HCl
 
Figure 1.1 Chemical structure of RTD, C13H22N4O3S.HCl (MW=350.869) 
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1.2.1.2 Solubility 
 
RTD is very soluble in water [8,10]. The solubility of RTD in different solvents is listed in 
Table 1.1. 
Table 1.1 Solubility of RTD in various solvents. Adapted from [8] 
Solvent Solubility 
Acetic acid Freely soluble 
Water Very soluble 
Methanol Soluble 
Ethanol Sparingly soluble 
Ethylacetate Very slightly soluble 
Isopropanol Very slightly soluble 
Dioxane Insoluble 
Chloroform Insoluble 
 
1.2.1.3 pH of solution 
 
The pH of a 1 % w/v solution of RTD is 4.5-6 [10]. 
 
1.2.1.4 pKa 
 
The dissociation constants of RTD determined by spectrophotometric and potentiometric pH 
titration at 25ºC were 1.89 and 8.65 respectively [11,12]. 
 
1.2.1.5 Melting range 
 
The melting range of RTD depends on the polymorphic form from which the compound was 
crystallized. RTD crystals derived from polymorph Form 1 have a melting range of 135-
136ºC and crystals derived from polymorph Form 2 have a melting range of 143-144ºC [8]. 
 
1.2.1.6 Ultraviolet absorption spectrum  
 
An ultraviolet scan of a 0.00064 % w/v solution of RTD depicted in Figure 1.2 revealed two 
absorption maxima at a wavelength of 229 nm (ε = 20779) and 313 nm (ε = 19123). The scan 
was generated using a Lamba 25 UV/VIS Spectrometer (Perkin Elmer
® 
Ltd, Beaconsfield, 
England) at a scan speed of 480 nm min
-1
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Figure 1.2 UV absorption spectrum of RTD in water generated at a scan rate of 480 nm min
-1
 
 
1.2.1.7 Infrared spectrum 
 
The infrared (IR) spectrum of RTD powder was generated using a Spectrum 100 Fourier 
transform-infrared (FT-IR) attenuated total reflectance (ATR) spectrometer (Perkin Elmer
® 
Ltd Beaconsfield, England). The IR spectrum was obtained at a 4000-650 cm
-1
 wave-number 
range, 4 scans and at a resolution of 4 cm
-1
. The typical IR spectrum of RTD is depicted in 
Figure 1.3 and the absorption band assignments are shown in Table 1.2 [8]. 
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Figure 1.3 IR spectrum of RTD generated at 4 scans and resolution of 4 cm
-1
 
 
Table 1.2  IR absorption band assignments 
Bands (cm
-1
) Assignment 
1080-1360 CN; C-N stretch 
2560-2640 H-N+R3; N
+
-H stretch 
3020-3100 CH; C-H stretch 
 
1.2.1.8 Stability 
 
RTD degrades readily when exposed to moisture, light and heat [8,10,13]. RTD powder is 
susceptible to degradation when incubated in 0.1 M solution of sodium hydroxide (NaOH) 
and when incubated in a 3% v/v hydrogen peroxide (H2O2) solution complete degradation of 
the drug occurred [14]. Similar results have also been reported following stability testing of 
RTD tablets and parenteral solutions under conditions of different temperature, light exposure 
and storage times [15].  
 
When RTD powder was incubated with 0.1 M of hydrochloric acid (HCl) in a tightly sealed 
amber-coloured bottle for 24 h, no degradation was observed when the samples were 
analyzed using high performance liquid chromatography (HPLC) [14]. 
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1.2.1.9 Clinical pharmacology 
 
1.2.1.9.1 Mode of action 
 
Histamine is produced by mast cells located in the stomach which secrete gastric acid 
following activation of the gastric parietal cells. Histamine binds to histamine-2 (H2)  
receptors located on the parietal cells resulting in an increase in levels of adenylcyclase, 
cyclic-AMP (cAMP) and intracellular calcium ultimately causing gastric acid secretion [16]. 
RTD is a H2 receptor antagonist that competes with histamine for the H2-receptor sites 
thereby, blocking histamine accessibility to the receptor reversibly, reducing acid secretion 
consequently lowering gastric acidity [5,16].  
 
1.2.1.9.2 Clinical use 
 
RTD has been used clinically for the management of gastro-oesophageal reflux disease 
(GORD), Zollinger-Ellison Syndrome (ZES) and ulcers since 1981 [8]. Furthremore, RTD is 
also used preoperatively to prevent acid reflux and aspiration during surgery [17-19]. Unlike 
cimetidine, RTD has a superior side-effects profile, exhibits fewer drug interactions and 
requires less frequent administration to exert a therapeutic effect [5,6,16,18]. 
 
1.2.1.9.3 Side effects and interactions 
 
Generally H-2 receptor antagonists are well tolerated with the exception of cimetidine 
[5,16,20]. The most common side effects associated with the use of RTD are diarrhoea, 
dizziness, somnolence, headache, rash and reversible hepatitis with or without jaundice  
[16,18,20]. 
 
Unlike cimetidine, RTD when administered at therapeutic doses does not inhibit the 
cytochrome P450 microsomal enzyme system, which makes it less likely to interact with 
other drugs that are metabolized or transported by this pathway [5,10,18,20]. However, with 
the exception of famotidine, all H2-receptor antagonists increase the bioavailability of ethanol 
by inhibition of gastric first-pass metabolism [16]. RTD increases the bioavailability of 
alcohol through facilitation of gastric emptying and reduction in first-pass metabolism as 
consequence of saturation of alcoholdehydrogenase [20,21].   
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An increase in plasma levels of acetaminophen was observed when it was co-administered 
with RTD due to the inhibition of acetaminophen glucuronyltransferase preventing hepatic 
first-pass metabolism [22]. 
 
1.2.1.9.4 High risk groups 
 
To date there have been no reported cases of risk when RTD was administered to pregnant 
women and nursing mothers however, RTD should only be administered to this group when 
it is absolutely necessary since it crosses the placenta and is secreted in breast milk [16,23-
25]. 
 
In geriatric patients, RTD has been known to cause central nervous system (CNS) 
dysfunction of which the most common symptoms include slurred speech, delirium and 
depression [5,6,16,18]. These side effects are transient and usually disappear when a change 
to treatment with an alternate H2-receptor antagonist is made. Chronic use of RTD has also 
been associated with vitamin B12 deficiency in geriatric patients [26], therefore long-term use 
in this patient group should be evaluated frequently. 
 
A dose adjustment for RTD in patients with renal impairment is necessary to avoid the risk of 
toxicity [5,6,16,18,18].  
 
There is a paucity of information relating to the safety of RTD in paediatric patients [18], 
therefore dose adjustment on a weight basis is of paramount importance since the presence of 
immature organs make these patients vulnerable to toxicity. 
 
1.2.1.10 Clinical pharmacokinetics 
 
1.2.1.10.1 Dosage 
 
RTD is available in different dosage forms such as tablets of 75 mg, 150 mg and 300 mg 
strength, syrup of 150 mg/10ml strength and an intravenous (IV) injection of 50 mg/2ml 
strength [6]. 
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The normal adult dose of RTD for the treatment of ulcers is 150 mg twice daily or 300 mg at 
night for 4-8 weeks [6,27,28], followed by once-daily dose of 150 mg as maintenance therapy 
[6]. IV infusion can be used if a patient is nauseous or vomiting and the recommended IV 
dose is 50 mg in 0.9 % m/v saline or 5% m/v dextrose solutions infused over 2 h [6,18].  
 
The treatment of ZES requires the use of large doses [16] of between 600-900 mg on daily 
basis [6]. This is usually sufficient for treatment when surgery is not indicated. However, 
depending on severity of the condition, doses of up to 6 g daily may be required [6]. 
 
For the relief of symptoms in patients presenting with hyperacidity and heartburn, a dose of 
75 mg administered 30 min before meals is usually sufficient to relieve the condition and in 
paediatric patients, 2-4 mg/kg administered orally twice  daily via the oral route has proven 
effective [6]. 
 
For prevention of acid reflux and aspiration during surgery, a dose of RTD of 150 mg 
administered orally 12 h and 2 h prior to surgery is recommended [18,29] 
 
1.2.1.10.2  Absorption 
 
RTD is well absorbed following oral administration with bioavailability ranging between 30-
88% [6,8,16,30], although in paediatric patients following oral administration to children 
aged between 3.5-16 years the bioavailability was approximately 48% [31]. The plasma 
concentration versus time profile of RTD following oral administration of 150 mg shows two 
peak concentrations [8,32] with the first and second peak occurring within 1.1±0.4 h and 
3±0.0 h, with a maximum serum concentration (Cmax) of 313±93.55ng/ml and         
296±68.01 ng/ml at each time respectively [32]. The administration of RTD with food or 
antacids has been shown to delay absorption and therefore the time to peak concentration is 
delayed although the total therapeutic effect remaining unchanged [18,33] 
 
1.2.1.10.3  Distribution 
 
Following oral or parenteral administration approximately 15% of the RTD administered 
binds to plasma proteins [6,34]. The approximate volume of distribution of RTD is             
0.1-1.9 l/kg and the distribution half-life is 6.1±0.9 min. [8,16,30,35]. The distribution, 
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absorption and excretion of C
14
 labelled RTD in rats following parenteral administration were 
monitored and relatively high concentrations of radio-labelled RTD were concentrated in the 
kidneys, liver and gastro-intestinal tract whereas lower concentrations were observed in the 
brain [36]. Similar results in which the concentration of RTD in the cerebro-spinal fluid of 
healthy subjects was 3.3-5.0% that in plasma have been reported [8]. 
 
RTD has been detected in breast milk with resultant concentrations higher than those found in 
serum [37]. Following multiple dose administration to breast-feeding mothers the minimum 
concentration in milk occurred between 1 and 2 h following dosing and the maximum 
concentration was observed at the end of the 12-hour dosing interval [37]. 
 
1.2.1.10.4  Metabolism  
 
Rantidine is susceptible to both oxidative and demethylation reactions and the sites at which 
these reactions occur are highlighted in Figure 1.4.  
Me
Me
Me
HCl
 
                                                                          Oxidation sites    
                                                                          Demethylation site  
Figure 1.4 Oxidation and demethylation sites of RTD 
 
Metabolic studies of RTD performed using isolated dog and rat hepatocytes revealed that, 
RTD is metabolised to desmethylranitidne (Figure 1.5 I), RTD S-oxide (Figure 1.5 II), RTD 
N-oxide (Figure 1.5 III) and two unidentified minor metabolites [8,30,38]. When RTD is 
administered intravenously and orally alone, 1.3±0.3% of the intravenous dose and 2.6±0.2% 
of the oral dose are converted to the desmethyl metabolite [8]. 
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Where, 
I   = DesmethylRTD 
II  = RTD S-oxide 
III = RTD N-oxide 
Figure 1.5 Metabolites of RTD 
 
1.2.1.10.5  Elimination 
 
RTD is primarily excreted as an unchanged (30-70%) drug in urine [30,34,39]. The 
elimination half-life of RTD is 1.9±0.1 hours and the plasma clearance is 709±62 ml/min 
[8,34] indicating that dose adjustment in patients presenting with renal dysfunction is 
necessary. The pharmacokinetics and pharmacodynamics of RTD in subjects with varying 
degrees of renal impairment have been investigated and reported that a dose reduction of up 
to 66% for patients with creatinine clearance of 50 ml/min results in sub-therapeutic 
concentration [40]. Therefore, to avoid therapeutic failure, a dose reduction by 50% in patient 
with a creatinine clearance of <10 ml/min should be sufficient to produce the desired 
therapeutic effect with safety [41].  
I 
II 
III 
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1.2.2 METRONIDAZOLE 
 
1.2.2.1 Description 
 
MTZ is a white or yellowish crystalline powder, odourless and bitter to taste [42,43]. The 
chemical name is 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole and the chemical structure is 
depicted in Figure 1.6. 
 
Me
 
Figure 1.6 Chemical structure of MTZ (C6H9N3O3 MW=171.16) 
 
1.2.2.2 Solubility 
 
The solubility of MTZ at 22ºC in monobasic potassium phosphate (KH2PO4) buffer solution 
of pH 1.2 is 64.8 mg/ml [44]. The solubility of MTZ in other solvents at 25ºC is summarized 
in Table 1.3. 
 
Table 1.3 Solubility of MTZ in various solvents [42] 
Solvent Solubility (mg/ml) 
Water 10.5 
Methanol 32.5 
Ethanol 15.4 
Chloroform 3.8 
Heptane <0.01 
  
1.2.2.3 pKb 
 
The base dissociation constant (pKb) of MTZ determined by UV spectrophotometry is 11.47 
[45].  
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1.2.2.4 pH of a solution 
 
The pH of a 0.1% m/v aqueous solution of MTZ determined at 20
°
C ranged between       
5.62-5.69.  
 
1.2.2.5 Ultraviolet absorption spectrum 
 
An ultraviolet scan of a 0.06% m/v solution of MTZ in methanol acidified with 0.05 M 
sulphuric acid revealed an absorption maximum at a wavelength of 275 nm (ε=13774) that is 
similar to a lambda max of 274 nm reported for MTZ in an acidified methanol solution [42]. 
The scan was generated using a Lambda 25 UV/VIS Spectrometer (Perkin Elmer
® 
Ltd 
Beaconsfield, England) at a scan rate of 480 nm min
-1
 as depicted in Figure 1.7. 
 
 
Figure 1.7 UV spectrum of MTZ in acidified methanol generated at a scan rate of 480 nm min
-1 
 
1.2.2.6 Infrared spectrum 
 
The IR absorption spectrum of MTZ was determined using a Spectrum 100 FT-IR 
Spectrometer with Universal ATR Sampling Accessory (Perkin Elmer
® 
Ltd Beaconsfield, 
England). The spectrum was generated in the range between 4000-650 cm
-1 
wave numbers,   
4 scans and at a resolution of 4 cm
-1
. A similar IR absorption spectrum of MTZ reference 
standard compressed in potassium bromide pellet has been reported [42]. The IR spectrum of 
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MTZ is depicted in Figure 1.8 and the band assignments for the absorption spectrum are 
summarized in Table 1.4. 
 
 
Figure 1.8 Infrared spectrum of MTZ generated at 4 scans and resolution of 4 cm
-1
  
 
Table 1.4  Absorption bands assignments. Adapted and modified from [42] 
Band (cm
-1
) Assignment 
3200-3550 OH stretch 
3020-3100 C=CH; C-H stretch 
1538;1350 NO2; N-O stretch 
970-1250 C-OH; C-O stretch 
830 C-NO2; C-N stretch 
 
1.2.2.7 Stability 
 
MTZ is a photo labile 5-nitroimidazole derivative and must be protected from light [46]. The 
degradation reaction involves several rearrangements of the 5-nitroimidazole structure as 
shown in Figure 1.9, and requires substitution on the ring nitrogen-1(N
1
) with functional 
group other than hydrogen [47]. N
1
 unsubstituted MTZ  can decompose in a similar fashion 
following prolonged heating in 1.5 M NaOH with copper catalysis [48]. Basic solutions can 
be used to distinguish between the substituted and unsubsituted N
1
 5-nitroimidazole and the 
degradation of MTZ in de-ionized water following irradiation with ultraviolet light at 254 nm 
and 200-400 nm has been reported [49]. 
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R
 
Where,  
R = CH2CH2OH 
I    = MTZ 
II   = 2-imidazoline-4,5-dione-4-oxime 
III = 1,2,4-oxidiazole-3-carboxamide 
IV = oxamide 
 
Figure 1.9 MTZ degradation scheme, redrawn from [50] 
 
As with any N
1
-subsituted 5-nitroimidazole, acid, alkaline hydrolysis of MTZ follows first-
order reaction kinetics with the reaction taking place in two phases viz. initially forming  
nitrite ions after which degradation of the parent compound occurs [51]. It has been reported 
that, alkaline hydrolysis of MTZ produces ammonia and acetic acid whereas an amine with at 
least one hydrogen atom is formed in acidic and alkaline hydrolytic conditions [51]. The 
degradation products of MTZ alkaline hydrolysis are shown in Figure 1.10. 
 
Me
A compound giving pink to violet
colour with ninhydrin reagent
 
Figure 1.10 Alkaline hydrolytic degradants of MTZ, redrawn from [52] 
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1.2.2.8 Clinical pharmacology 
 
1.2.2.8.1 Mode of action 
 
MTZ has a similar mode of action to other 5-nitroimidzoles and the antimicrobial activity 
depends on the formation of an intermediate toxic metabolite in the cells of susceptible 
protozoa and bacteria [53]. The drug enters the cell of susceptible protozoa or anaerobic 
bacteria by passive diffusion. The nitro functional group is chemically reduced by ferrodoxin 
to form a nitro radical that binds to deoxyribose nucleic acid (DNA) and consequently causes 
inhibition of nucleic acid synthesis [54,55]. The mechanism of action of MTZ is depicted in 
Figure 1.11. 
Me
Me
Hy H2O, O2-
Pyruvate Acetyl CoA
PFOR (oxd) PFOR (red)
Fd (oxd) Fd (red)
2HH2
O2
H2O2,
 
Where, 
Oxd= oxidised 
Red=  reduced 
Hy  =  Hydrogenase 
 
Figure 1.11 MTZ activation scheme. Adapted and modified from [56] 
 
1.2.2.8.2 Spectrum of activity 
 
The spectrum of activity of MTZ in bacteria depends on the presence of a ferrodoxin-linked 
dehydrogenase associated mechanism in the cell, which is a common metabolic activity in 
most obligate anaerobic microorganisms such as the Bacteroides and Clostridium species 
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[43,57,58]. MTZ is also active against protozoal species such as Balantidium coli, 
Blastocystis hominis, Entamoeba histolytica, Giardia lamblia and Trichomona vaginalis 
[43,53,58] and facultative anaerobes such as Gardnella vaginalis and Helicobacter pylori 
[43]. 
 
1.2.2.8.3 Resistance 
 
Anaerobic gram-negative bacterial resistance to MTZ is extremely low with less than 1% of 
the Bacteroides species showing resistance [59]. However a better understanding of the 
mechanism by which resistance is developed is of importance, since an increase in the 
number of resistant strains of anaerobic bacteria and protozoa will lead to treatment failure. 
The resistant strains of Bacteroides fragilis have plasmid encoded genes that are transferred 
to sensitive strains by conjugation [56]. These strains of microorganism have low levels of 
pyruvate ferrodoxine oxidoreductase (PFOR), an enzyme that is responsible for the reduction 
of ferrodoxin (Fd) and decarboxylation of pyruvate to form acetyl CoA as shown in       
Figure 1.11 [56,60]. The decreased level of PFOR consequently results in low levels of 
reduced Fd, thereby compromising the formation of the nitro radical that is responsible for 
the inhibition of nucleic acid synthesis [56].  
 
The existence of resistant strains of Helicobacter pylori to MTZ have been reported [61]. The 
resistance in these strains can be attributed to the low activity of nicotinamide adenine 
dinucleiotide (NADH) oxidase and  NADH nitroreductase in comparison to that in sensitive 
strains [61]. Similar results were observed in studies in which the resistance of Helicobacter, 
Bacteroides, Clostridium, Giardia, Entamoeba and Trichomonads were investigated at a 
molecular level and all resistant strains had altered or reduced levels of the proteins 
responsible for drug activation [62]. 
 
1.2.2.8.4 Clinical use 
 
MTZ is used to treat infections caused by anaerobic bacteria and protozoa. It is also reported 
to have a radio-sensitising effect on hypoxic tumour cells [43,63]. It is clinically indicated for 
treatment of susceptible protozoal infections such as balantidiasis, amoebiasis, giardiasis, 
trichomoniasis and Blastocytis hominis infection [43,53,58,64]. 
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MTZ is also used for treatment and prophylaxis of anaerobic bacterial infections such as 
bacterial vaginosis, acute necrotising ulcerative gingivitis, pelvic inflammatory disease, 
antibiotic associated colitis, tetanus and infections caused by Bacteroides fragilis [43,58]. 
 
MTZ is indicated for the treatment of meningitis, endocarditis, brain abscess and septicaemia 
caused by susceptible anaerobic bacteria [58]. In addition, also it is used for the eradication of 
Helicobacter pylori infections in peptic ulcer disease, treatment of guinea worm infection, 
Crohn’s disease, hepatic encephalopathy and prophylaxis of infections following bowel 
surgery [43,58]. 
 
1.2.2.8.5 Side effects and interactions 
 
The most common side effects of MTZ are dose related and include headache, nausea, dry 
mouth or a metallic taste in the mouth. Infrequent side effects include diarrhoea, vomiting, 
constipation, weakness, dizziness, ataxia, insomnia and passing of dark urine [43,53,58,64]. 
Moderate neutropenia and thrombocytopenia have also been reported following 
administration of MTZ [43,53]. Rare side effects associated with the use of MTZ include 
cholestatic hepatitis, pancreatitis, jaundice, or thrombophlebitis following intravenous 
infusion. Cases of CNS side effects such as seizures, ataxia and reversible encephalopathy 
have also been reported [43,53,58]. Irreversible encephalopathy in a 38-year-old woman was 
attributed to treatment with a high dose of MTZ [65]. 
 
MTZ is known to cause a disulfuram-like reaction when taken concomitantly with alcohol. 
Phenytoin and phenobarbital have been reported to accelerate the metabolism of MTZ with a 
consequent reduction in effectiveness [43,53,58,64]. MTZ also potentiates the anticoagulant 
effects of coumarin type anticoagulants such as warfarin and it also known to reduce the 
excretion of lithium and therefore has the potential to cause lithium toxicity [43,64]. 
Cimetidine has been reported to increase the plasma levels of MTZ by decreasing MTZ 
clearance, consequently increasing the risk of neurological side effects [43,53,64]. 
 
MTZ and its hydroxy metabolite are mutagenic to bacterial cells, however, in vivo and in 
vitro studies performed on mammalian cells did not reveal any mutagenic effect [43,53]. In 
spite of this finding, lymphocyte mutation was observed in sheep following treatment with 
MTZ in therapeutic doses of 1 g per day for 10 days [66]. As there is insufficient data relating 
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to genotoxicity of MTZ in humans, evidence of carcinogenicity is still unclear and the 
question of whether MTZ is carcinogenic in humans remains unanswered [43,66]. 
 
1.2.2.8.6 High risk groups 
 
The mutagenic effect of MTZ on bacterial cells and some mammalian cells still poses a 
question relating to safe use of MTZ in pregnant women. A meta-analysis study has 
concluded that there is no risk of teratogenicity to the foetus following MTZ administration to 
pregnant women [67]. Nonetheless cases of signal association between vaginal administration 
of MTZ during pregnancy and congenital hydrocephalus have been reported [68]. Similarly 
treatment with MTZ during pregnancy and the occurrence of adrenal neuroblastoma in 
infants has also been reported [69]. Although the use of MTZ during pregnancy is still 
questionable it has been suggested that risk assessment of the teratogenic potential and 
trichomoniasis and bacterial vaginosis perinatal outcome should be undertaken, prior to use 
[70]. 
 
MTZ is secreted in breast milk giving the milk a bitter taste and consequently impairing 
feeding [43]. It is therefore recommended that breast feeding to be discontinued for 12-24 h 
following single-dose therapy [43,64]. 
 
Geriatric patients are prone to the risk of developing blood dyscrasias due to the long-term 
use of high doses of MTZ [64]. Therefore blood level monitoring is advised for geriatric 
patients placed on MTZ therapy for longer than 10 days. Furthermore dose adjustments 
maybe necessary in patients with impaired hepatic function [43,64], a condition that is likely 
to be prevalent in this patient group. 
 
1.2.2.9 Clinical pharmacokinetics 
 
1.2.2.9.1 Dosage 
 
MTZ is administered in different dosage forms including solid, semi-solid, suspension and 
infusion technologies. Tablets are usually taken with or after food, however it is usually 
preferred that MTZ be taken with food to minimize gastro-intestinal irritation [43,53]. In 
suspensions, MTZ benzoate should be taken at least an hour before food, after which it is 
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hydrolysed in the gastro intestinal tract to release MTZ that is subsequently absorbed. MTZ 
can be applied topically as a cream or gel, administered rectally as a suppository or 
parenterally as an infusion of MTZ or MTZ hydrochloride [43]. 
 
The ultimate dose to be administered is dependent on the type and severity of infection to be 
treated and whether that infection is parasitic or bacterial in origin. 
 
In order to treat amoebiasis effectively, MTZ is administered orally in doses of 400-800 mg 
three times daily for 5-10 days [43,64]. The paediatric dose to be administered depends on 
the age of the patient. Children aged between one to three years receive 100-200 mg three 
times daily, children aged between three and seven years receive 100-200 mg four times daily 
and children aged between seven and ten years receive 200-400 mg three times daily [43,64]. 
An alternate approach may be to use a dose of 35-50 mg/kg in divided doses for 5-10 days. 
 
The treatment of giardiasis requires a dose of 2 g daily to be given orally for three 
consecutive days or 400 mg three times daily for 5 days. For paediatric patients children aged 
between 1-3 years receive 500 mg per day, children aged between three and seven years 
receive 600-800 mg per day and children aged between seven and ten years receive 1 g per 
day for three days. An alternate approach may be to use a dose of 15 mg/kg daily in divided 
doses for 5-7 days [43,64]. 
 
For the treatment of trichomoniasis MTZ can be administered as a single oral dose of 2 g or 
as a two-day course in divided doses of 800 mg and 1200 mg in the morning and evening 
respectively [43,64].  Alternatively 200 mg three times daily or 400 mg twice daily for seven 
days may be administered. In paediatric patients children aged between one and three years 
receive 50 mg three times daily, children aged between three and seven years receive 100 mg 
twice daily and children aged between seven and ten years receive 100 mg three times daily 
for seven days. An alternate approach may be to use a dose of 15 mg/kg daily in divided 
doses for seven days [43,64]. 
 
The treatment regimen for the management of bacterial vaginosis is similar to that for the 
management of trichomoniasis or by application of  0.75% w/w gel at a dose of 5 g once or 
twice daily for 5 days [43]. 
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For the treatment of anaerobic bacterial infections MTZ is administered at an initial oral dose 
of 800 mg followed by 400 mg 8 hourly for seven days or, as an intravenous infusion of    
500 mg (5 mg/ml) at a rate of 5 ml/min every 8 h. An alternate approach may be to use 
suppositories at a dose of 1 g every 8 h for three days, followed by 1 g every 12 h after which 
treatment continues by oral therapy [43,64]. For paediatric patients a dose of 7.5 mg/kg 
administered orally or intravenously every 8 h has proved to be effective. An alternate 
regimen may be to use suppositories at  dose of 125 mg for children less than one year,      
250 mg for children aged between one and five years and 500 mg for children aged between 
five and ten every 8 h for three days and twice daily there after [43]. 
 
For the post-operative prophylaxis of anaerobic bacterial infections in patients who have 
undergone bowel surgery, the doses are similar to those used for treatment but MTZ is 
usually used in combination with an aminoglycoside or betalactam antibiotic [43,71,72]. 
 
The treatment of peptic ulcers with MTZ is used in combination with an acid suppressant or 
inhibitor and an antibiotic. The regimens that are recommended for use have been described 
in the introduction of this chapter. 
 
For the treatment of rosacea the topical application of a thin film of MTZ gel  0.75% w/w has 
proven effective  [43,73,74]. 
 
1.2.2.9.2 Absorption 
 
MTZ is almost completely absorbed following oral administration with a Cmax of 
approximately 6-12 µg/ml being achieved within 1-3 h of dosing [42,43,53,64]. Food may 
delay the absorption of MTZ but total absorption remains unaffected [43]. Rectal absorption 
of MTZ is slower than that observed following oral administration with a resultant 
bioavailability of 60-80%. The Cmax following rectal administration is half that achieved 
following an oral dose of MTZ [43,64] with adequate concentrations attained within 3 h after 
insertion of the dosage form [64]. 
 
Vaginal absorption following administration of pessaries is poor with a resultant 
bioavailability of 20-25% and a Cmax of 2 µg/ml [43]. Despite the poor bioavailability it was 
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concluded that intravaginal application was as effective as the oral dose in the treatment of 
bacterial vaginosis [75]. 
 
1.2.2.9.3 Distribution 
 
Following absorption, MTZ is widely distributed in body tissues and fluids with the 
intracellular concentration rapidly reaching extracellular levels, [43,53,58,64]. Similarly the 
distribution of C
14 
MTZ in rats following administration of an oral dose revealed that MTZ 
was rapidly absorbed and equilibration between blood and most tissues was rapid [76]. MTZ 
enters the foetal circulation rapidly and less than 20% of the drug is bound to plasma proteins 
[43,53]. The approximate volume of distribution at steady state ranges between 0.5-1.1 l/kg 
[77]. 
 
1.2.2.9.4 Metabolism 
 
The metabolism of MTZ occurs in the liver as a result of side chain oxidation and 
glucuronidation of the parent drug [43]. The oxidative metabolites are 1-( 2-hydroxyethyl)-2-
hydroxymethyl-5-nitroimidazole which possesses antimicrobial activity of 30-65% that of the 
parent compound [77] and 2-methyl-5-nitroimidazole-1-acetic acid [42,43,58]. The 
metabolism of MTZ in man and dogs was similar [78]. However following oral dosing, only 
the parent drug and the active metabolite were detected in vaginal fluids [42]. The 
metabolism of MTZ in human liver microsomes accounts for 75% of the intrinsic clearance 
of MTZ [79]. 
 
1.2.2.9.5 Elimination 
 
The major route of elimination of MTZ from the body is via urinary excretion with 10-20% 
unchanged drug present in urine and 6-15% of MTZ excreted in faeces. The elimination half-
life of MTZ is approximately 7.5-8 h and is slightly longer for the hydroxymetabolite 
[43,53,58,58,64]. However, in infants the elimination half-life has been reported to range 
between 25-109 h [43]. Upadhyaya et al [80] observed results that are close to the lower 
range previously reported [43], an elimination half-life of 22.3-22.5 h was observed in 
neonatal patients following administration of 7.5 mg/kg MTZ as an infusion. The half-life of 
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MTZ is prolonged in infants due to their under developed renal and hepatic function, but as 
the infant matures, the half-life values are reduced closer to those observed in adults [81]. 
 
The elimination of active metabolites is prolonged in patients with renal dysfunction and 
there are no reports of toxicity in these cases, consequently dose adjustments in renal 
dysfunction may not be necessary [77]. 
 
1.3 CONCLUSION 
 
In sub-Saharan Africa, gastric and duodenal ulcer disease has mostly been associated with 
Helicobacter pylori infection [82]. The infection with Helicobater pylori accounts for 10-
15% of gastric and duodenal ulcers cases, where 80% of the population in the developing 
countries have shown evidence of Helicobater pylori infection [82]. Thus eradication of 
Helicobacter pylori constitutes a fundamental part in the treatment of ulcers since it reduces 
the risk of recurrence and complications of the disease [83]. 
 
Triple therapy is a common approach for the management and treatment of uncomplicated 
ulcers. Nonetheless the pill burden and duration of therapy makes adherence a challenge with 
a consequence of potentiating morbidity and even mortality. RTD and MTZ have been used 
in combination as a part of triple therapy, however, with the discovery of proton pump 
inhibitors (PPI) in 1981 [84] the role of RTD in triple therapy has become minimal. 
 
Even though PPI are effective and safe, they exhibit large inter-patient variability with 
respect to their pharmacokinetics and some have the propensity to interact with other drugs 
[85]. Furthermore, the use of PPI for treatment of ulcers is more expensive compared to the 
use of H2-receptor antagonist [86]. In contrast RTD does not show such activity and 
variability. In South Africa RTD is used as second line therapy in the management of ulcers 
or as an alternate drug for patients in which the use of PPI are contraindicated [6]. Therefore 
the development of a FDC of RTD and MTZ may help reduce the pill burden for patients and 
consequently reduce morbidity and mortality. In addition, the cost of treatment and 
medication error may be reduced following the use of FDC formulation.  
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Therefore the objective of the work has been to manufacture FDC for these two drugs, and in 
the process develop an analytical method for the quantitation of these drugs in 
pharmaceutical dosage forms.  
 
RTD and MTZ have similar physiochemical properties such as hydrophilicity and 
crystallinity which makes them good candidates for formulating a FDC solid dosage form of 
these compounds. In addition the similarity of physiochemical properties facilitates the 
selection of an appropriate analytical technique for the simultaneous analysis of these 
compounds, since variation of analytical conditions may not be required to ensure the 
production of accurate and precise results.  
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 CHAPTER TWO  
HPLC METHOD DEVELOPMENT AND VALIDATION 
 
2.1 INTRODUCTION 
 
2.1.1 Historical background 
 
Chromatography is a technique used to separate compounds in a complex matrix into the 
constituent parts of that mixture. It is estimated that at least 5% of the chemical research 
conducted in the United States of America (USA) in 2003 involved some form of 
chromatographic technique [87]. Chromatography was first described by Mikhail 
Semenovich Tswett in 1901, he used liquid-adsorption chromatography with calcium 
carbonate (CaCO3) as an adsorbent and a petrol ether ethanol mixture as eluant to achieve 
separation of the constituents of chlorophyll, xanthophyll and carotenoid from leaves [88,89]. 
In 1931 the method reported by Tswett was used successfully to purify xanthophylls on a 
CaCO3 adsorption chromatographic column [88]. This application led to the emergence of 
different chromatographic techniques such as partition chromatography consisting of liquid-
liquid chromatography (LLC) and gas-liquid chromatography (GLC), paper chromatography 
(PC), thin layer chromatography (TLC) and ion exchange chromatography (IEC). Braithwaite 
and Smith [90] published a review of commonly used chromatographic techniques as 
summarized in Figure 2.1. 
 
2.1.2 Overview 
 
Different chemical and spectroscopic analytical methods have been used for the analysis of 
MTZ and RTD in pharmaceutical dosage forms or biological fluids such as plasma and urine. 
However most of these methods report the analysis of a single compound at any one time 
from a sample matrix. Despite the rapid advancement in analytical technology and 
techniques,  HPLC is still the preferred tool for the analyses of active pharmaceutical 
ingredients (API) and products as reported in most official compendia [91]. The objective of 
this study was to develop an HPLC method for the simultaneous determination of RTD and 
MTZ in pharmaceutical solid dosage forms. 
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Chromatography  
Chromatographic principle Type of mobile phase Apparatus for stationary 
phase 
Types of chromatography 
Adsorption chromatography, 
competition between solid 
adsorbent and mobile phase 
Partition chromatography, 
competition between liquid 
stationary phase and mobile 
phase 
Ion exchange chromatography, 
competition between ion 
exchange resins and mobile 
phase 
Permeation chromatography, 
competition between polymer 
matrix and mobile phase 
Gas 
Liquid 
Gas 
Liquid 
Liquid 
Liquid 
Column 
Column 
Planar layer 
Column 
Column 
Column 
Column 
Gas solid chromatography 
Liquid column chromatography 
High performance liquid 
chromatography 
Thin layer chromatography 
Paper chromatography 
Gas liquid chromatography 
Super critical fluid chromatography 
Liquid-liquid chromatography 
High performance liquid 
chromatography 
Ion exchange chromatography 
High performance ion exchange 
chromatography 
Gel permeation/filtration chromatography 
Figure 2.1 Classification of chromatographic techniques. Adapted from [91] 
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2.1.3 Classification of HPLC 
 
The development of liquid chromatography that has taken place over approximately thirty 
years has resulted in the development of a technique that is currently known as HPLC. 
However, the principles of HPLC have remained the same as those for liquid chromatography 
with the exception that automated sample injection, continuous solvent pumping and  
reusable stationary phases or columns have become the norm [92]. 
 
HPLC techniques can be classified into four types viz. normal phase (NP), reversed-phase 
(RP), ion exchange (IE) and size exclusion (SE) chromatography, with each technique 
defined according to the dominating molecular interaction and forces that prevail in the 
separation process [89,90]. 
 
2.1.3.1 Normal Phase-HPLC (NP-HPLC) 
 
NP-HPLC makes use of polar interactions between an analyte in a mixture and the stationary 
phase to achieve an effective separation. As with any other liquid chromatographic method, 
the analyte is in continuous competition with molecules of the mobile phase for adsorption 
sites located on the stationary phase. Therefore the stronger the interaction between an 
analyte and the stationary phase the longer the time that the analyte is retained on the column 
and vice versa [89].  
 
In NP-HPLC the backbone of the stationary phase is usually comprised of porous silica oxide 
(SO2) or aluminium oxide (Al2O3) with hydroxyl (OH) group linkages covering the surface of 
the stationary phase, thereby ensuring the presence of polar surface [89]. The mobile phase 
for NP-HPLC technique is mainly comprised of  non-polar solvents such heptane and hexane 
and small quantities of polar components, such as MeOH and ethanol, may sometimes be 
added to produce optimum resolution and retention conditions for the compounds to be 
separated [93]. NP-HPLC has been shown to be a superior technique for the separation of 
complex mixtures, however, it is not without shortcomings, which include, but are not limited 
to, limitations in solvent choices, lengthy equilibration times and limited sample applicability. 
Consequently this has led to the development of bonded-phase chromatography [94], also 
known as reversed-phase HPLC (RP-HPLC). 
  
27 | P a g e  
 
2.1.3.2 Reversed-phase HPLC (RP-HPLC) 
 
RP-HPLC is a commonly used chromatographic technique in pharmaceutical sciences 
research and accounts for 90% of all low molecular weight compound analyses [89]. RP-
HPLC uses a non-polar stationary phase in conjunction with a polar mobile phase, although 
the addition of non-polar mobile phase fractions is not uncommon when required to achieve 
an adequate separation. The stationary phase is comprised of a hydrocarbon chain of varying 
carbon lengths, chemically bonded to the silica backbone or support. The silica support can 
also be bonded chemically to different functional groups such as amino, cyanopropyl, ethers 
and diols to produce polar stationary phases such as for NP-HPLC. Alternatively ion-
exchange functional groups such as sulphonic acid, amino and quaternary ammonium may be 
used and these are similar to those applied in IE-HPLC [90,95].  
 
The retention of analyte(s) in RP-HPLC  occurs primarily through dispersive forces such as 
hydrophobic or van der Waal’s interactions [89]. Analyte(s) interact differently with the 
stationary phase depending on their polarity, resulting in longer and shorter retention times 
for non-polar and polar compounds respectively [89,92]. The retention of analyte(s) also 
depends on the polarity of the eluant, the more polar the eluant the longer the retention of 
nonpolar compounds and vice versa. In RP-HPLC the retention of hydrophobic analyte(s) on 
a stationary phase increases with increasing polarity and the strength of the eluant [92,96]. 
Despite the capability for using RP-HPLC for the analysis of different compounds, the pH of 
a mobile phase remains the major complication in sample separation, therefore it is 
recommended that analyses are performed with an eluant pH in the range 2.0-8.5 as 
hydrolysis or cleavage of the stationary phase may occur at extremes of the pH range [90,96].  
 
2.1.3.3 Ion exchange HPLC (IE-HPLC) 
 
IE-HPLC is commonly used for the separation of biological materials such as nucleic acid, 
amino acids and/or sugars [93,97]. Furthermore, inorganic samples known to have poor 
detectability and organic samples with poor UV absorptivity have been successfully 
separated using IE-HPLC [97]. IE-HPLC has also been used in preparative separations of 
analyte(s) by evaporation of volatile buffers such as ammonium acetate and ammonium 
formate [98] without adulteration of the analyte(s) [93,96].  
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The stationary phase in IE-HPLC is similar to those used for RP-HPLC with the exception of 
the bonded groups. In IE-HPLC the bonded phase is comprised of quaternary ammonium or 
amine functional groups for the separation of anions, or carboxylate or sulphonate groups for 
the separation of cations [93,96]. The retention of analyte(s) in IE-HPLC occurs through the 
exchange of ions between a charged stationary phase and counter ions of the analyte(s) of 
interest in the mobile phase, held at a specific pH and ionic strength [93,97]. As a result 
anionic or acidic analyte(s) are separated using anion-exchange columns as described in 
Equation 2.1 and separation of cations or protonated basic analyte(s) is achieved by using 
cation-exchange columns  as described in Equation 2.2  [96]. 
 
                    Equation 2.1   
                                            Equation 2.2 
Where, 
   = anion exchange stationary phase 
    = cation exchange stationary phase 
    = cationic analyte 
    = anionic analyte 
 
The separation of ionisable analyte(s) depends on the pH and ionic strength of the eluant 
[93,97]. Acidic analyte(s) lose proton(s) as the pH of the mobile phase increases, whereas 
basic analyte(s) gain proton(s) as the pH of the mobile phase decreases. Therefore as the pH 
of the mobile phase increases the retention time of acidic compounds will decrease and the 
retention for basic material will increase and vice versa. However this is true for only certain 
ranges of pH, specifically those that are similar to the pKa values of the analyte(s) of interest 
[93]. Furthermore, incorporation of sufficient buffer salt at appropriate concentrations in the 
mobile phase is essential for the maintenance of an optimal pH for the effective separation of 
compounds of interest [93,96,99]. 
 
2.1.3.4 Size exclusion-HPLC (SE-HPLC) 
 
SE-HPLC is also known as gel permeation chromatography (for organic mobile phases) or 
gel filtration chromatography (for aqueous mobile phases) [100]. SE-HPLC is a separation 
technique in which the relative size or hydrodynamic volume of macromolecules with respect 
to the pore shape and size of the stationary phase is critical to achieving a suitable separation 
[93]. The elution of larger molecules is achieved through the void volume of the column 
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whilst smaller molecules, depending on their relative size, are eluted through the pores of the 
column particles. As a result smaller molecules take longer to elute due to their permeation in 
and through the stationary phase [101-104].  
 
SE-HPLC has been used for the separation of biological samples such as immunoglobulin, 
for sample clean-up, to separate  monomers, dimers, trimers and larger aggregates of protein 
and polysaccharide [105], for the estimation of molecular mass and separation of reaction 
products from reaction mixtures amongst others [101].  
 
SE-HPLC can be used over a wide range of mobile phase conditions since an effective 
separation requires minimal analyte(s) and stationary phase interaction, and is primarily 
dependant on the size of the molecule rather than enthalpic interactions as in NP, RP and IE 
HPLC [106]. Furthermore, the need to apply gradient elution is not necessary in SE-HPLC 
due to the nature of the separation mechanism (size or hydrodynamic volume) and 
consequently the instrumentation is simpler since no special pumping mechanism is required 
to produce a solvent gradient in comparison to other HPLC techniques [104]. 
   
2.2 ANALYTICAL METHODS FOR THE ANALYSIS OF RANITIDINE AND 
METRONIDAZOLE 
 
The initial conditions used for the development of an HPLC method for the simultaneous 
analysis of RTD and MTZ were selected from published HPLC methods that had been used 
for the analysis of these compounds alone or in combination with each other. A summary of 
the conditions reported are listed in Table 2.1. 
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Table 2.1 Summary of HPLC conditions for the analysis of ranitidine and metronidazole 
Analyte(s) Sample matrix Column Mobile phase Flow rate Detector Retention time Reference 
RTD: MTZ Human plasma Shim-pack C18: 
5µm 300 x 4.6 mm 
10% v/v acetonitrile (ACN) 
in 10mM phosphate buffer; 
pH= 3.5 
1 ml/min UV 315 nm 6.4 min: 9.7 min 
respectively 
[107] 
RTD Raw material YMC-Pack ODS-
AM: 5µm 150 x 
4.6 mm 
43% v/v methanol (MeOH) 
in 10mM SDS, 50mM 
phosphate buffer; pH 6.8 
1 ml/min UV 228 nm 27.0 min [108] 
RTD Dosage forms Phenomenex
®
 
Luna II column 
Agilent: 5µm 250 x 
4.6 mm 
10% v/v ACN in 10mM 
phosphate buffer; pH 7.1 
1 ml/min UV 230 nm 5.4 min [14] 
RTD Human plasma Symmetry
®
 C18 : 
5µm 150x 3.9 mm 
12% v/v ACN in 50mM 
phosphate buffer; pH= 6.5 
1 ml/min UV 313 nm 2.8 min [109] 
RTD Blood µBondapak™ C18: 
10µm 150 x 3.9 
mm 
8% v/v ACN in 10mM 
phosphate buffer; pH= 5.1 
2.5 ml/min UV 330 nm 5.0 min [110] 
MTZ Raw material Waters 
Spherisorb
®
 C18: 
5µm 250 x 4.6 mm 
ACN: Water (14:86)% v/v 1 ml/min UV 310 nm 7.6 min [111] 
MTZ Blood Hypersil ODS: 
5µm  
150x 4.6 mm 
10% v/v ACN in 50 mM 
phosphate buffer containing 
0.1% triethylamine ; pH=7 
1 ml/min UV 317 nm 6.7 min [112] 
MTZ Human plasma Merck 
Lichrosphere
®
 100 
RP 18: 5µm 125 x 
4 mm 
15% v/v ACN in 10mM 
phosphate  buffer; pH= 4.7 
1 ml/ min UV 318 nm 2.6 min [113] 
MTZ Tissue Zorbax SB-phenyl: 
5µm 150 x 4.6 mm 
15% v/v MeOH in 10mM 
phosphate buffer; pH= 4.0 
1 ml/ min UV 313 nm 9.2 min [114] 
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It is evident that the majority of methods reported for the analysis of RTD and MTZ have 
been selected for their determination in biological samples and that there is a dearth of 
analytical methods for the analysis of these API in raw materials and pharmaceutical dosage 
forms [14,107,108,110-113]. The majority of the methods use RP-HPLC with C18 or C8 
stationary phases or, on rare occasions, a phenyl support has been used to achieve a 
separation [115]. The retention times for both compounds is in general   10 min, however a 
retention time as long as 27 min has been reported for MTZ [108].  
 
The most commonly used organic modifier and buffer solution for mobile phase preparation  
has been ACN, and mono-basic potassium phosphate and the pH of the buffer ranged 
between 3.5-7.1 and the ACN content between 5-14% v/v [14,107-109,111,115,116]. Where 
ACN was not used in the mobile phase MeOH has been used [108,114]. 
 
The separation of molecules that ionize is best achieved in systems in which the mobile phase 
is buffered (§ 2.1.3.3). RTD is a weak acid (§ 1.2.1.4) and MTZ a weak base (§ 1.2.2.3), 
therefore buffer systems have been necessary to achieve suitable separation of these 
compounds [14,107-110,115,116] although a mobile phase in which no buffer was used has 
been  reported for the analysis of MTZ raw material [111].   
 
Ultraviolet (UV) absorption spectroscopy has been used for the detection of these compounds 
at wavelengths of between 228-230 nm or 315-330 nm for RTD and wavelengths of between 
310-342 nm for MTZ  [111,115]. In one instance, a wavelength of 274 nm was used for the 
detection of MTZ benzoate [116]. 
 
The published studies provide sufficient data on the chromatographic conditions for the 
analysis of RTD and MTZ in a variety of sample matrices (Table 2.1). Consequently these 
conditions were used as a starting point for the development and selection of an appropriate 
HPLC technique for simultaneous analysis of MTZ and RTD in raw material, powder blends 
and dosage forms. Therefore a RP-HPLC method using UV detection was selected as the 
preferred analytical tool for the quantitation of RTD and MTZ during formulation 
development and assessment studies. 
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2.3 EXPERIMENTAL  
 
2.3.1 Materials and reagents 
 
RTD, MTZ and ornidazole were purchased from Sigma Aldrich (St Louis, Missouri, USA). 
ACN (UV cutoff 200 nm) and MeOH (UV cutoff 215 nm) were purchased from Romil Ltd 
(Waterbeach, Cambridge, United Kingdom). Sodium hydroxide pellets and potassium 
dihydrogen orthophosphate were purchased from Merck Chemicals Ltd (Modderfontein, 
Gauteng, South Africa) and triethylammine was procured from SaarChem Pty Ltd 
(Krugersdorp, Gauteng, South Africa). 
 
HPLC grade water for buffer and sample preparation was purified using a Milli-RO
® 
15 
water purification system (Millipore Co., Bedford, Massachusetts,  USA) that consisted of a 
Super C
®
 carbon cartridge, two ion-X
®
 ion exchange cartridges and an Organex-Q
®
 cartridge. 
The water was filtered through a 0.22 µm Millipak
®
 stack filter (Millipore, Bedford, 
Massachusetts, USA) prior to use. 
 
2.3.2 HPLC system 
 
The modular HPLC system consisted of a model P100 dual piston solvent delivery module 
(Thermo Separation Products, San Jose, California, USA), a model AS100 autosampler 
(Thermo Separation Products, San Jose, California, USA) fitted with a Rheodyne
® 
Model 
7010 injector (Rheodyne, Reno, Nevada, USA), a fixed volume 20 µl loop and a Gastight
®
 
250 µl Model 1725 syringe (Hamilton Co., Reno, Nevada, USA). A linear UV/VIS-500 
Model 6200-9060 detector (Linear Instrument Co., California, USA) and  Spectra Physics SP 
4600 integrator (Thermo Separation Products, San Jose, California, USA) were used for 
detection and data collection respectively. Separation was achieved on a Nova-Pak
® 
C18 60 Å 
4 µm, 3.9 x 150 mm cartridge column (Waters Association, Milford, Massachusetts, USA) at 
22±0.5
°
C. 
 
2.3.2.1 Column selection 
 
The selection of a suitable column for RP-HPLC analyses is dependent in part on the 
physiochemical properties of the analyte(s) of interest as these determine the nature and 
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magnitude of the interactive forces that are involved between analyte(s) and the stationary 
phase to achieve a suitable separation [89,92,96,101].  
 
As indicated in § 1.2 RTD is a weak acid and MTZ is a weak base and their physiochemical 
properties have been described in detail in Chapter One. Following evaluation of the 
physiochemical properties of these compounds and a review of the relevant literature, a RP 
C18 column was selected for use in this study, despite operating pH limitations and the silanol 
effect usually observed when analysing basic molecules with silica based stationary phases 
[89,90]. 
 
The resolution and peak height of a response for a compound of interest on a chromatogram 
are dependent in part on the particle size and diameter of the material used for the stationary 
phase [117]. Columns with particles of particle size ranging between 3-10 µm have been 
reported to be an excellent compromise in terms of resolution, resultant back pressure and 
column lifetime and the best results have been reported when using columns with stationary 
phases of particle size diameter of 5 µm [96]. Although the risk of column plugging is 
increased with smaller particle sizes [96,118] the benefits of using such materials outweigh 
the limitations, therefore a column with 4 µm particle size diameter was selected for use in 
these studies. 
 
The choice of a specific length and internal diameter of a column depends on the 
requirements for analysis. In general a range of between 3-4.6 mm for the internal diameter 
(id) and a length of 150 mm is considered adequate for normal analytical applications, whilst 
larger diameter columns have mostly been reserved for preparative purification of samples 
[96]. Narrow bore columns have improved separation and reduced solvent consumption and 
reports suggest that solvent consumption may decrease four times when a 2.1 mm id column 
is used in comparison to  when a 4.6 mm id column is used [96]. Therefore a column        
with 3.9 mm id, 150 mm length and 4 µm particle size was selected for use in these studies. 
 
The interaction of an analyte(s) with the stationary phase depends on the diffusivity of the 
analyte(s) through the pores of the column particles [118]. Columns with a larger pore size 
usually exhibit poor interactions between small dimension analyte molecules or particles due 
to a reduced relative surface area [96,118]. For routine analysis of molecules of < 2000 Da, a 
pore size of between 70-120 Å has been reported to be effective [96]. 
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Following evaluation of the factors related to column performance and the review of 
literature, a Nova-Pak
® 
C18 60 Å 4 µm, 3.9 id x 150 mm HPLC cartridge column (Waters 
Association, Milford, Massachusttes, USA) was selected for the development of a RP-HPLC 
UV method for the simultaneous analysis of RTD and MTZ in pharmaceutical dosage forms. 
 
2.3.2.2  Internal Standard (IS) selection 
 
Quantitative analyses of finished products usually require sample preparation that often 
results in sample loss as a direct consequence of the extensive sample manipulation prior to 
analysis. Furthermore, biological samples usually require pre-treatment prior to analysis and 
the pre-treatment process often results in sample loss [96,119]. In addition, instrumental 
variation such as variability in flow rate and injection volume may result in variability in 
detector response to the same concentration of an analyte(s). Therefore to compensate for 
these deficiencies, an internal standard (IS) may be added to calibration and sample solutions 
to reduce analytical method variability [96,120].  
 
A suitable IS should be well resolved from all components of a mixture and have a retention 
time close to that of the compound(s) of interest and, if possible, a similar chemical structure 
to facilitate detection [96,120]. Furthermore, the response factor of an IS must be of the same 
order of magnitude as the compounds which are to be analyzed [121] and must also be stable 
under the analytical conditions used to achieve an effective separation [122]. 
 
Frequently used IS for the analysis of RTD include procainamide or metoclorpromide [110] 
whereas for MTZ, tinidazole [112-114], ornidazole and phenylpropanolamine hydrochloride 
have been used [112].  
 
Ornidazole was selected as the preferred IS since it exhibits a similar structure to MTZ, does 
not elute close to the analytes viz. MTZ and RTD and is readily available. 
 
2.3.2.3 Preparation of stock solutions 
 
Stock solutions of RTD (100 µg/ml), MTZ (100 µg/ml) and IS (100 µg/ml) were prepared by 
accurately weighing 10±0.05 mg of each compound using a Model AG135 Mettler Toledo 
top-loading analytical balance (Mettler Instruments, Zurich, Switzerland) and quantitatively 
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transferring each to a separate 100 ml A-grade volumetric flask. Each sample was dissolved 
in a mixture of MeOH:water (80:20) % v/v followed by sonication for 1 min using a Model 
B-12 Ultrasonic bath (Branson Cleaning Equipment Co., Shelton, Connecticut, USA). 
Aliquots from each stock solution were harvested and transferred to 5 ml A-grade volumetric 
flasks to produce mixture solutions of MTZ, RTD and the IS. The resultant mixture solutions 
were serially diluted using MeOH:water (80:20) to produce RTD:MTZ solutions of 
concentration 1:2.5, 2:5, 4:10, 6:15, 8:20 µg/ml respectively and that for the IS of 40 µg/ml.  
 
2.3.2.4 Preparation of buffers 
 
Phosphate buffer (50 mM) was prepared by accurately weighing 6.8 g of potassium 
dihydrogen orthophosphate into a 1000 ml A-grade volumetric flask and adding 2 ml 
triethylamine, and the solution was made up to volume with HPLC water. The buffer pH was 
adjusted to 6.7 using 0.1 M sodium hydroxide solution and the pH was monitored using a 
Crison GLP 21 pH-meter (Crison Instruments, Barcelona, Spain). The pH of the buffer 
solution was adjusted prior to the addition of organic modifier to avoid imprecise pH 
measurement due to drift of electrode response that is attributed to the presence of an organic 
modifier [96].  
 
2.3.2.5 Preparation of mobile phase 
 
The mobile phase was comprised of ACN 9% v/v in phosphate buffer at a pH of 6.7 
containing 0.2% triethylamine. The mobile phase was degassed under vacuum using a Model 
A-25 Eyela Aspirator (Tokyo Rikakikai Co., Tokyo, Japan) and filtered through a  0.45 µm 
Durapore
®
 HVLP membrane filter (Millpore Co., Billerica, Massachusetts, USA) prior to 
use. 
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2.4 RESULTS AND DISCUSSION 
 
2.4.1 Effect of organic solvent composition 
 
The retention time (Rt) and resolution (Rs) of RTD, MTZ and the IS were significantly 
influenced by the ACN content of the mobile phase as shown in Figure 2.2 and Table 2.2 
respectively.  
 
 
Figure 2.2 The effect of organic solvent composition on the Rt of MTZ, RTD and IS 
 
Table 2.2 The effect of ACN content on peak Rs  
ACN content (%) v/v Rs 
8 4.3 
9 3.3 
10 1.8 
 
The Rt of MTZ, RTD and IS were 3.7, 4.6 and 14.6 min respectively when ACN was used at 
9% v/v in the buffer. A reduction in the ACN content to 8% v/v in the buffer had an impact 
on the Rs between MTZ and RTD which changed to 4.3 from a value of 3.3 when 9% v/v 
ACN was included in the mobile phase as shown in Table 2.2. Furthermore the Rt of the IS 
increased to 16 min and consequently the run time had to be increased to 19 min. This change 
may be due to the decrease in competition between ACN molecules and IS molecules for the 
adsorbent sites on the stationary phase as a result of the low concentration of organic 
modifier. When the ACN content was increased to 10% v/v the Rs between MTZ and RTD 
changed to 1.8 and the Rt of the IS decreased to approximately 12 min. This may be due to 
0
3
6
9
12
15
18
7 8 9 10 11 12
R
et
en
ti
o
n
 t
im
e 
(m
in
)
% v/v Acetonitrile
MTZ RTD IS
  
37 | P a g e  
 
displacement of analyte molecules from the adsorbent sites on the stationary phase as a 
consequence of an increase in ACN concentration. The FDA recommends that the resolution 
between peaks of interest be not less than 2 [123]. Therefore, despite the optimal run time 
achieved at 10% v/v ACN content, the best compromise for resolution and the analytical run 
time was obtained at a concentration of 9% v/v ACN.  
 
2.4.2 Effect of buffer molarity 
 
In general buffer concentration has a relatively minor effect on the retention times of ionic 
sample when using reversed-phase chromatographic methods [96]. The effect of buffer 
molarity on the Rt of RTD is depicted in Figure 2.3. 
 
 
Figure 2.3 The effect of buffer molarity on the Rt of MTZ, RTD and IS 
 
The results show that a change in the buffer molarity had an effect on the Rt of RTD whilst 
the Rt of MTZ and the IS were not as significantly affected. Increasing the molarity of a 
buffer from 10 to 50 mM resulted in a decrease in the Rt of RTD from 5.2 to 4.6 min. This 
may be due to an increase in competition between the buffer anions and RTD for the silanol 
sites as a consequence of the high buffer concentration. Furthermore, increasing the buffer 
concentration to 80 mM resulted in no change in the Rt of RTD.  
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2.4.3 Effect of triethylamine 
 
The separation of basic compounds using silica-based stationary phases is often associated 
with changes in peak asymmetry and peak tailing due to what is known as the “silanol” 
effect. However the use of buffers in the mobile phase may sometimes alleviate the problem 
with varying degrees of success and that is dependent on the basicity of the analyte of interest 
[96,124].  
 
The addition of triethylamine to a mobile phase has been reported to improve peak 
asymmetry and separation efficiency for basic compounds [96,125,126]. The addition of 
triethylamine to the mobile phase reduced peak tailing for RTD more efficiently than changes 
of the buffer molarity as described in Table 2.3.  
 
Table 2.3 The effect of triethlyamine on peak tailing factor 
Buffer molarity (mM) Peak tailing factor 
10 3.5 
50 1.8 
50* 1.25 
*Buffer solution contains 0.2% v/v triethylamine 
 
The peak tailing factor at 10 mM and 50 mM mobile phase buffer concentrations were 3.5 
and 1.8 respectively, and on addition of 0.2% triethylamine to a mobile phase containing     
50 mM buffer solution the peak tailing factor was reduced to 1.25. This may be due to 
preferential attachment of triethlyamine molecules to the acidic hydrogen atoms located on 
the silanol ends of the stationary phase backbone. A peak tailing factor of ≤ 2 is considered 
acceptable for routine quantitative analyses [123] and the addition of triethlyamine was 
necessary for the accurate quantitation of MTZ and RTD. 
 
2.4.4 Effect of buffer pH 
 
The pH of the buffer used to prepare the mobile phase had a significant effect on the Rt of 
RTD as depicted in Figure 2.4.   
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Figure 2.4 Effect of buffer pH on the retention time of MTZ, RTD and IS 
 
A change in pH from 3.5 to 4.5 had no effect on the Rt of MTZ and RTD. However at a pH of 
6.7 the Rt of RTD changed to 4.6 min with better resolution between MTZ and RTD being 
achieved. 
 
2.4.5 Effect of flow rate 
 
In general flow rate has an effect on the analytical run time. The effect of mobile phase flow 
rate on analytical run time is described in Table 2.4. 
 
An increase in the flow rate of the mobile phase facilitates shorter analytical run times. 
Increasing the flow rate from 1 to 1.5 ml/min resulted in a change in the analytical run time 
from 20 to 18 min. Increasing the flow rate to 2 ml/min facilitated analytical run times of    
16 min, whereas a flow rate of 2.5 ml/min resulted in a 14 min analytical run time. Despite 
the short analytical run time observed at a flow rate of 2.5 ml/min, the 3.9 mm id of the 
column was not suitable for the flow rate (2.5 ml/min). Therefore with respect to the id of the 
column, a flow rate of 2 ml/min resulted in an optimal analytical run time since flow rates of 
1.0-2.0 ml/min are recommended for columns with id of 3.9 mm [127].  
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 Table 2.4 The effect of mobile phase flow rate on analytical run time 
Flow rate (ml/min) Analytical run time (min) 
1.0 20 
1.5 18 
2.0 16 
2.5 14 
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2.4.6 Chromatographic conditions 
 
The final HPLC chromatographic conditions for the simultaneous analysis of MTZ and RTD 
are summarized in Table 2.5 and a typical chromatogram obtained with these conditions is 
depicted in Figure 2.5. 
 
Table 2.5 Chromatographic conditions 
Column C18 Nova-Pak
® 
4 µm 3.9 x 150 mm cartridge 
Flow 2 ml/min 
Injection volume 20 µL 
Detection 317 nm 
Temperature 22 ± 0.5°C 
Mobile phase ACN: 50 mM buffer pH 6.7 (9:91) %v/v containing 0.2% v/v triethylamine 
Detector sensitivity 0.005 AUFS 
Chart speed 2.5 mm min-1
 
   
 
                                                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Typical chromatogram of MTZ, RTD and IS at a concentration of 10, 4 and 40 µg/ml 
respectively obtained using the conditions described in Table 2.4 
Time (min) 
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2.5 METHOD VALIDATION 
 
2.5.1 Introduction 
 
Reliable and reproducible analytical methods are critical for the assessment of quality of a 
starting material, intermediate and finished product in the pharmaceutical, cosmetic, chemical 
and food industries. However many of the analytical methods fail to produce the expected 
results when different environmental conditions, instrumentation, equipment or different 
analysts are used. To minimise the issues encountered due to variability of this nature, it is of 
paramount importance that analytical methods are validated prior to implementation [96,128]. 
The validation of analytical methods is an integral part of the requirements for submission of 
analytical methods to regulatory authorities such as Food and Drug Administration (FDA), 
Tanzania Food and Drug Authority (TFDA), Medicine Control Council (MCC) and 
compendia such as the United States Pharmacopoeia (USP) and the British Pharmacopoeia 
(BP) amongst others [128]. The types of studies performed for method validation depends on 
the goal(s) of the specific analytical method under investigation. For instance methods 
developed for the trace analysis of materials requires a different approach and acceptance 
criteria in comparison to major component analysis. However at the early stages of method 
development specificity, accuracy, precision, range and linearity studies of the analytical 
method must be considered [96,129].  
 
2.5.2 Linearity and range 
 
The linearity of an analytical method describes whether the response of an analyte(s) in 
relation to the concentration of that analyte is linear  [129]. The acceptability of linearity data 
depends on the correlation coefficient (R
2
) generated following least square linear regression 
analysis of analyte response versus analyte concentration. An R
2
 value of > 0.999 is generally 
acceptable for major component assay [96,128]. For assay purposes linearity studies are 
performed at 50%, 75%, 100%, 125% and 150% of the target levels for analyte that exhibit 
linear response at these concentrations [96,128]. 
 
The range of an analytical method is the interval between the upper and lower concentrations 
of an analyte for which the accuracy, precision and linearity are within acceptable limits 
[96,128]. 
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The linearity and range for the analysis of RTD and MTZ were established by plotting the 
peak height ratios of MTZ/IS and RTD/IS versus the concentration of MTZ and RTD 
respectively as summarized in Table 2.6.  
 
Table 2.6 The resultant peak height ratios as function of concentration 
MTZ RTD 
Concentration 
(µg/ml) (n=5) 
Average peak 
height ratio 
% 
RSD 
Concentration 
(µg/ml) (n=5) 
Average peak 
height ratio 
% 
RSD 
2.5 0.22±0.005 2.56 1 0.05±0.001 3.10 
5.0 0.42±0.015 3.62 2 0.12±0.004 3.92 
10.0 0.86±0.024 2.78 4 0.25±0.004 1.72 
15.0 1.27±0.033 2.61 6 0.37±0.013 3.52 
20.0 1.66±0.049 2.97 8 0.49±0.016 3.39 
 
The equation of the line and R
2
 for MTZ was                  and 0.9995 
respectively and that for RTD was                  and 0.9995 respectively. The 
respective calibration curves for MTZ and RTD are depicted in Figures 2.6 and 2.7 
respectively. The resultant curve for MTZ was linear at concentrations of 2.5, 5, 10, 15, and 
20 µg/ml and that for RTD at concentrations of 1, 2, 4, 6, and 8 µg/ml. 
 
 
Figure 2.6 Range and linearity curve for MTZ plotted using the data listed in Table 2.6 
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Figure 2.7 Range and linearity curve for RTD plotted using the data listed in Table 2.6 
 
2.5.3 Precision 
 
The precision of an analytical method is the closeness of agreement of the test results 
obtained following multiple analyses of the same homogenous sample under the prescribed 
conditions [96,129]. Precision can be further subdivided into repeatability, intermediate 
precision and reproducibility [96,128]. Precision is usually reported as the percent of relative 
standard deviation (% RSD). In this study a %RSD of <5 was set as the tolerance limit.  
 
2.5.3.1 Repeatability 
 
Repeatability is also known as intra-assay precision and is the precision of an analytical 
method used under the same operating conditions over a short time interval [129]. These 
types of studies are performed to test instrument performance [96]. A minimum of nine 
determinations covering the specified range for the procedure are required for repeatability 
studies [96,128,130]. Repeatability was determined following triplicate injection of three 
concentrations covering the calibration range at low, medium and high levels. The 
repeatability data generated within the previously determined calibration range on Day 1 are 
summarized in Table 2.7.     
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Table 2.7 Repeatability and intermediate precision data for the simultaneous analysis of  MTZ and 
RTD 
 MTZ RTD 
DAY Concentration 
(µg/ml) 
Mean 
concentration 
determined 
(µg/ml) 
(% RSD) Concentration 
(µg/ml) 
Mean 
concentration 
determined 
(µg/ml) 
(% RSD) 
1 2.50 2.52 ± 0.026 1.04 1.00 1.01 ±0.005 0.56 
10.00 9.69 ± 0.135 1.40 4.00 3.83 ± 0.045 1.17 
20.00 20.16 ± 0.533 2.64 8.00 8.00 ± 0.066 0.83 
2 2.50 2.70 ± 0.070 2.59 1.00 1.19 ± 0.017 1.45 
10.00 10.05 ± 0.270 2.68 4.00 3.91 ± 0.070 1.81 
20.00 20.35 ± 0.350 1.72 8.00 7.87 ± 0.115 1.47 
3 2.50 2.59 ± 0.117 4.55 1.00 0.94 ± 0.450 2.97 
10.00 9.75 ± 0.387 3.97 4.00 3.86 ± 0.119 3.08 
20.00 19.95 ± 0.560 2.80 8.00 7.79 ± 0.231 2.97 
 
2.5.3.2 Intermediate precision 
 
The intermediate precision of an analytical method expresses the precision of that method 
under various laboratory conditions [96]. These studies test the impact of different days or the 
use of different analysts or equipment on the analytical method [96,130]. Intermediate 
precision of the method was determined on two additional consecutive days. The analysis 
was performed in triplicate at the three concentrations covering the determined range at low, 
medium and high levels. The intermediate precision data for Days 2 and 3 are summarized in 
Table 2.7. 
 
2.5.3.3 Reproducibility 
 
The reproducibility of an analytical method is the precision of that method when analyses are 
conducted using the same method in different laboratories. These studies are usually 
performed if standardization of an analytical procedure is required [96,130]. However, for 
this study standardization of the analytical procedure was not necessary since the analysis 
was undertaken using the same equipment and analyst in the same laboratory.  
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2.5.4 Accuracy 
 
Accuracy is defined as the closeness of agreement between a measured value and a value 
which is accepted as the conventional true value or accepted reference value for a sample 
undergoing analysis [130]. Usually accuracy is determined by use of recovery studies 
although analyte standard addition, reference standard comparison and spiked blank matrix 
analyte recovery studies have also been used for accuracy determination [96]. The FDA  
recommends accuracy studies to be performed at 80%, 100% and 120% levels of the product 
label claim [123] and these studies should be performed at levels within the expected final 
product concentration range [96,130]. Accuracy was performed in triplicate at three levels 
viz. high, medium and low in order to cover the necessary range of concentration that were to 
be investigated (§ 2.5.2). A tolerance of 5% was set for the % RSD and a % bias of <5% for 
the bias and the results of accuracy assessment are summarized in Table 2.8. 
 
Table 2.8 Accuracy results for the simultaneous analysis of MTZ and RTD 
MTZ RTD 
Concentration 
(µg/ml) 
Mean 
concentration 
determined 
(µg/ml) (n=3) 
Precision 
(% RSD) 
% 
Bias 
Concentration 
(µg/ml) 
Mean 
concentration 
determined 
(µg/ml) (n=3) 
Precision 
(% RSD) 
% 
Bias 
2.50 2.52 ± 0.026 1.04 -0.90 1.00 1.01 ± 0.005 0.56 -1.75 
10.00 9.60 ± 0.135 1.40 3.27 4.00 3.83 ± 0.040 1.17 4.18 
20.00 20.16 ± 0.533 2.64 -0.82 8.00 8.00 ± 0.006 0.83 -0.06 
 
2.5.5 Limits of quantitation (LOQ) and detection (LOD) 
 
The limit of quantitation (LOQ) is the lowest concentration of an analyte that can be 
quantitated with acceptable precision and accuracy under the prescribed experimental 
conditions [96,123,130]. The limit of detection (LOD) of an analyte is the lowest 
concentration of an analyte that produces a measurable response but cannot accurately be 
quantitated under the stated experimental conditions [96,123,130]. The USP recommends the 
use of signal to noise ratio for the determination of LOQ and LOD of an analytical [129]. 
Signals of samples with known low concentration of the analyte(s) are compared to signals of 
blank samples in order to establish the analyte concentration that produces a signal to noise 
ratio of 10:1 for LOQ and 3:1 for LOD [129] as listed in Table 2.9.  However the application 
of this method requires analytical methods that exhibit substantial baseline noise. Further, this 
method is detector specific, thus analyses of the same sample performed on different 
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detectors may produce different signal noise ratios and consequently different results for the 
LOQ and LOD may be observed. An alternate approach for the determination of LOQ and 
LOD of an analytical method may be the use of the standard deviation (σ) of the response and 
the slope of the line. A calibration curve in the range of LOQ or LOD is constructed followed 
by determination of the slope and standard deviation of the y-intercept of the resultant 
equation of the line. The relationship between the slope and the standard deviation in 
determination of LOQ and LOD is described in Table 2.9. 
 
Table 2.9 Methods for the determination of  LOQ and LOD 
Method LOD LOQ Reference 
Signal to noise ratio 3 or 2: 1 10: 1 [96,130,131] 
Based on standard deviation 
of the response and the slope 
    
     
 
   
     
 
[130,131] 
Based on precision value. Not stated % RSD > 3 [96] 
 
The LOQ and LOD for this method were established by use of the signal to noise ratio 
method. Both MTZ and RTD had similar LOQ and LOD values viz. 0.3 µg/ml and 0.1 µg/ml 
respectively.  
 
2.5.6 Specificity 
 
The specificity of an analytical method is the ability of the method to accurately quantitate an 
analyte in the presence of compounds such as impurities, excipients and matrix materials that 
may interfere with the analysis [128,132]. In method development studies the establishment 
of specificity is vital since the reliability, accuracy, precision and linearity of a method are 
dependent on the specificity of the method [96]. 
 
The specificity of the method was established by assessing the resolution of MTZ and RTD 
in a mixture spiked with potential formulation excipients in the same ratio as they would be 
used in a product. Furthermore, commercial tablets of MTZ and RTD were used for 
specificity studies. Both MTZ and RTD were well resolved from the excipients tested, which 
suggesting that the method is specific when used for the simultaneous analysis of both 
compounds. 
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2.5.7 Forced Degradation Studies 
 
Most regulatory authorities have adopted the ICH guidelines for method validation that 
require analytical methods for drug product analyses to be stability indicating. The guideline 
requires that an analytical method shows discrimination between an analyte and degradation 
products that may occur following forced degradation studies [52]. Furthermore forced 
degradation studies should be performed under a variety of environments including light, 
oxidative, acidic, basic and heat conditions [133]. In addition the ICH guidelines require the 
analysis of individual degradation products qualitatively and quantitatively, however 
qualitative analyses of degradation products only were used for this research. 
 
2.5.7.1 Method 
 
Analysis of degradation studies was performed by comparing chromatograms generated 
during forced degradation studies and those following analysis of a freshly prepared standard 
solution of MTZ and RTD.  
 
2.5.7.1.1 Sample preparation 
 
Approximately 1 mg of MTZ and RTD were weighed separately and quantitatively 
transferred into 10 ml A-grade volumetric flasks. With the exception of oxidative studies, the 
drug substance was dissolved and made up to volume with a medium specific for that 
degradation study, to yield a solution at a concentration of 100 µg/ml. 
 
2.5.7.1.1.1 Oxidative degradation 
 
MTZ and RTD exhibit poor solubility in H2O2. It has been reported that an appropriate 
solvent may be used to improve drug solubility in the degradation medium [134]. Thus each 
drug substance was dissolved in 4 ml of MeOH:water (80:20) and the resultant solutions were 
made up to volume (10 ml) with a 10% v/v H2O2  (Allied Drug Company Ltd, Durban, 
KwaZulu-Natal, South Africa) after which each sample was refluxed for 8 h at 50±0.5
°
C. 
Sample aliquots (2 ml) were collected prior to refluxing and after every hour during 
refluxing. Aliquots (2 ml) of IS that had been prepared as described in § 2.3.2.3 were added 
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to each sample and the resultant solution was made up to volume (10 ml) with MeOH:water 
(80:20) and analyzed using HPLC. 
 
2.5.7.1.1.2 Acid degradation studies 
 
The drug substances were dissolved and made up to volume (10 ml) using 0.1 M HCl and the 
solutions were refluxed for 8 h at 50±0.5
°
C. Sample aliquots (2 ml) were collected prior to 
refluxing and after every hour during refluxing and transferred to a 10 ml A-grade volumetric 
flask followed by addition of 2 ml of IS that had been prepared as per method in § 2.3.2.3. 
The resultant solution was made up to volume using MeOH:water (80:20) prior to analysis by 
HPLC. 
 
2.5.7.1.1.3 Alkali degradation studies 
 
The drug substances were dissolved and made up to volume (10 ml) using 0.1 M NaOH and 
the solutions were refluxed for 8 h at 50±0.5
º
C. Sample aliquots (2 ml) were collected prior to 
refluxing and hourly after refluxing had commenced and transferred to a 10 ml A-grade 
volumetric flask followed by addition of 2 ml of IS that had been freshly prepared as 
described in § 2.3.2.3 and the resultant solution made up to volume with MeOH:water 
(80:20) prior to analysis by HPLC. 
 
2.5.7.1.1.4 Photolysis 
 
The drug substances were dissolved and made up to volume (10 ml) with distilled water and 
the resultant solutions were exposed to sunlight for 8 h. Sample aliquots (2 ml) were collected 
prior to exposure and hourly following the commencement of exposure and transferred to a 
10 ml A-grade volumetric flask followed by dilution with 2 ml of IS that had been prepared 
as described in § 2.3.2.3, and the resultant solution made up to volume with MeOH:water 
(80:20) prior to analysis by HPLC. 
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2.5.7.2 Results and Discussion 
 
2.5.7.2.1 Oxidative degradation 
 
Both compounds did not exhibit appreciable degradation when they were incubated in a   
10% v/v H2O2 solution at room temperature, however significant degradation was detected 
for RTD samples in comparison to MTZ samples after 1 h of refluxing. MTZ and RTD 
produced peaks at 3.7 and 4.6 min respectively as shown in Figure 2.8 (I) but the analyses of 
degradation samples revealed a decrease in the peak height for RTD peak at 4.6 min and the 
appearance of a new peak at 1.8 min after 1 h of refluxing as depicted in Figure 2.8 (II). The 
total disappearance of the peak for RTD was observed at the end of the second hour of 
refluxing (Figure 2.8 III). This may be due to degradation of RTD to rantidine S-oxide. 
Similar results following incubation of RTD syrup in 3% H2O2 have been reported [14]. 
 
Unlike RTD, MTZ is relatively stable in a 3% v/v H2O2 solution and the chromatogram 
revealed neither a change in Rt nor the peak characteristics for MTZ. Similar results 
following 6 h incubation of MTZ in 3% v/v H2O2 solution have been reported although 30% 
degradation was detected following incubation in a 30% H2O2 solution [111]. 
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Figure 2.8 Chromatograms of standard solution each at a concentration of 20 µg/ml (I) and oxidative 
degradation of RTD after 1 h (II) and 2 h (III) of reflux 
 
2.5.7.2.2 Acid degradation 
 
Analyses performed following acid hydrolysis of RTD revealed no degradation under these 
conditions. The peak characteristics and Rt of RTD were similar to those of the standard 
solution. These results are in agreement with those observed following incubation of RTD in 
0.1 N HCl [14]. Similarly no degradation was detected following the analysis of MTZ 
samples. However, these results did not agree with those of Bakshi et al. [111], where 20% 
degradation of MTZ was recorded when heated in 0.1 M HCl. The lack of degradation 
observed for MTZ may be ascribed to short refluxing time, viz. 8 h, and low heating 
temperature, viz, 50
°
C. 
I II III 
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2.5.7.2.3 Alkali degradation 
 
Both RTD and MTZ were observed to degrade when exposed to alkaline degradation. The 
chromatograms observed following exposure of MTZ to alkali conditions revealed a new 
peak at 6.9 min as can be seen in Figure 2.9 (I). The periodic sample analyses over the first 3 
h showed appearance of new peak at 1 min, and both peaks viz. peak at 1 and 6.9 min existed 
at the expense of the parent peak at 3.7 min (Figure 2.9 II) and there was total disappearance 
of both peaks following 5 h of refluxing (Figure 2.9 III). This may be due to the formation of 
non-chromorphic degradants since MTZ degrades under alkali conditions to produce acetic 
acid and ammonia [52,111]. Furthermore 95% degradation of MTZ and the presence of non-
chromorphic degradants following incubation of the drug in 0.1 M NaOH at 80
°
C has been 
reported [111]. 
 
                                                               
Figure 2.9 Chromatograms of alkali degradation of MTZ at 0 h (I), 3 h (II) and 5 h (III) 
 
I II III 
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Similarly analyses of RTD following alkali degradation revealed the presence of two new 
peaks at 6.9 min prior to commencement of refluxing (Figure 2.10 I) and the presence of a 
second peak at 2.0 min after 1 h of refluxing (Figure 2.10 II). Subsequent analyses of samples 
showed that the two peaks existed with a decrease of the parent peak at 4.6 min (Figure 2.10 
III) followed by complete disappearance of the drug and degradant peaks after 5 h of 
refluxing. These results were in agreement with those previously reported following 
incubation of rantidine syrup in 0.1 N NaOH [14].  
 
                                                                     
Figure 2.10 Chromatograms of alkali degradation of RTD at 0 h (I); 1 h (II) and 3 h (III) 
 
2.5.7.2.4 Photo degradation  
 
The analyses of samples following exposure to light revealed that both compounds are 
susceptible to photolysis. The peaks heights of MTZ and RTD decreased as refluxing 
continued when the solutions were compared to those of a standard solution of the same 
concentration. The lack of detection of the degradants may be due to the formation of non-
chromorphic degradants or degradants with different λmax in comparison to the parent 
compound. These results were similar to the reported  photodegradation studies of MTZ and 
RTD respectively [14,111]. 
 
I II III 
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2.6 CONCLUSIONS 
 
The use of an appropriate and validated analytical technique is essential for the generation of 
reliable data in the analysis of raw materials, intermediate and finished pharmaceutical 
products. A suitable analytical method must ensure that the compound(s) of interest is well 
resolved and free from interference from excipients used in the formulation and the IS. A 
successful chromatographic resolution is dependent on a variety of factors and these include 
suitable column and mobile phase composition, buffer concentration and pH, flow rate and 
temperature.   
 
An HPLC method has been developed that has the necessary specificity, precision and 
accuracy for the simultaneous assessment of RTD and MTZ. The method was found to be 
linear within the range of 2.5–20 µg/ml and 1–8 µg/ml for MTZ and RTD respectively and 
the coefficient of determination of 0.9995 for both compounds viz. MTZ and RTD. 
Furthermore the method can also be used for the assessment of individual compounds in solid 
dosage forms and raw materials. In addition the separation of degradation products of the two 
compounds has been achieved using the same chromatographic conditions. 
 
Furthermore MTZ and RTD can be used as an IS for the analysis of the other compound in 
analyses with analytical run times of <10 min. 
 
The method is stability indicating, however additional instrumentation such as mass 
spectrometer and photodiode array detection must be used in order to detect and identify 
more degradation products.  
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 CHAPTER THREE 
PREFORMULATION AND POWDER ASSESSMENT  
 
3.1 INTRODUCTION 
 
Pharmaceutical dosage forms are usually mixtures of several excipients that are included in a 
formulation to facilitate the manufacturing process and ensure drug delivery to the systemic 
circulation. The mode of action of excipients is fairly well understood, however each 
excipient has a specific function(s) in a formulation and together they ensure optimal dosage 
form performance. The choice and use of an excipient in a dosage form depends on the type 
of dosage form to be produced and on the physiochemical and mechanical properties of the 
API. The preferred choice of an excipient(s) depends on the experience of a formulation 
scientist and access to relevant scientific data that describe the effect(s) of the excipient(s) in 
a formulation. The data that describes the effect of excipient(s) on a formulation is usually 
obtained from a series of tests or studies performed on the excipients with and without the 
API. These studies that are used to characterize the physiochemical and mechanical 
properties of an API and the excipients are known as preformulation studies [135]. 
 
Preformulation studies gained popularity in the 1950s where the use of this approach was 
aimed at reducing the trial and error approach that had to that point been used in the design of 
formulations. In the pharmaceutical industry, preformulation studies is a multidisciplinary 
study approach that involves different research teams in the areas of quality control, basic 
pharmaceutics, dosage form development and analytical research, amongst others [136,137]. 
 
There are myriads of tests that are performed during preformulation studies, however, 
commonly performed evaluations include but are not limited to establishing the pKa, particle 
size, aqueous solubility, pH solubility profile, dissolution rate of pure drug substance 
(intrinsic dissolution), polymorphism and excipient compatibility with the chemical moiety.  
 
RTD and MTZ have been used for the clinical management of different pathological 
conditions as mentioned in § 1.2.1.9.2 and § 1.2.2.8.4 respectively and the physiochemical 
properties have been described in Chapter One vide infra. Preformulation data for RTD and 
MTZ has also been well documented [8,42]. In this chapter, the influences of the molecular 
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properties and the physiochemical properties of these API and excipients on tablet dosage 
form development are discussed. 
 
3.1.1 Physiochemical properties 
 
3.1.1.1 Particle size and shape 
 
The content uniformity of tablets is markedly influenced by the particle size and shape of an 
API and excipients. For a low dose formulation, the attainment of blend homogeneity can be 
a particularly challenging issue. Spherical particles have a low contact surface area in 
comparison to acicular or prism shaped materials and consequently they pose fewer mixing 
problems compared to the alternate shaped materials. Spherical particles have better flow 
properties resulting in minimal weight variation of tablets during compression. However, the 
concept of blend homogeneity and powder flow properties does not entirely depend on 
particle shape: other factors such as particle density, surface and size have been reported to 
exert significant effects [138,139].    
 
Particle size has a significant influence on the dissolution rate of a material. Small particles 
exhibit better dissolution rates than larger particles as a consequence of their larger apparent 
surface area. The effect of surface area on dissolution rate has been documented [140] and the 
interrelation of other contributing factors on the dissolution rate can be described 
mathematically using Equation 3.1.  
 
  
  
     
 
 
  
      
 
                                                     Equation 3.1 
Where  
 
  
  
 = Dissolution rate 
A = Surface area of the dissolving particles 
D= Diffusion coefficient of the solute 
h = Hydrodynamic layer thickness 
Cs= Equilibrium solubility 
C = Solute concentration in the bulk of the solution 
V = Volume of medium 
 
It is evident that an increase in the surface area of the particles results in an increase in the 
dissolution rate (Equation 3.1), however increased surface area can cause blend 
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heterogeneity. Mixing properties of powders may be compromised as the particle size 
decreases since smaller particles have the potential to acquire a surface charge and 
consequently adhere to particles that have an opposite charge on their surfaces. In addition, 
segregation with a consequence of poor blend uniformity is inevitable when powders of 
different particles sizes are blended [141]. Therefore the determination of the properties of 
powders and particles provides preliminary data that can be used to guide a formulation 
scientist during the selection of an appropriate manufacturing method. Nonetheless the choice 
of a manufacturing process should take into account the molecular and physiochemical 
properties of a drug substance and potential excipients to be used since the selection of an 
inappropriate manufacturing process may alter the molecular and physiochemical properties 
of the drug and/or excipient(s) [142]. A summary describing the effects of manufacturing 
processes on drug molecular properties is described in Table 3.1.  
 
Table 3.1 The effect of manufacturing processes on molecular properties of drugs. Adapted and 
modified from [135].  
Processing step Purpose of step  Possible solid-state 
transformation 
Implication on tablet 
formulation 
Milling Size reduction; to 
improve powder flow and 
content uniformity 
Polymorphic conversion, 
dehydration, amorphous 
phase transformation 
 
Chemical stability, 
dissolution rate and 
bioavailability. 
Roller compaction Dry granulation, size 
increase; to improve 
powder flow and content 
uniformity  
Polymorphic conversion, 
dehydration and 
amorphous phase 
transformation 
 
Chemical stability, 
dissolution rate and 
bioavailability. 
Wet massing Wet granulation, size 
increase to improve 
powder flow and content 
uniformity 
Polymorphic conversion, 
hydrate formation, salt to 
free acid/base conversion; 
amorphous phase 
transformation 
Chemical and physical 
stability and dissolution 
rate 
 
3.1.1.2 Powder density 
 
In formulation development the density of individual powder components and blends may 
contribute to the behavioural characteristics of the material during the manufacturing process. 
The compressibility, compactability and flow properties of powders depend on or are closely 
associated with the density of the individual material or its behaviour when placed in a 
mixture [138,139]. The determination of the density of powders is a complicated procedure 
due to the nature of the material being evaluated. Powders are comprised of an infinite 
number of discrete particles that impart different types of density to a material, depending on 
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the equipment and conditions used for the evaluation process. However, in solid dosage form 
development the true, bulk and tapped densities of powders are the most important 
characteristics that must be evaluated. 
 
3.1.1.2.1 Bulk density 
 
The bulk density of a powder is the ratio of the mass of that powder to the volume that the 
mass of powder occupies. The volume of the powder includes the interparticle volume and 
envelope volume of the particles of the powder [143,144]. The bulk density of a powder has 
often been thought to have a direct relationship to the flowability of the material. However 
the inter-particulate interaction that influences the bulk properties of a powder are the same 
interactions that interfere with the flow properties of the material [145]. Therefore the 
determination of the bulk density of a powder provides valuable information pertaining to 
equipment requirements with respect to fill capacity of the equipment required for a 
particular method of manufacture [143]. In addition the bulk density of the powder is usually 
used to establish Carr’s Index (CI) that describes the flow properties of a powder system. The 
interpretations of CI values are described in Table 3.2. 
 
Table 3.2 Interpretation of Carr’s index values 
Carr’s index (%) Flow 
  5 – 15 Excellent 
12 – 16 Good 
18 – 21 Fair  
23 – 35 Poor 
33 – 38 Very poor 
> 40 Very very poor 
 
3.1.1.2.2 Tapped density 
 
The tapped density of a powder is in effect the bulk density of a powder that is established 
after tapping or vibrating the powder in a specific manner for a period of time. Different 
types of instruments can be used to determine the tapped density of powders; they exhibit 
similarity in that the use of a fixed weight or volume of powder for the determination of 
tapped density is required. A given mass or volume of powder is dropped (tapped) from a set 
distance at a specified frequency for a fixed period of time until the equilibrium volume of 
the powder is reached, and the tapped density is then calculated mathematically [143]. The 
relationship between bulk density and tapped density of powders provides useful information 
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relating to properties of the powders such as flowability and compactability. Materials with a 
high compressibility value exhibit poor flow properties and vice versa [146,147]. The 
Hausner ratio (HR), that is, the ratio of tapped bulk density and aerated bulk density, provides 
information that describes the relationship between the cohesiveness of powder particles and 
powder flowability. Powders with a HR  ≥ 1.4 are considered to be cohesive and difficult to 
fluidize and those with ratios ≤ 1.25 are characterized as free flowing [144,148]. 
 
3.1.1.2.3  True density 
 
The true density of a substance is the average mass per unit volume of that material with all 
voids that are not a fundamental part of the molecular packing arrangement having been 
excluded [139]. The true density of powders translates to the average mass per unit volume of 
a unit powder particle, and is a critical parameter in the characterization of the mechanical 
properties, porosity and fluidization characteristics of a powder. The true density of powders 
has been used to calculate the porosity of a tablet on which tablet hardness and strength are 
dependent [139,149]. There are a variety of ways to determine the true density of powders, 
however, helium pycnometry is a commonly used method despite its lack of accuracy in 
samples containing loosely bound solvents [139,149]. In addition the mass of a powder 
compact has also been used to establish the true density of materials [150].    
 
3.1.2 Molecular properties of powders 
 
3.1.2.1 Polymorphism and solvatomorphism 
 
It is not uncommon for organic compounds to exhibit the same elemental composition in 
different crystalline structures and hydration states. Compounds exhibiting these properties 
are considered to be polymorphs and this phenomenon is defined as polymorphism [151]. In 
addition, the solvation or hydration state of different crystal forms of a material may differ 
and the existence of crystal forms with different hydration states is defined as 
solvatomorphism [151-153]. 
 
The presence of polymorphs and solvatomorphs may have a significant effect on the solid 
state properties of a particular system in which the material is located. Different crystal forms 
of a compound may exhibit different solubilities, intrinsic dissolution rates and sometimes 
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different bioavailabilities [151]. Furthermore, different crystal forms of a solid system may 
exhibit different stability in a formulation and consequently behave differently during 
manufacture [151,154,155]. 
 
The identification of polymorphs and solvatomorphs of a compound is usually achieved using 
X-Ray Powder Diffraction (XRPD) in combination with other techniques. The techniques 
that are commonly used include polarizing light microscopy, differential scanning 
calorimetry (DSC) and thermogravimetric analysis (TGA), solid-state vibrational 
spectroscopy and/or solid-state NMR spectrometry [151].  IR spectroscopy also has been 
used for identification of polymorphic forms of materials [154].  
 
RTD has been reported to exist in two major polymorphic forms, viz. polymorph 1 and 
polymorph 2, in addition to pseudo-polymorphic forms [8,9,153,155]. Despite the differences 
in aqueous solubility, physical stability and melting point, the two polymorphs are 
therapeutically equivalent and both are used in the manufacture of commercial formulations 
[156]. The two forms have been reported to undergo inter-conversion during certain 
manufacturing processes and under specific storage conditions [154]. Form 2 is the most 
stable polymorph of RTD and the two forms of RTD have been distinguished by IR 
spectroscopy [8].  
 
The use of thermal analytical techniques to elucidate the properties of a compound is well 
known and, in such methods, materials are subjected to linear increases in temperature 
applied from an external source whilst evaluating heat flow (DSC) or weight change (TGA) 
continuously as analysis takes place [151,157]. Thermal analysis has been used for more than 
eleven decades in different disciplines for a variety of purposes that are listed in Table 3.4 In 
the pharmaceutical industry interest in the use of thermal analysis commenced during the 
1960s [157]. 
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Table 3.3  Applications of thermal analysis. Adapted from [158] 
Application field Applied techniques 
Forming reaction and its kinetics Thremogravimetry (TG), differential thermal analysis 
(DTA), evolve gas analysis (EGA), microscopic 
observation, emanation thermal analysis 
 
Crystalline transition DTA, thermo-dilatometry 
 
Melting and glass transition DTA, microscopic observation 
 
Oxygen content TG (Temperature program reduction) EGA 
 
Non-stoichiometry TG, EGA, temperature program reduction 
 
Sintering and crack formation Thermodilatometry 
 
Matching of thermal expansion in thin-film formation 
 
Thermodilatometry 
Critical temperature Thermo-electrometry 
 
Phase diagram for single-crystal formation DTA 
 
Vapour pressure and volatilization for metal organic 
chemical vapour deposition 
 
TG, EGA, evolve gas detection (EGD) 
Heat capacity Differential scanning calorimetry (DSC) 
 
In addition to the identification of polymorphs and solvatomorphs of drug substances, 
thermal analysis (DSC) has often been used to establish the purity of compounds. The 
differences in behaviour of eutectic mixtures of a drug substance and/or excipient and its 
impurities form the foundation for the assessment of purity [151,157]. The prediction of 
potential interactions and instability of an API during manufacturing has also been performed 
using thermal analysis [157]. Thermal analysis has proven to be a vital tool in screening for 
API excipient incompatibilities [157,159] and the detection of a physical changes in a dosage 
form such as the conversion of a molecule from the anhydrous to hydrous state, for example 
anhydrous lactose to lactose monohydrate [157]. 
 
The thermal stability of RTD polymorphs has been studied [153,160]. Polymorph 2 degrades 
at 156
°
C whereas polymorph 1 undergoes degradation at 166
º
C [8,160]. MTZ does not 
exhibit polymorphism and therefore it poses fewer challenges in formulation development 
than RTD. The determination of the thermal stability of a drug substance provides useful 
information that can guide the formulation scientist in the selection of a suitable method of 
manufacture and formulation composition. 
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3.1.3 Drug-excipient compatibility 
 
Excipients have been described as inert components of a formulation that are added to APIs 
to facilitate the production of dosage forms, enhance drug stability and absorption and to 
improve taste and other sensory requirements for the patient. However, reports on 
interactions between API and excipients are abundant [161-163] and excipients are better 
defined as enabling rather than inert substances [159]. The interaction between drug and 
excipients may be classified as physical, chemical, and/or physiological or biopharmaceutical 
that may be either beneficial or detrimental [142,159,164].  
 
3.1.3.1 Beneficial drug-excipient interactions 
 
Beneficial drug-excipient interactions have been used to facilitate the manufacturing of drug 
delivery technologies. Such interactions include, for example, the addition of magnesium 
stearate to powder blends for lubrication purposes. Magnesium stearate is a fine powder that 
is hydrophobic in nature and adheres to the surfaces of equipment and powders during 
blending. However, excessive blending following addition of magnesium stearate is not 
recommended since it results in abrasion of the magnesium stearate particles with a 
consequent increase in surface coverage of the blend, leading to poor tablet performance and 
drug dissolution [159,164]. 
 
Another example of a beneficial interaction occurs in certain dry powder inhalers and 
explores the differences in particle size between the drug and excipient to facilitate drug 
delivery. A carrier material, usually lactose, is used to facilitate delivery of small API of     
2.9 µm mean diameter into deep tissues of the lung [165,166]. This delivery technology uses 
the variation in air velocity and relative humidity, amongst other factors, to facilitate and 
dislodge the drug particle from the carrier in order to deposit the API in the alveolar regions 
of the lungs [165,167]. 
 
Aqueous pharmaceutical preparations such as liquids and semi-solids are usually susceptible 
to microbial degradation unless preservatives are incorporated into the formulations. 
Penetration enhancers such as laurocapram, cylcodextrins and a variety of encapsulating 
systems have been used in transdermal products to promote drug delivery in the systemic 
circulation [164,168]. The interaction between sodium bicarbonate and citric acid in an 
  
63 | P a g e  
 
aqueous environment has been explored to facilitate the disintegration of tablets through the 
use of effervescence [164,169]. 
 
3.1.3.2 Detrimental drug-excipient interactions 
 
Detrimental interactions between API and excipients include the commonly occurring 
Maillard reaction [170]. Compounds with a primary amine interact with the glycosidic 
hydroxyl group of a reducing sugar resulting in the formation of an imine and ultimately an 
amadori compound that has a characteristic yellow-brown colour. Several factors such as 
water activity, heating time and temperature, oxygen, light, presence of metal ions, pH and  
the type and the concentration of buffer have been reported to catalyse this reaction 
[164,171,172]. Nonetheless the Maillard reaction is not limited to primary amines only and 
secondary amines also undergo this reaction without the yellow-brown discolouration as the 
reaction does not proceed to the formation of an amadori compound in these cases [164]. 
 
Acetylsalicylic acid is an ester drug that is susceptible to hydrolysis in the presence of 
alkaline metal or earth salts. The degradation of acetylsalicylic acid in a suspension 
containing magnesium stearate was attributed to the alkaline environment that is formed 
following the formation of a buffer system comprised of the magnesium stearate 
acetylsalicylic acid salt and acetylsalicylic acid [164,173]. 
 
Primary amines may also undergo a reaction analogous to the Michael addition reaction with 
excipients that contain α-β unsaturated ketone [174] such as sodium stearyl fumarate and 
sorbitan monooleate. Such reactions have also been reported between flovoxamine maleate 
and maleic acid counter ions [164].  
 
A further detrimental interaction occurs due to proximity between a heteroatom and active 
hydrogen resulting in the formation of lactones in benezapril molecule. Oxidative interactions 
between atovarstatin, cytidine nucleoside analogues and fumed metal oxides of silica, titania 
or zicornia have also been reported [164]. 
 
These examples of drug-excipient interactions are just a few of many that have been reported. 
For a new drug molecule, drug-excipient interaction data must be generated and screening for 
drug/excipient compatibilities constitutes an important part of preformulation studies 
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[164,175]. Well-known molecules have, on the other hand, been investigated, but due to 
differences in environmental conditions and synthetic procedures for an API, may behave 
differently necessitating the drug-excipient compatibility testing. Screening for excipient 
compatibility provides the formulation scientist with useful information pertaining to the 
suitability of excipients(s) that may be included in a formulation of a specific drug [164,175]. 
 
There are several techniques that may be used to screen materials for potential drug-excipient 
incompatibility. However, thermal techniques such as isothermal stress testing (IST) and 
DSC are frequently used although FT-IR spectroscopy  has also been successfully applied to 
screening for physical or chemical reactions associated with drug-excipient interactions 
[164,176,177]. IR spectroscopy analysis results in the generation of peaks due to bending, 
stretching, twisting, wagging, rocking  and scissoring (vibration) of the bonds in a molecule  
[178]. Furthermore each functional group in the molecule has a specific vibrational frequency 
and therefore the appearance of a peak at particular vibrational frequency is an indication of a 
presence of a particular functional group in the molecule and vice versa [178,179]. Therefore 
this property of specificity in vibrational frequency constitutes the basis for detecting 
potential drug-excipient incompatibility. 
 
3.2 METHODS 
 
3.2.1 SEM 
 
The determination of particle size and morphology was performed using a Vega
©
 Scanning 
Electron Microscope (Tescan, Vega LMU, Czechoslovakia Republic). Small amounts of 
MTZ, RTD, microcrystalline cellulose (MCC) pH 102 and dibasic calcium phosphate (DCP) 
were dusted onto a graphite plate separately after which gold coating was applied for 20 min 
under vacuum. The samples were visualized using SEM at an accelerated voltage of 20 kV. 
 
3.2.2 Powder density 
 
The tapped density of the materials was determined using a Model SVM 203 (Erweka 
GmbH, Heuseastamm, Germany) at rate of 220 taps per minute for 2 min. Approximately   
10 g of MTZ, RTD, MCC and DCP were passed separately through a 850 µm sieve and filled 
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into individual tarred 100 ml graduated measuring cylinders. The bulk and tapped volume Vbk 
and Vtp were established. The test was performed in triplicate for each material investigated. 
The bulk density and the tapped density were calculated using Equation 3.2 and the powder 
porosity (ε), CI and HR were calculated using Equations 3.3, 3.4 and 3.5 respectively. 
 
  
 
 
      Equation 3.2 
Where,  
m = mass 
v  = volume 
ρ  = true density 
ρbk= bulk density where v = Vbk 
ρtp= tapped density where v = Vtp 
 
      
   
 
                                          Equation 3.3 
 
     
         
   
                                       Equation 3.4                                                         
                                                    
   
   
   
                                                       Equation 3.5  
Where, 
ɛ    = Powder porosity 
CI  = Carr’s index 
HR = Hausner ratio 
 
The true density was established using a compacted mass of the powder. MTZ, RTD, MCC 
and DCP were separately filled manually into the dies and compressed to a steady state 
compact mass of 400 mg tablets using Manesty
®
 B3B rotary tablet press (Manesty, 
Knowsley, Merseyside, England) fitted with six 12.00 mm flat punches that was operated 
manually. The true density of each material was calculated from the average weight and 
volume of the respective tablets (n=6) using the Equation 3.2. 
 
3.2.3 IR spectroscopy 
 
The IR spectra of individual components and 1:1 mixture of API and excipients viz. MCC, 
DCP, sodium starch glycolate (SSG), corscarmellos sodium (CCS), povidone-K30 (PVP-
K30) and magnesium stearate were generated using a Spectrum 100 FT-IR ATR 
Spectrophotometer (Perkin Elmer
® 
Ltd Beaconsfield, England). The powders were prepared 
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by mixing the components using a mortar and pestle. A small amount of the powder blend 
was placed on the diamond crystal and analyzed (n=4 scans) between 4000-650 cm
-1
 wave 
number range
 
and resolution of 4 cm
-1
. 
 
3.2.4 Thermogravimetric analysis 
 
TGA was performed using a Model TGA 7 Thermogravimetric analyzer                       
(Perkin Elmer 
®
Norwalk, Conneticut, USA). Approximately 1 mg of each material was used 
and the measurements were performed in a nitrogen atmosphere at a flow rate 20 ml/min in a 
temperature range of 30
°
C to 200
°
C and 70
°
C to 220
°
C for RTD and MTZ respectively. The 
heating rate was set at 10
°
C/min.  
 
3.2.5 DSC 
 
Approximately 3 mg samples of the individual components and mixtures of API and 
excipient in a binary 1:1 mixture were used for DSC analyses. The DSC scans were generated 
between 25-350
°
C using a Model DSC 7 (Perkin Elmer
®
, Norwalk, Connecticut, USA) with 
equipment and PC control unit TAC 7 (Perkin Elmer
®
, Norwalk, Connecticut, USA) at a 
heating rate of 10
°
C/min and nitrogen at a flow rate of 20 ml/min. Data analysis was 
performed using Pyris™ Manager software.  
 
3.3 RESULTS AND DISCUSSION 
 
3.3.1 SEM 
 
SEM images depicting the particle morphology and sizes of RTD, MTZ, DCP, and MCC are 
shown in Figures 3.1 and 3.2 respectively.  
 
SEM images of RTD dry powder reveal the presence of sub-angular particles of medium 
sphericity (Figure 3.1 I) as reported [180] with  equivalent spherical diameters of between 
317.22 µm and 554.70 µm as shown in Figure 3.2 I. MTZ was shown to exist as prism 
(polyhedral) shaped particles (Figure 3.1 II) with the width of the particles (Feret’s diameter) 
ranging between 90.29 µm and 539.16 µm as shown in Figure 3.2 II, and the polyhedral 
particle morphology is indicative that butanol was the recrystallization medium [181]. DCP 
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and MCC exhibited particles of high sphericity and angular with medium sphericity 
respectively as shown in Figures 3.1 III and IV.  DCP exhibits better flowability and has 
smoother particles compared to MCC [182-186].  
 
                  
I                                                                         II 
 
                        
III                                                                           IV 
 
Figure 3.1 Typical SEM showing particle morphology of RTD (I); MTZ (II); DCP (III) and MCC 
(IV)  
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    I                                                                 II 
 
 
                           
 
    III                                                                             IV 
 
Figure 3.2 Typical SEM image showing the particle size range of RTD (I), MTZ (II), DCP (III) and 
MCC (IV) 
 
As can be seen in the SEM images MTZ powder may exhibit poor flow properties as a 
consequence of the shape and wide particle size distribution of the powder, therefore to 
improve flowability and subsequent manufacture, particle size reduction may be considered 
as a means for improvement of particle sphericity and size distribution. RTD exists as large 
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particles but with better sphericity, therefore particle size reduction may also be useful for the 
prevention of blend segregation as a consequence of particle size distribution differences. 
 
The SEM images of DCP and MCC depict that both excipients exhibit similar particle size as 
seen in Figures 3.2 III and IV. This similarity is likely to facilitate the comparison of the 
physiochemical properties of the resultant tablets and consequently selection of an 
appropriate excipient for future optimization studies.   
 
3.3.2 Powder density 
 
3.3.2.1 True density 
 
A summary of the reported and actual true density values determined in these studies are 
summarized in Table 3.4. The true density determined using the compacted mass of 
respective powders was in disagreement with those reported and that are usually established 
using helium pycnometry. This may be attributed to the use of different instrumentation or 
material characteristics that are a consequence of differences in the synthetic processes used 
to manufacture the API.   
 
Table 3.4 True density values for raw materials 
Raw material Actual value (g/ml) Literature value 
(g/ml) 
Reference  
RTD 1.23 Not stated  
MTZ 1.32 1.44-1.52  [181,188] 
DCP 2.17 2.35 [182,189,190] 
MCC 1.36 1.41-1.66  [182,187,190-192] 
 
The true density of powders provides useful information that can be used for characterization 
of the mechanical properties of powders on which tablet hardness, tensile strength and elastic 
modulus are dependent [139]. The true density was used for determination of the porosity of 
the powders in which the compressibility of the powder material is dependent.  
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3.3.2.2 Bulk and tapped density 
 
The bulk and tapped density of RTD, MTZ, DCP and MCC are summarized in Table 3.5.  
 
Table 3.5 A list of raw materials bulk and tapped density values 
Material Bulk density Tapped density 
 Actual  
(g/ml) 
Literature 
(g/ml) 
Reference Actual 
(g/ml) 
Literature 
(g/ml) 
Reference 
RTD 0.55 0.68  [193] 0.76±0.012 Not stated  
MTZ 0.72 0.60  [181] 0.86±0.001 0.81  [181] 
DCP 1.05 0.94  [182,189,190] 1.19±0.008 1.10 [182,190] 
MCC 0.35 0.36  [182,190,192] 0.46±0.004 0.41  [182,190,192] 
 
The values for CI and HR of MCC shown in Table 3.6 indicate that MCC has good 
compressibility and flow properties compared to DCP. This may be due to irregular shape of 
the MCC particles compared to particles of DCP.  
 
Table 3.6 Powder porosity, Carr’s Indices and Haussner Ratios for raw materials  
Material CI HR Powder porosity (%) 
RTD 27.63 1.38 38.21 
MTZ 25.92 1.35 34.84 
DCP 14.54 1.17 45.16 
MCC 12.19 1.12 66.17 
 
Spherical particles exhibit poor compressibility properties in comparison to irregularly 
shaped particles [194]. Spherical particles give rise to symmetrically opposite forces on 
particle contact points on compression, and consequently compressive deformation of 
particles results. However, unlike spherical particles, irregular particles develop asymmetrical 
opposite forces that lead to shear deformation [194]. Although the HR value indicates that 
MCC may exhibit better flow properties than DCP, previous studies indicate that DCP 
exhibits better flow properties [182]. The apparent difference in the results may be attributed 
to hygroscopic properties of MCC since it absorbs moisture from the atmosphere, resulting in 
an initial increase in the true density of the material followed by a decrease in the true density 
of the material, ultimately affecting the bulk and tapped density and HR for this powder 
[191].  
 
It is evident that MCC is the most porous of the materials tested and consequently more 
compressible than DCP, as shown in Table 3.6. These results indicate that blends produced 
with MCC may exhibit better compressibility compared to those produced using DCP as a 
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diluent. Similar results were also observed following investigation of the tableting behaviour 
of pellets comprised of DCP and MCC in different compositions [195]. 
 
3.3.3 Polymorphism 
 
The occurrence of the two polymorphs of RTD is a result of the space orientation, viz. 
cis/trans of  the methylamine and nitro group in the molecule, and is also dependant on the 
polarity of the recrystallization solvent used during the manufacture of the raw material 
[153,196]. Less polar or non-polar crystallization solvents favour the formation of polymorph 
1, whereas polymorph 2 is the major end product when polar crystallization solvents are used 
[196-198]. 
 
Polymorph 2 of RTD has a characteristic absorption band at 1045 cm
-1 
and polymorph 1 
exhibits a band at wave number of 1551 cm
-1 
[153].  
 
The infrared absorption scan of RTD depicted in Figure 3.3 shows the characteristic 
absorption band at 1045 cm
-1
 which suggests that this RTD sample is comprised primarily of 
polymorph 2. 
 
 
Figure 3.3 Typical IR spectrum of RTD generated at 4 scans and 4cm
-1
 resolution 
 
The differences in intramolecular hydrogen bonds determine the occurrence of the 
characteristic absorption bands for each polymorph [153,196]. Polymorph 1 has strong 
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intramolecular hydrogen bonds compared to polymorph 2. The low water content of a less 
polar solvent used during crystallization favours the formation of intramolecular hydrogen 
bonds, whereas the presence of water in polar solvents favours the formation of both 
intramolecular and intermolecular hydrogen bonds. As a result, weak intramolecular 
hydrogen bonds with low vibrational frequency (1045 cm
-1
) are formed in polar solvents 
[153,196]. These findings were confirmed using DSC analyses of  the RTD samples  and the 
DSC thermogram depicts a melting point of 147.83
°
C which is in close agreement with that 
of 145.3
°
C [160]. 
 
3.3.4 Thermogravimetric analysis 
 
The thermogram depicted in Figure 3.4, generated following TGA of RTD, indicates that the 
drug is stable to approximately 153
°
C followed by 20% decomposition at 200
°
C.  
 
 
Figure 3.4 A typical TGA plot of RTD at 10
°
C/min heating rate 
 
This value is in slight disagreement to the previously reported decomposition temperature of 
156
°
C [160]. The difference in degradation temperature between the experimental and 
reported values may be due to the use of different synthetic pathways in drug synthesis and 
may perhaps be due to difference in instrumentation. Therefore since RTD exhibits thermo 
stability up to 153
°C it may be inferred that the “normal” temperature range, viz. 50-80°C, 
used during manufacturing processes would have a negligible effect on the stability of RTD. 
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The thermogravimetric analysis curve for MTZ depicts a 2.76% decrease in weight of the 
drug following heating from 80
°
C to approximately 162
°
C that may be a consequence of 
dehydration. Following dehydration there is a drastic decline in the curve up to a temperature 
of 209
°
C that correlates with 97.22% loss in weight of the drug as a result of degradation as 
shown in Figure 3.5. Similar results were observed following heating of MTZ to 900
°
C 
[199,200].   
 
 
Figure 3.5 A typical TGA plot of MTZ at 10
°
C/min heating rate 
 
3.3.5 DSC 
 
 MTZ and RTD exhibit melting endotherm peaks at 161.5
°C (ΔH= 171.7437 J/g) Figure 3.6 I 
and 147.83
°C (ΔH= 102.8577 J/g) Figure 3.6 II respectively with an evaporation endotherm 
peak for MTZ at 273.67
°
C.  
 
These results are in close agreement with the previously reported analyses by Kiss et al. 
[201,202] and Mimehrabi et al. [153] following thermal analysis of MTZ and RTD 
respectively. However, in this study RTD exhibited a higher melting point compared to the 
reported 137.8
°
C [153] but is in close agreement to that of 145.3
°
C [8,160]. Thus the melting 
point exhibited by RTD suggests that the sample is primarily made up of polymorph 2. 
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Figure 3.6 Typical DSC thermograms of MTZ (I) RTD (II) and binary mixture of MTZ and RTD 
(III) at a heating rate of 10
°
C/min
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The thermogram for a binary mixture of RTD and MTZ depicts a broad endotherm peak at 
137
°
C and none reflecting the endotherm for MTZ or RTD at 161.5
°
C and 147.83
°
C 
respectively (Figure 3.6 III). This suggests that RTD and MTZ exhibit an interaction at high 
temperature that results in the formation of a eutectic mixture. However the IR scan of the 
binary mixture of these compounds depicts the characteristic bands of both drugs as 
described in § 3.3.6. Therefore, due to the evidence of a potential interaction using thermal 
analysis, long term stability testing may be necessary for dosage forms in which therapeutic 
amounts of MTZ and RTD are included. 
 
 DCP exhibited a melting endotherm at 194
°C (ΔH=436.3717 J/g) as shown in Figure 3.7 and 
this may be attributed to the loss of water of crystallization. DCP loses water of 
crystallization in two stages, viz. between 120-160
°
C and between 250-300
°
C, that correlates 
with the loss of 0.5 and 1.5 moles of crystalline water respectively [201].  
 
 
Figure 3.7 A typical DSC thermogram of DCP at a heating rate of 10
°
C/min 
 
Similarly, thermograms of MCC, PVP-K30, SSG and CCS reveal no significant thermal 
events for the temperature ranges scanned in Figures 3.8-3.11. 
 
 
Figure 3.8 A typical DSC thermogram of MCC at a heating rate of 10
°
C/min 
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Figure 3.9 A typical DSC thermogram of PVP-K30 at a heating rate of 10
°
C/min 
 
 
Figure 3.10 A typical DSC thermogram of SSG at a heating rate of 10
°
C/min 
 
 
Figure 3.11 A typical DSC thermogram of CCS at a heating rate of 10
°
C/min 
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The thermogram of a binary mixture of MTZ and DCP depicted in Figure 3.12 reveals one 
endotherm peak at temperature of 161.37
°
C which is due to the melting of MTZ, and the 
endotherm peak due to loss of crystalline water by DCP is not present. 
 
 
Figure 3.12 A typical binary mixture DSC thermogram of MTZ and DCP at a heating rate of 
10
°
C/min 
 
This suggests an interaction between the two compounds, and incompatibility between MTZ 
and other pharmaceutical excipients has been reported [201]. However the IR scan of a 
binary mixture of MTZ and DCP did not indicate a potential incompatibility since the 
characteristic peaks for both compounds were evident. This suggests exposure to a high 
temperature facilitates an interaction between MTZ and DCP.  
 
The thermogram for the mixture of MTZ and MCC revealed a slight increase in the melting 
temperature for MTZ as depicted in Figure 3.13. The 1.3
°
C increase in the melting point of 
MTZ may be attributed to the shielding effect of MCC on MTZ. It has been reported that a 
3
°
C increase in the melting point temperature of MTZ was observed following thermal 
compatibility studies of nitroimidazole and pharmaceutical excipients [203]. 
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Figure 3.13 A typical binary mixture DSC thermogram of MTZ and MCC at a heating rate of 
10
°
C/min 
 
The analysis of a binary mixture of MTZ and PVP-K30 shown in Figure 3.14 exhibited an 
insignificant change in the melting temperature of MTZ, however the decomposition 
endotherm peak of MTZ between 250-300
°
C occurred in triplet in comparison to the singlet 
observed in the pure component. This may be attributed to the shielding effect of PVP-K30 
on MTZ although this is not as effective as that observed for MCC and DCP. 
 
 
Figure 3.14 A typical DSC thermogram for binary mixture of MTZ and PVP-K30 at a heating rate of 
10
°
C/min 
 
A slight change in the melting temperature of RTD was observed in binary mixtures 
comprised of RTD: MCC (Figure 3.15), RTD:DCP (Figure 3.16) and RTD: PVP-K30 (Figure 
3.17). 
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Figure 3.15 A typical binary mixture DSC thermogram of RTD and MCC at a heating rate of 
10
°
C/min 
 
 
Figure 3.16 A typical binary mixture DSC thermogram of RTD and DCP at a heating rate of 
10
°
C/min 
 
 
 
Figure 3.17 A typical DSC thermogram of binary mixture of RTD and PVP-K30 at a heating rate of 
10
°
C/min 
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However, these changes were not significant and did not support a conclusion relating to the 
presence of incompatibilities. Furthermore, the  broad melting endotherm observed for RTD 
in all binary mixtures may be attributed to the low sample mass and a change in reaction 
kinetics as consequence of the dilution effect of the excipients. It has been reported that 
sample mass, heating rate and reaction enthalpy significantly affect the peak height in DSC 
analyses [204].  
 
With the exception of the binary mixture of MTZ:magnesium stearate that exhibited a 3.2
°
C 
increase in the melting temperature of MTZ (Figure 3.18), similar results to other binary 
mixtures with  RTD were observed for RTD:magnesium stearate mixture as depicted in 
Figure 3.19.  
 
 
Figure 3.18 A typical DSC thermogram for a binary mixture of MTZ and magnesium stearate at a 
heating rate of 10
°
C/min 
 
 
Figure 3.19 A typical binary DSC thermogram of a binary mixture of RTD and magnesium stearate at 
a heating rate of 10
°
C/min 
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DSC analyses of the mixtures comprised of drug substance and MCC in combination with all 
excipients revealed two endotherms at 142.87
°
C and 160.2
°
C which may be due to the 
melting of RTD and MTZ respectively (Figure 3.20). However no significant thermal activity 
was noted in their respective counterpart mixture of DCP as depicted in Figure 3.21. This 
may be attributed to shielding and dilution effect of the excipients on each other and on MTZ 
and RTD. 
 
 
Figure 3.20 A typical DSC thermogram of MCC, MTZ and RTD in combination with all excipients 
at heating rate of 10
°
C/min 
 
 
Figure 3.21 A typical DSC thermogram of DCP, MTZ and RTD in combination with all excipients at 
heating rate of 10
°
C/min
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3.3.6 IR spectroscopy 
 
The absorption band frequencies used for the interpretation of the IR spectra are described in 
Table 3.3 and  have been reported [8,205]. 
 
Table 3.3 IR absorption band assignments. Adapted and modified from [8,205]. 
Wave number (cm
-1
) Group assignment 
3100-3260 NH and OH stretch 
3105 C=CH; C-H stretch 
3017-3066 C-H; stretch furane 
2908-2970 C-H; stretch aliphatic 
2560-2653 H-N+R3; N-H stretch 
1670-1820 C=O 
1500-1620 N-H; bending 
1590 =C-NO2; C-N stretch 
1538, 1350 NO2;N-O stretch 
1570 NH 
1350-1480 C-H; bending  
1380 =C-NO2; C-N stretch; N-O stretch  
1137-1226 C-N stretch 
1078 C-OH; C-O stretch 
760-990 CH 
 
The IR spectrum of a binary mixture of RTD and MTZ depicted in Figure 3.22 III revealed 
the presence of the typical band characteristics for both compounds.  
 
The spectrum showed the tertiary amine N-H stretch absorption band of RTD at 2553
-1
cm as 
well as the hydroxyl band of MTZ at 3201
-1
cm. Furthermore the N-O stretch vibrational 
frequency at 1354
 
cm
-1
 and 1534 cm
-1
 due to the nitro group in MTZ (Figure 3.22 II) was 
clearly visible, indicating the absence of hydrogen bonding interactions. In addition the 
spectrum revealed peaks at 1589 cm
-1
 and 1164 cm
-1
 that are a characteristic of N-H stretch 
and at 1133 cm
-1
 that is a characteristic band of aliphatic C-N stretch absorption. However, 
the intensity of these bands decreased compared to the band intensity of their respective pure 
components (Figure 3.22 I and II) which may be due to the dilution effect that one 
component has on the other.   
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Figure 3.22 Typical IR spectrum of RTD (I), MTZ (II) and binary mixture of RTD and MTZ (III) 
generated at 4 scans and 4 cm
-1
 resolution 
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The IR spectrum of a binary mixture of RTD and PVP-K30 shown in Figure 3.23 II revealed 
characteristic peaks of RTD at 1220 cm
-1
, 1620 cm
-1
 and 2552 cm
-1
 that are due to C-N 
stretch, N-H bending and N-H stretch vibrational frequency. However, the absorption band 
frequency at 1652 cm
-1
 due to ketone group in the PVP-K30 was not present. This may be 
attributed to hydrogen bonding between the carbony-carbon oxygen in PVP-K30 and the 
amine-hydorgen in RTD that resulted in a change in absorption frequency of the ketone group 
from 1652 cm
-1
to 1620 cm
-1
. A close examination of the absorption band at 1620 cm
-1 
in 
Figure 3.23 II, a broad band is observed at the peak base that gradually tapers at the top 
which suggest consolidation of the two absorption bands viz. C=O stretch and N-H stretch as 
shown in the spectrum. As has been reported hydrogen bonding causes redshift in absortion 
frequencies [206]. 
 
 
Figure 3.23 Typical IR spectrum of PVP-K30 (I) and RTD PVP-K30 binary mixture (II) generated at 
4 scans and 4 cm
-1
 resolution 
2947.58
844.28
1420.90
1270.01
1652.00
110
108
106
104
102
100
98
96
94
62
90
88
86
84
82
80
78
%T
112.2
4000 3000 2000 1500 1000 650
76.7
cm-1
94
92
90
88
86
84
82
80
78
76
74
72
70
68
80.6
96.2
4000 3000 2000 1500 1000 650
%T
3191.95
2916.35
2552.33
2459.46
1620.66
1419.23
1194.89
1378.77
1263.87
1220.27
1045.22
992.35
800.25
694.10
760.84
cm-1
II 
I 
  
85 | P a g e  
 
The IR spectra of binary mixtures of MTZ and MCC (Figure 3.24 II) and RTD and MCC 
(Figure 3.24 III) were similar to those of the individual components. However, the O-H 
absorption peak at 3217 cm
-1
 in the binary mixture of MTZ and MCC was slightly broader 
compared to that of pure MTZ and this again may be due to intermolecular hydrogen bonding 
interactions between MTZ and MCC. 
 
Similarly the IR spectrum of a binary mixture of MTZ and DCP (Figure 3.25 II) revealed 
similar absorption peaks to those of the individual components in Figures 3.22 II and Figure 
3.25 I respectively.  However the disappearance of the O-H bending vibrational frequency of 
DCP at 1646 cm
-1
 depicted in Figure 3.25 I was noted in RTD and DCP binary mixture 
spectrum as shown in Figure 3.25 III. The cause for this disappearance could not be 
established since the binary mixture spectrum exhibited all characteristic peaks for RTD 
depicted in Figure 3.22 I. It may be concluded that there is interaction/incompatibility 
between RTD and DCP since the DSC analysis of the same mixture revealed the loss of DCP 
crystalline water at 188.7
°
C for DCP (Figure 3.16) instead of 194.03
°
C (Figure 3.7) that was 
previously recorded for the pure component. 
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Figure 3.24 Typical IR spectra of MCC (I)  MCC MTZ binary mixture (II) and MCC RTD binary 
mixture (III) generated at 4 scans and 4 cm
-1
 resolution 
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Figure 3.25 Typical IR spectrum of DCP (I) MTZ DCP binary mixture (II) and RTD DCP binary 
mixture (III) generated at 4 scans and 4 cm
-1
 resolution 
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The IR spectra of binary mixtures of MTZ and SSG, MTZ and magnesium stearate, and MTZ 
and CCS revealed all the characteristic peaks of MTZ and the respective excipients as 
depicted in Figures 3.26-3.28.  
 
 
Figure 3.26 Typical IR spectrum MTZ and SSG binary mixture generated at 4 scans and 4 cm
-1
 
resolution 
 
 
Figure 3.27 Typical IR spectrum of MTZ and magnesium stearate binary mixture generated at 4 
scans and 4 cm
-1
 resolution  
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Figure 3.28 Typical binary mixture IR spectrum of MTZ and CCS generated at 4 scans and 4 cm
-1
 
resolution 
 
Similarly the IR absorption spectra of binary mixtures of RTD and SSG, RTD and 
magnesium stearate, RTD and CCS shown in Figures 3.29-3.31 revealed all the characteristic 
peaks of the drug and the respective excipients. 
 
 
Figure 3.29 Typical IR spectrum of RTD and SSG binary mixture generated at 4 scans and 4 cm
-1
 
resolution 
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Figure 3.30 Typical IR spectrum of RTD and magnesium stearate binary mixture generated at 4 scans 
and 4 cm
-1
 resolution 
 
 
Figure 3.31 Typical binary mixture IR spectrum of RTD and CCS generated at 4 scans and 4 cm
-1
 
resolution 
 
A change in the absorption frequency for the N-H stretch to a higher wave length was 
observed for the IR spectrum of MCC in combination with MTZ, RTD and all the excipients 
with exclusion of DCP as shown in Figure 3.32. The shift in the absorption band from 1589 
and 1164 cm
-1
 to 1575 and 1158 cm
-1
 respectively can be ascribed to hydrogen bonding. A 
similar observation was made for the spectrum of DCP in combination with MTZ, RTD and 
all the excipients as depicted in Figure 3.33. 
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Figure 3.32 Typical IR spectrum of MTZ, RTD MCC and all the excipients generated at 4 scans and 
4 cm
-1
 resolution 
 
 
Figure 3.33 Typical IR spectrum of a mixture of MTZ, RTD, DCP and all the excipients 
 
3.4 CONCLUSIONS 
 
Preformulation studies are of great importance in formulation development since they 
provide a formulation scientist with relevant data that facilitates the prediction and the 
behaviour of a product during manufacturing and on long-term storage. Although the data 
offers no certainty, these studies form the foundation of building quality into a 
pharmaceutical product. 
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The DSC data has demonstrated that interactions between the drug substances and the 
excipients may occur. MTZ and RTD have shown interaction under the influence of high 
temperature but not incompatibility as has been evidenced following IR analysis. 
Furthermore, it can be concluded that the RTD sample studied is comprised of polymorph 2 
as can be seen by the melting temperature and the enthalpy change. In addition, an interaction 
between RTD and DCP was noted in the DSC and IR analyses of RTD and DCP binary 
mixture, however it was not conclusive for incompatibility. 
 
Based on the IR spectra, MTZ and RTD showed all the characteristic peaks in binary 
mixtures. Therefore it can be concluded that MTZ and RTD are compatible with most of the 
excipients tested despite the interactions that are hydrogen-bonding related. However, RTD 
interaction with DCP is of major concern and further investigation is warranted before the 
conclusion of incompatibility can be categorically reached. Furthermore, the IR spectrum for 
RTD has revealed the characteristic peak at 1045 cm
-1
 that is ubiquitous to polymorph 2. It 
can be concluded that the possibility of polymorphic change during manufacturing is minimal 
since form two is a stable polymorph. 
 
Thermogravimetric analyses of RTD and MTZ have clearly confirmed the stability of both 
compounds under potential manufacturing conditions, and the degradation temperatures for 
both drugs have been confirmed following DSC analysis of the same material.  
 
The physical characteristics of MCC and DCP indicate that both compounds possess suitable 
flowability and compressibility properties as evidenced by their respective CI, HR and ε 
values. Furthermore SEM indicates that size reduction for MTZ and RTD may be required in 
order to attain homogenous powder blend following blending with the potential excipients  
It can be concluded that these studies have provide significant data on the suitability of 
formulating a fixed dose combination of MTZ and RTD with the aforementioned excipients. 
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 CHAPTER FOUR 
FORMULATION DEVELOPMENT AND MANUFACTURE OF FIXED DOSE 
COMBINATION TABLETS 
 
4.1 INTRODUCTION 
 
4.1.1 Overview 
 
Active Pharmaceutical Ingredients (APIs) can be delivered to the body using a variety of 
different approaches. The choice of a specific route of administration is dependent on a 
number of factors including but not limited to the nature of the API, site and onset time of 
action, frequency of administration and age of the patient. The oral route of administration is 
considered the most convenient route for drug delivery as it is an acceptable and convenient 
route of administration for patients and solid dosage forms are relatively easy to manufacture 
[207]. Drug delivery systems for oral administration include tablets, capsules, syrups, 
solutions, elixirs, suspension, gels and powders. However solid oral dosage forms (SODF), 
viz. tablets and capsules, are the most frequently administered technology for adult patients 
whereas liquid oral dosage forms are primarily used for paediatric and geriatric patients 
[208,209]. Tablets and capsules are further categorized into formulation types as summarized 
in Table 4.1 
 
Table 4.1 Tablet and capsule formulation types adapted from [209] 
Formulation Type Description 
Immediate release 
tablet/capsule 
The drug is released immediately following administration 
Delayed release tablet/capsule A physical event determines the when drug will be released 
Sustained release 
tablet/capsule 
The drug is released slowly over an extended period of time 
Soluble tablet The tablet is dissolved in water prior to administration 
Dispersible tablet The tablet is added to water to form suspension prior to administration 
Effervescent tablet The tablet is added to water to form an effervescent solution following release 
of carbon dioxide 
Chewable tablet The tablet is chewed and swallowed 
Chewable gum The formulation is chewed for a specified time and then removed from the 
mouth 
Buccal and sublingual tablet The tablet is placed in oral cavity for local or systemic action 
Orally disintegrating tablet The tablet dissolves or disintegrates in mouth without water 
Lozenge The tablet is designed to be sucked and dissolves slowly 
Pastille The tablet is comprised of gelatine and glycerine and is designed to dissolve 
slowly in the mouth 
Hard gelatine capsule A two-piece capsule shell filled with powder, granulate, semi-solid or liquid 
materials 
Soft gelatine capsule A single shell capsule containing a liquid or semi-solid material 
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Tablets have been used as a drug delivery technology since the nineteenth century with the 
earliest form used, viz. the pill, resembling manually rolled gum [209,210]. The pill was 
manufactured manually by mixing a gum with a herbal extract known to possess 
pharmacological activity. The manual production of pills was not efficient to meet the 
growing demand for this type of SODF and therefore the development of a mechanized 
manufacturing procedure was undertaken [210]. Further improvement of the pill 
manufacturing process was achieved by use of a piston to drive a punch in a die to compress 
mixtures of drug substance(s) and excipients leading to the production of tablets [210]. 
 
During the early stages of tablet development the application of pressure to an API did not 
always result into the formation of a suitably compacted mass. With the addition of binding 
agents and other excipients the compressibility and flow properties of the material were 
significantly improved, and the good compressibility and flowability exhibited following the 
addition of excipients led to the establishment of parameters that describe the quality of a 
suitable tablet and which are continuously reviewed during and after manufacture [210]. 
These parameters include but are not limited to appearance, dissolution, disintegration, 
weight variation, content uniformity, thickness, hardness and friability of the SODF [209]. 
 
4.1.2 Manufacture of compressed tablets 
 
In general the simplest tablet formulation is usually an uncoated product manufactured by 
direct compression or by use of a wet or dry granulation process [209]. A suitable tablet 
formulation is uniform in content, exhibits drug stability and an optimal dissolution rate, and 
ensures that drug is available for absorption [208,209]. A typical manufacturing process for 
tablets includes weighing, milling, granulation and drying, blending and lubrication, 
compression and/or coating [211,212]. Each processing step may itself involve a number of 
processes that facilitate the production of robust tablets with suitable characteristics [209]. 
The manufacturing process of tablets can be further classified into three methods, viz. direct 
compression, wet and dry granulation which are discussed in the subsequent sections of this 
chapter.   
 
The successful manufacture of compressed tablets is also dependent on the presence and 
appropriate use of excipients in a formulation. These additives facilitate the manufacture of 
dosage form by masking inadequate characteristics of a drug substance with respect to 
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compressibility, stability and  ultimately absorption of that API [211]. Powder blends that are 
compressible and free flowing are readily compressed into tablets since their free-flowing 
nature ensures smooth and continuous uniform die filling for high-speed compression [211]. 
However, blends that exhibit poor flowability and/or compressibility pose difficulties during 
compression since inadequate flowability results in variable die filling, ultimately leading to 
the production of tablets that vary in weight and strength and that usually exhibit poor tensile 
strength [212]. Granulation is usually used in these instances to improve the flow properties, 
material density and powder compressibility of formulations [211,212]. The choice of 
excipients, equipment and process parameters used for the manufacture of tablets are usually 
determined during preformulation and process development studies. 
 
4.1.3   Excipients 
 
An excipient is a material that is added to pharmaceutical formulations to facilitate the 
manufacture of dosage forms and, where appropriate, to ensure drug delivery to the systemic 
circulation. Commonly used excipients in tablet manufacture include but are not limited to 
binders, diluents, disintegrants, lubricants, glidants, antiadherents, adsorbents, moistening 
agents, flavourants and colourants.  
 
4.1.3.1 Binders 
 
A binder is a substance that facilitates the adhesion of particles ultimately leading to the 
formation of cohesive agglomerates of granules that in due course form cohesive compacts 
following compression of the granular or powder mass. Binding agents are usually added in 
dry or liquid form depending on the method of tablet manufacture used to produce the 
material for compression. The addition of a binder in the dry state is common practice when 
tablets are manufactured by direct compression, whereas in a wet granulation process the 
binder is added to the powder blend in a liquid form [212]. Commonly used binders for  wet 
granulation manufacture include polyvinylpyrrolidone (PVP), starch, gelatine, alginic acid 
derivatives, cellulose derivatives, glucose and sucrose amongst others, whilst microcrystalline 
cellulose and silicified microcrystalline cellulose have been reported to be effective binders 
for direct compression manufacturing [190,212]. 
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4.1.3.2 Diluents 
 
A diluent is a substance that is added to formulations to increase the mass of product, in 
particular for low-dose API, to a practical size for compression [213] and to improve the 
mechanical and physiochemical properties of the tablet [182]. Tablets with a mass of             
≥ 50 mg are considered to be convenient to handle [212], thus very low dose drugs such as 
digoxin require bulking agents or diluents to increase the overall tablet mass to a size that is 
easy for patients to handle. In addition a diluent may also be added to an API to improve the 
flowability and compressibility of the resultant powder system to form tablets. Furthermore, a 
diluent may also be used to facilitate dissolution of an API known to possess poor aqueous 
solubility and it is usual that a water-soluble diluent is used for this purpose [208]. Some 
examples of commonly used diluents for the manufacture of SODF include lactose, dibasic 
calcium  phosphate, starches, microcrystalline cellulose, dextrose, sucrose, mannitol, sorbitol 
and sodium chloride [190,212].  
 
4.1.3.3 Disintegrants 
 
A disintegrant is substance that is added to a blend prior to compression to facilitate the 
disintegration of a tablet once it comes into contact with the gastrointestinal tract fluids. 
Tablet disintegration results in an increase in the effective surface area of the material and is 
necessary to ensure effective dissolution of the API contained in the tablet [212]. 
Disintegration occurs by a number of mechanisms but usually involves wicking and swelling 
of the disintegrant following exposure to a liquid, with a consequence of disruption of the 
bonds that hold the tablet together, ultimately leading to tablet breakage. This mechanism of 
disintegration is exhibited by disintegrants that are derived from cellulosic material such as 
CCS [212,214]. Furthermore, tablet disintegration can be achieved through the production of 
a gas such as carbon dioxide following reaction of an organic acid with an inorganic base. By 
way of example, this mechanism of disintegration is used in effervescent tablets that are 
comprised of calcium carbonate or sodium bicarbonate in combination with an organic acid 
such as citric acid [215]. When placed in an aqueous environment the acid and base react 
through molecular movement and contact between the reactants and consequently liberation 
of carbon dioxide that causes fragmentation of the tablet [216]. 
 
  
97 | P a g e  
 
4.1.3.4 Anti-frictional agents 
 
Anti-frictional agents are used in SODF formulation to overcome the frictional forces that 
powders or the compressed tablets are exposed to during tablet manufacture. These agents are 
classified according to their primary anti-frictional activity and take the form of lubricants, 
anti-adherents and glidants. 
 
4.1.3.4.1 Lubricants 
 
Tablets may sometimes abrade due to friction occurring between the edges of the tablet and 
walls of the die cavity during the tablet ejection process following compression. In order to 
minimize friction, wear of punches and dies and to facilitate the production of tablets with 
smooth and high sheen appearance, lubricants are added to the powder blends [212]. The 
most commonly used lubricants are hydrophobic in nature and are comprised of fragile and 
fine particles that fragment easily and adhere to powder particles in a blend during the mixing 
process [159,164]. Lubricants can be categorized into two groups, viz. hydrophilic and 
hydrophobic. Typical examples of hydrophilic lubricants include magnesium and sodium 
lauryl sulphate, sodium benzoate, polyethyleneglycols and sodium chloride, whereas 
hydrophobic lubricants are materials such as magnesium stearate, stearic acid and 
hydrogenated vegetable oil  [190,208].  
 
4.1.3.4.2 Glidants 
 
Powder flowability is a critical property that impacts tablet weight uniformity during 
compression. As most powders and blends do not flow readily, the addition of glidants to a 
formulation to reduce the interparticulate friction and improve powder flow properties is 
essential [212]. In general, good glidants usually exhibit poor lubricant properties [217]. 
However some glidants also possess lubricant properties and are able to serve a dual function 
in a formulation. Glidants, with the exception of talc, are frequently used at low 
concentrations (usually ≤ 1% w/w) and are often added to a powder blend immediately prior 
to compression. An excipient such as talc exhibits glidant, lubricant and anti-adherent 
properties. Other commonly used glidants include fumed or colloidal silica and starch 
[190,208]. 
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4.1.3.4.3 Anti-adherents 
 
Some powder blends may be produced with materials that have a tendency to adhere to the 
surfaces of punches and dies due to their sticky nature. This property may be a consequence 
of poor drying of a granulation or a high equilibrium moisture content of the material [209]. 
This effect usually results in the production of tablets with rough surfaces and this may 
exhibit sticking and/or picking. In general the addition of a lubricant to a formulation is 
sufficient to prevent adherence, however, in extreme cases the addition of an anti-adherent to 
overcome this defect may be necessary [218]. Commonly used anti-adherents include starch, 
talc and colloidal silicon dioxide at concentrations of between 1-2% w/w [190]. 
 
4.1.3.5 Adsorbents 
 
Adsorbent are excipients that are capable of holding liquids and maintaining the appearance 
of an apparent dry state [212]. The addition of an adsorbent is useful in formulations that 
require the addition of a semi-solid or semi-liquid material, such as for example a volatile 
flavouring agent or fluid extract, or is useful in formulations that contain hygroscopic 
excipients and/or APIs. However, the addition of an adsorbent is not without its challenges 
and often abrasive tablets are produced, therefore the use of a fine and grit-free grade 
adsorbent is essential [212,218].  Examples of commonly used adsorbents include but are not 
limited to kaolin, bentonite, Fuller’s earth, magnesium carbonate and microcrystalline 
cellulose. 
 
4.1.3.6 Solvents 
 
There are different types of liquids (solvents) that are used for wet granulation, viz. water, 
isopropanol and ethanol, however, due to safety and environmental concerns the use of 
organic liquids such as alcohol in pharmaceutical formulation has largely been surpassed by 
use of aqueous based systems. These liquids have a dual function, viz. solvation of the binder 
and wetting of the powder blend. During wet granulation wetting of the powder blend is of 
paramount importance since the resultant compactability of the resultant granular material is 
dependent, in part, on the residual moisture content of the granules following drying. A 
moisture content of ≤2% w/w for a granulation mass has been reported to offer a good 
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compromise between compactability and adherence of the powder blend to the punch 
surfaces [212]. 
 
4.1.3.7 Dyes and flavourants 
 
Flavouring and colouring agents are added to a formulation to enhance the palatability and 
aesthetic appearance of the dosage form. Sweeteners have a dual role in a formulation, viz. 
bulk volume reduction and taste improvement. The use of dyes in a formulation is not 
without its challenges and patients may exhibit allergic reactions. Allergic reaction in patients 
may manifest as asthma or asthma-like symptoms or anaphylaxis following the use of a 
pharmaceutical product that has yellow or blue dyes, for example Sunset Yellow  and 
Brilliant Blue [219]. Furthermore azo dye dermatitis has been observed in subjects who are 
sensitive to para-amino compounds [220]. This cross-reaction may be attributed to structural 
affinities or to metabolic conversion of these materials in tissues following consumption of 
the causative agent [221].  
 
4.1.4 Wet granulation 
 
Wet granulation is the oldest approach for the manufacture of materials suitable for 
compression and has been used by pharmaceutical industry for the manufacture of tablets for 
longer than the use of dry granulation or the direct compression approach [211,222]. Wet 
granulation involves the wetting of a powder blend with a granulation liquid that is either 
sprayed onto the powder as fine droplets or is poured slowly onto the powder bed. The 
formulation of a granulation liquid is usually comprised of a binder or wetting agent that is 
dissolved in an aqueous solvent, however, alcoholic and hydro-alcoholic solvents have also 
been used for the granulation of powders containing an API that is susceptible to hydrolysis 
[222]. The use of aqueous granulation fluids is preferred as they are economical, safe and 
versatile with respect to use in a variety of different equipment. 
 
The characteristics of granules such as pore structure, particle size and distribution are 
dependent on the conditions and the method of granulation. Furthermore the experience of a 
formulator may also contribute significantly to the ultimate properties of the granules that are 
produced [211,222]. It is challenging to predict the properties of granules due to the 
complexity of interrelating factors such as granulation conditions, method of granulation and 
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experience of the formulation scientist. The mechanism of granule formation has been 
thoroughly studied and reported [223-227] as a three-step process and this is discussed in      
§ 4.1.4.1 vide infra. 
 
4.1.4.1 Granule formation 
 
4.1.4.1.1 Wetting and nucleation 
 
The formation of granules is commonly viewed as a combination of three rate processes that 
involve coalescence and breakage of particles [224]. In the initial stages of granule formation, 
viz. wetting and nucleation, a liquid binder is distributed on the surfaces of dry powder 
particles resulting in the formation of nuclei as shown in Figure 4.1. There is limited 
information pertaining to the processes that control nucleation, however the thermodynamics 
of wetting and binder dispersion have been reported to significantly influence the size of the 
initial nuclei that are formed [224,225]. 
 
 
Figure 4.1 Wetting and nucleation stage of granule formation. Adapted and modified from [224] 
 
4.1.4.1.2 Growth and consolidation 
 
The growth and consolidation of granules is determined by the rate of collision of the nuclei 
granules, viz. coalescence, pre-existing granules and fine powder, viz. layering and/or granule 
and equipment surfaces [228]. Granule growth occurs as soon as a liquid binder solution is 
added to the agitated powder mass and growth may continue following completion of binder 
addition. In some cases granule growth is significantly influenced by nucleation conditions. 
In these systems the incorporation of limited amounts of binder solution is usually sufficient 
to produce conditions that favour the optimal growth of granules by nucleation [224].  
 
Granule growth is also dependent on the mechanical properties of the material used to 
manufacture the granules in addition to properties of the binder solution. During agitation of 
binder droplet
powder particles
distribution of binder nuclei granule
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the wet powder mass, granules may exist in different states of liquid saturation, viz. pendular, 
funicular, capillary and droplet, and each state is differentiated from the other by the degree 
of granule saturation as shown in Figure 4.2 [224,229].  
 
 
Figure 4.2 Different stages of saturation of liquid-bound granules. Adapted from [224] 
 
In the pendular state, particles are bound together at their contact points by liquid bridges that 
occur as a result of the presence and addition of binder. The addition of further binder 
solution leads to the formation of the funicular state in which agglomeration of particles 
occurs, and this is followed by the formation of liquid bridges between the agglomerates in 
the capillary and droplet states. The strength of the resultant liquid-bound granule is 
attributed to two categories of forces, viz. liquid bridge and inter-particle frictional forces.  
These forces are interrelated in a complex manner that ultimately determine the mechanical 
properties of the resultant granules [224,230]. 
 
The properties of a binder solution such as content of binding agent, viscosity and surface 
tension have a significant effect on the consolidation of powder to form granules, as shown in 
Figure 4.3. 
  
 
Figure 4.3 Granule growth as function of consolidation and coalescence. Adapted and modified from 
[224] 
 
It has been reported that a high concentration of low-viscosity binder increases the initial rate 
and extent of powder consolidation to form granules due to increased particle mobility 
[224,227], whereas an increase in viscosity of the binder solution decreases the rate of 
granule consolidation due to reduced particle mobility. However, this relationship between 
the viscosity of a binder solution and the rate of consolidation has a critical value for binder 
viscosity, below which the viscosity has no effect on the rate of consolidation. The effect of 
Pendular Funicular Capillary Droplet
coalescence
nuclei granules
densification
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surface tension of the binder solution on granule consolidation is dependent on the type of 
equipment used in the granulation process. A non-significant change in the rate of granule 
consolidation was observed following an increase in the surface tension of binder solution 
when used in a high shear mixer [231]. However, in a tumbling drum mixer a decrease in 
surface tension of a binder resulted in an increase in the rate of consolidation but a decrease 
in the extent of consolidation [232]. 
 
4.1.4.1.3 Attrition and breakage 
 
The attrition and breakage of granules depicted in Figure 4.4 shows two scenarios, viz. the 
breakage of wet granules as result of collision with other granules and/or the wall of the 
granulator, or attrition of dry granules in the granulator or dryer due to subsequent handling 
due to brittleness of the agglomerates [224,233].  
 
 
Figure 4.4 Attrition and breakage of granules. Adapted and modified from [224] 
 
There is a dearth of information pertaining to granule breakage and attrition during 
granulation, nonetheless, it appears that attrition and breakage is extensive in high intensity 
mixers and hybrid granulators [233]. During granulation the control of wet granule breakage 
favours the production of granules with a narrow particle size distribution since the attrition 
of granulation is exhibited at the limit of granule breakage following the initial growth of the 
granules. The impact of the velocity of an impeller and chopper in a granulator and the 
turnover of granules through a high impact region in the manufacturing bowl are contributing 
factors that determine the size distribution of the granules produced during granulation 
[224,233,234]. 
 
4.1.4.2 Screening and drying of wet powder mass 
 
The resultant wet mass produced following granulation is usually forced through a screen of 
pore size between 2380 and 3360 µm  to produce relatively uniform granules, and different 
screen sizes may also be used depending on the properties of the wet material [211]. 
breakage
collision 
attrition
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Alternatively uniform granules may be manufactured by extruding the damp mass through a 
screen with perforations of a predetermined size using an extruder to produce pellets that are 
subsequently spheronized to produce spherically-shaped particles [235]. 
 
The granules are dried following screening by use of thermostatically controlled ovens or 
fluidized bed dryers. The drying time and the final moisture content of the granule blend is 
usually established with due consideration of the stability of an API, the effect of moisture 
content on compressibility of the granules, and the equilibrium moisture content of the 
material equilibrated to the relative humidity of the manufacturing environment [222]. 
 
4.1.4.3 Dry screening, lubrication and tablet compression 
 
The dried granules are once again passed through a screen of aperture size between 354 and 
841 µm. The extent of granule size reduction is usually dependent on the size of the tablet to 
be produced and the physical characteristics of the tooling used during the compression 
process. Resizing of the granules facilitates the rapid and complete filling of die cavities and 
the production of tablets that are uniform in weight and thickness. The compression of large 
granules is not recommended due to their potential to create voids or air spaces within die 
cavities and consequently the production of tablets of uneven dimension and variable dose 
content following compression [211]. 
 
Lubricants are often passed through a fine screen of pore size between 149 and 250 µm prior 
to blending with the granules using a process known as bolting. The blending process is 
usually much shorter and is often between 2-5 min in duration,  however, on rare occasions 
10 min may sometimes be required depending on the nature of the lubricant, viz. particle 
surface area and aqueous solubility [208,236].  
 
Following the addition of lubricant to the granules the powder blend is then compressed into 
tablets using a rotary tablet press fitted with multiple punches and dies or, on rare occasions, 
a single punch press. Despite the differences in the number of stations on the tablet presses, 
they are all operated in a similar manner and usually differ in the output in terms of number 
of units produced per hour [211]. Tablet compression occurs using a stainless steel (grade 
316) die cavity and as a result of pressure exerted by the movement of two stainless steel 
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punches located above and below the die. The type of tooling to be used is usually 
established during preformulation studies. 
 
4.1.5 Dry granulation 
 
API and other materials that are sensitive to heat and/or moisture are best manipulated for 
compression by a dry granulation process, if the material exhibits poor flowability and 
compressibility properties that do not permit the use of a direct compression approach to 
manufacture and if the API or other excipients are cohesive in nature [212]. The dry 
granulation process entails force-feeding a powder blend into the die cavity of a tablet press 
and compacting the materials to form slugs by a process called slugging, or alternatively the 
powder blend may be forced between rollers and compacted into ribbons by a process called 
roller compaction [211,212,237]. The resultant slugs or ribbons are milled and screened prior 
to lubrication and the lubricated granules are then compressed into tablets. 
 
4.1.6 Direct compression 
 
The compression of powder blends into tablets without prior modification of the physical 
nature of the material, is defined as direct compression tableting [208]. Formerly this method 
was reserved for the manipulation of a few materials that were crystalline in nature and that 
possessed physical characteristics such as flowability and cohesiveness that are necessary for 
the application of this approach to tablet production [208]. Such materials included potassium 
salts such as chlorate, bromide, iodide, nitrate and permanganate, ammonium chloride and 
methenamine [208,211]. Due to advances in excipient and manufacturing technology there 
are far fewer limitations in the use of direct compression for the large scale production of 
SODF. This is primarily due to the availability of excipients that exhibit good compressibility 
and flowability properties and that lend themselves to the application of direct compression to 
a wide range of drug substances. 
 
In general the manufacture of tablets by direct compression consists of three unit operations, 
viz. sizing or milling, blending and compression [212]. Resized excipients and API are mixed 
using an appropriate blender and the resultant homogenous blend is then lubricated prior to 
compression into tablets. Excipients that are commonly used for direct compression 
formulations include diluents such as spray-dried lactose, microcrystalline cellulose and 
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dibasic calcium phosphate and disintegrants including sodium carboxymethylcellulose, cross-
linked polyvinylpyrrolidone and cross-linked carboxymethylcellulose fibres. The lubricants 
that are used include magnesium stearate and talc, and fumed silicone dioxide is often used as 
a glidant [190,211]. 
 
4.2 METHODS 
 
4.2.1 Study design for the development of a method of manufacture  
 
The initial stages of developing FDC tablets involved screening for an appropriate method of 
manufacture. Tablets were manufactured using wet granulation and direct compression using 
the formulae described in Table 4.2 (Batches RM 001 and 002). The success of the method of 
manufacture was determined by assessing the suitability of the resultant granules/powder 
blends in terms of CI, HR and the physico-mechanical properties of the resultant tablets, viz. 
weight uniformity, disintegration time and friability to compendial specifications.  
 
Table 4.2 Formulae used for the manufacture of FDC tablets by direct compression and wet 
granulation 
Raw material Direct compression (% w/w) 
Batch RM 001 
Wet granulation (% w/w) 
Batch RM 002 
RTD 16.8 16.8 
MTZ 50.0 50.0 
MCC 28.0 27.0 
PVP- K30 - 1.0 
SSG 4.0 4.0 
Colloidal silicone dioxide 0.2 0.2 
Magnesium stearate 1.0 1.0 
 
Following this initial evaluation, optimization of the selected method of manufacture was 
undertaken. The optimization studies were aimed at establishing a blending time that would 
produce a homogenous blend of API with the excipients of choice using the standard 
formulation composition summarized in Table 4.2. The success of the optimization procedure 
was determined by assessing the content uniformity of powder blends using the HPLC 
method described in Chapter Two.  
 
The content of API was established and limits of 100±15% and a RSD of <5% were adopted 
as the acceptance criteria for the blend uniformity assessment. Tablets from these blends were 
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subjected to content uniformity analysis, assay and physico-mechanical tests to establish the 
optimal manufacturing conditions.  
 
4.2.2 Materials 
 
RTD and MTZ were purchased from Changzhou Longcheng Medicine Raw Material Co., Ltd 
(Changzhou City, Jiangsu, China) and Huanggang Hongya Pharmaceutical Co. Ltd 
(Huanggang, Hubei, China) respectively. MCC, DCP, SSG, CCS, colloidal silicon dioxide 
and magnesium stearate were purchased from Aspen Pharmacare (Port Elizabeth, Eastern 
Cape, South Africa). 
 
4.2.3 Manufacturing equipment 
 
All raw materials were weighed using a top-loading analytical balance Model PM4600 
(Mettler Instruments, Zurich, Switzerland) with a sensitivity of 0.01g. Blending and 
granulation was performed in a Saral
®
 vertical axis high-shear mixer granulator fitted with a 
3.5 l bowl (Saral Engineering Company, Vapi, India). A model 7521-001 Cole Palmer 
peristaltic pump (Cole-Palmer Instruments Co., Barrington, Illinois, USA) consisting of a 
spray gun fitted with a pressure gauge was used for the addition of binder solution. The 
granules were dried using a Memmert
®
 dry heat oven (Memmert GmbH Co., Schwabach, 
Germany) and tablet compression was performed on Manesty
®
 B3B rotary tablet press 
(Manesty, Speke, Liverpool, England) tooled with six 12 mm flat-faced punches. All 
materials were sieved using wire cloth sieves conforming to DIN 4188 standards. 
 
4.2.4 Method of manufacture 
 
4.2.4.1 Direct compression 
 
4.2.4.1.1 Manufacturing procedure 
 
RTD, MTZ and MCC, were weighed and passed through a screen of aperture size 850 µm 
and blended for 5 min with 50% of the SSG at an impeller speed of 100 rpm. The resultant 
blend was then mixed for a further 3 min with colloidal silicone dioxide, magnesium stearate 
and the balance of the SSG that had been sieved through a screen of aperture size 315 µm. 
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The powders were then tested for bulk and tapped densities as described in § 3.2.2. The 
lubricated blend was transferred to the tablet press and compressed into 500 mg tablets at a 
turret speed of 25 rpm to a target hardness of 80-120 N. An example of a typical executed 
batch manufacturing record used to record the manufacturing process is included in Appendix 
1. The formulation used for direct compression manufacture of tablets is summarized in 
Table 4.2 and schematic diagram of the manufacturing method is depicted in Figure 4.5. 
 
4.2.4.2 Wet granulation 
 
4.2.4.2.1 Preparation of binder solution 
 
Approximately 12.5 g of PVP-K30 was accurately weighed and slowly added in a beaker that 
contained 100 ml of purified water. The solution was stirred gently until the PVP-K30 had 
dissolved to produce a solution of 12.5% w/v concentration. 
 
4.2.4.2.2 Rheological studies of binder solutions 
 
The viscosity of the binder solution was measured using a Model DV-II+ Brookfield 
viscometer (Brookfield Engineering Laboratories, Middleboro, Massachusetts, USA). The 
test was performed using 600 ml of binder solution that had been prepared as described in § 
4.2.4.2.1. The viscometer was fitted with a RV spindle and operated at 100 rpm for 5 min 
prior to data collection. The test was performed in triplicate at a temperature 20±0.5
°
C.  
 
4.2.4.2.3 Manufacturing procedure 
 
Prior to addition of the granulation fluid the powders were dry blended as described in § 
4.2.4.1.1.  The resultant blend was granulated with 40 ml of PVP-K30 solution (12.5% m/v) 
delivered at a rate of 36 g/min using a pump speed of 25 rpm and a spray pressure of 52 psi. 
The blend was mixed with an impeller and chopper speed of 100 and 1000 rpm respectively. 
The granulation was mixed for a further minute after completion of wetting of the powder 
mass and the power consumption of the equipment was used to establish the endpoint of 
granulation prior to drying in oven at 50±0.5
°
C for 24 h. The dried granules were passed 
through a screen of aperture size 350 µm and lubricated for a further 3 min with the 
previously screened colloidal silicone dioxide, magnesium stearate and the balance of the 
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SSG (10 g). The granules were then assessed for bulk and tapped densities as described in § 
3.2.2. The lubricated granules were compressed into 500 mg tablets at speed of 25 rpm to get 
a hardness of 80-120 N. The formulation used for the wet granulation manufacture of tablets 
is summarized in Table 4.2. The schematic diagram of the manufacturing method is depicted 
in Figure 4.5 and an example of a typical batch manufacturing record used to record the 
manufacturing processes is included in Appendix 1.   
 
4.2.5 Physical characterization of tablets 
 
4.2.5.1 Weight uniformity 
 
The individual weight of 10 randomly selected tablets was measured using a top-loading 
electronic balance Model AG 135 (Mettler Instruments, Zurich, Switzerland) with a 
sensitivity of 0.1 mg and the average weight calculated. 
 
4.2.5.2 Crushing strength and diameter 
 
The crushing strength and diameter of the tablets was determined using a Model PTB 311 E 
hardness tester (Pharma Test AG, Hainburg, Germany). Each tablet was placed in the tester 
to facilitate horizontal application of the crushing force and the crushing strength and 
diameter of 10 randomly selected tablets was established simultaneously. 
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Figure 4.5 Schematic diagram of the methods of manufacture of tablets
Compress 
Manesty® B3B Rotary 
Tablet Press 
Blend and granulate 
Saral® High Shear Mixer-
granulator 
Dry at 50ºC 
Memmert® dry heat 
oven  
Sieve 350 µm 
pore size 
Weigh 
Analytical 
balance 
Sieve 850 µm 
pore size 
Blend and lubricate  
Saral® High Shear Mixer-
granulator 
Direct compression 
Wet granulation 
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4.2.5.3 Friability 
 
The friability of 20 randomly selected tablets was established using a Model TA3R friabilator 
(Erweka GmbH, Heusenstamm, Germany). The compressed tablets were de-dusted and 
weighed using a top-loading balance Model PM 4600 (Mettler Instruments, Zurich, 
Switzerland). The tablets were allowed to tumble at 25 rpm for 4 min (100 drops), removed 
and de-dusted and then reweighed. The friability was then calculated using Equation 4.1  
 
     
     
  
                                                   Equation 4.1 
Where, 
w1 = weight prior to tumbling 
w2 = weight after tumbling 
Fr = friability 
 
4.2.5.4 Tensile strength 
 
The tensile strength of the resultant tablets was calculated using data generated in the 
diametral-compression test using Equation 4.2. 
 
                                                 
  
   
      Equation 4.2 
Where, 
F = crushing strength, N 
T = tablet thickness, mm 
d = tablet diameter, mm 
σo = tensile strength, MPa 
 
4.2.5.5 Disintegration test 
 
The disintegration time of the manufactured tablets was established using a Model ZT 61 
tablet disintegration apparatus (Erweka GmbH, Heusenstamm, Germany). Six tablets were 
used for the determination of disintegration time. Each tablet was placed into a cylinder of the 
basket-rack and covered with a disc. The basket was set to oscillate vertically inside a beaker 
containing 700 ml of distilled water maintained at 37±0.2
°
C at a speed of 30 cycles/min and 
the time for disintegration of each tablet was recorded automatically on completion of the 
test.   
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4.2.5.6 Tablet assay 
 
Twenty randomly selected tablets were crushed into a powder using a mortar and pestle. An 
aliquot equivalent to the weight of one tablet (approximately 500 mg) was weighed using a 
top-loading analytical balance Model AG 135 (Mettler Instruments, Zurich, Switzerland) and 
quantitatively transferred into a100 ml A-grade volumetric flask. The granules were dissolved 
in MeOH:water (80:20) followed by sonication for 5 min using a Model B-12 Ultrasonic bath 
(Branson Cleaning Equipment Co., Shelton, Connecticut, USA). The resultant solution was 
made up to volume using MeOH:water (80:20) and filtered through an ashless S &S round 
filter paper (Schleicher & Schüll GmbH, Postfach, Dassel, Germany) of 12 µm pore size and 
125 mm diameter. A 1 ml aliquot of the filtrate was transferred into 100 ml A-grade 
volumetric flask and filled to mark with MeOH:water (80:20). Aliquots of 1 ml were 
collected and transferred into a 5ml A-grade volumetric flask followed by addition of  2 ml of 
the IS and filled to mark using MeOH:water (80:20). The resultant solution was filtered 
through 0.22 µm Acrodisc
®
 PSF syringe filter (Pall Corporation, Port Washington, New 
York, USA) and injected into the HPLC. The analysis was performed in triplicate and the 
results were expressed as the mean ± SD. 
 
4.2.6 Blend homogeneity studies  
 
A blending time of 2-10 min has been reported to be ideal for processing of powders [238] 
although times of 10-20 min and even 60 min have also been used [239]. The optimal 
blending time was determined by assessing the homogeneity of the powder blend at different 
mixing time intervals as summarized in Table 4.3 using the validated HPLC method 
described in Chapter Two.  
 
Table 4.3 Mixing times used to prepare blends for homogeneity analysis  
Batch number Mixing time  
RM 003 5 
RM 004 10 
RM 005 15 
RM 006 2 
RM 007 3 
RM 008  7 
RM 009 9 
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Aliquots of powder of approximately 1±0.05 g (n=6) were collected for HPLC analysis using 
the spoon end (length of 2.54 cm) of a nickel/stainless steel laboratory spatula. Initially 
samples from batches RM 003, RM 004 and RM 005 were collected at 5, 10 and 15 min 
respectively after commencement of blending. In order to characterize the blend uniformity 
further, samples for analysis were collected from batches RM 006, RM 007, RM 008 and RM 
009 following 2, 3, 7 and 9 min after the commencement of blending respectively and the 
content of API established. 
 
4.2.7 Optimisation of tablet manufacturing process  
 
4.2.7.1 Manufacture of tablets  
 
Blend uniformity was found to be satisfactory following 9 min of mixing and therefore 
tablets from blends mixed following 8, 9, 10 min were manufactured using the methods 
described in § 4.2.4.2.3 as shown in Table 4.4.  
 
Table 4.4 Batches of tablets manufactured  
Batch  Mixing time (min) 
RM 010 8  
RM 011 9 
RM 012 10 
 
4.2.7.2 Content uniformity of tablets  
 
Content uniformity analysis of tablets was performed on batches that were manufactured, viz. 
Batches RM 010, RM 011 and RM 012 respectively as shown in Table 4.4. Ten tablets from 
each batch were selected and then crushed individually using a mortar and pestle. 
Approximately 100 mg of each tablet was accurately weighed and transferred into a 100 ml 
A-grade volumetric flask. The powders were dissolved in MeOH:water (80:20) and the 
mixture was sonicated for 5 min using a Model B-12 Ultrasonic bath (Branson Cleaning 
Equipment Co., Shelton, Connecticut, USA). The resultant solution was made up to volume 
using MeOH:water (80:20) and filtered through an ashless S &S round filter paper 
(Schleicher & Schüll GmbH, Postfach, Dassel, Germany) of 12 µm pore size and 125 mm 
diameter. Aliquots (0.05 ml) of the filtrate were collected and transferred into a 5 ml A-grade 
volumetric flask followed by addition of 2 ml of the IS solution that had been prepared as 
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described in § 2.3.2.3 and the solution made up to volume using MeOH:water (80:20) and 
filtered through 0.22 µm Acrodisc
®
 PSF syringe filter (Pall Corporation, Port Washington, 
New York, USA) prior to HPLC analysis. 
 
4.3 RESULTS AND DISCUSSION  
 
4.3.1 Micromeretic analysis of granules  
 
 Information obtained about the relationship between bulk and tapped density provides data 
that infers the compressibility and flow properties of a powder as described in § 3.1.1.2.1 and 
§ 3.1.1.2.2. The CI and HR for the blends that are reported in Table 4.5 suggest that the wet 
granulation method of manufacture is likely to be the most suitable method of manufacture of 
these tablets since granules with good compressibility and flow properties were produced. 
 
Table 4.5 Carr’s index and Hausner ratio values of powder and granules following blending for direct 
compression and wet granulation prior to compression     
Batch number CI HR 
RM 001* 18.36 1.22 
RM 002 15.12 1.17 
RM 003 14.98 1.16 
RM 004 15.55 1.18 
RM 005 15.53 1.18 
RM 006 15.42 1.17 
RM 007 15.12 1.17 
RM 008 14.14 1.16 
RM 009 13.11 1.15 
* Indicates powder blend obtained following direct compression method of tablet manufacture 
 
4.3.2 Physico-mechanical properties of the tablets 
 
The tablets manufactured by wet granulation appeared to be better than those manufactured 
by direct compression method when evaluating the data summarized in Table 4.6.  
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Table 4.6  Physico-mechanical properties of the tablets 
Parameter Method of manufacture 
Direct compression Wet granulation 
Appearance Off-white coloured tablets with 
capping 
Cream coloured and sheen 
tablets 
Weight variation (mg) 483.47±5.53 496±4.11 
Diameter (mm)  11.83±0.03 11.93±0.05 
Thickness (mm)  3±0.08 3.28±0.02 
Disintegration (min.)  4.08±0.20 13.61±0.29 
Crushing strength (N)  41.5±2.91 165.4±8.01 
Tensile strength* (MPa)  0.74 2.77 
Friability (%)  2.05 0.31 
*The mean values of crushing strength, diameter and thickness of the tablets were used to compute for 
tensile strength.  
 
The tablets manufactured by direct compression capped following compression and this may 
be a consequence of the relatively high content of MTZ (≈ 50% w/w) in the formulation and 
the poor compressibility properties exhibited by MTZ [240]. These results are similar to those 
reported by Odeniyi et al. [188] following investigations in which the effect of the diluent 
concentration on compressibility, porosity and flow properties of MTZ binary mixtures were 
evaluated. The tablets manufactured by direct compression also exhibited a low crushing 
strength and were friable in comparison to those manufactured by wet granulation. This may 
also be due to the intrinsic nature and poor compressibility of MTZ crystals [181,241].  
 
Tablets manufactured by wet granulation exhibited better friability and crushing strength, 
however disintegration was slower compared to the tablets manufactured by direct 
compression (Table 4.6). This may be attributed to the compactability and compressibility of 
the granules that led to the production of tablets with a high crushing strength. It has been 
reported that granulation improves blend porosity and densification of granules on 
compression and the mechanical strength of tablets is dependent on this occurring [181]. The 
long disintegration times observed in tablets manufactured by wet granulation may be 
attributed to poor medium penetration as a consequence of the high tensile strength of the 
tablets.  
 
4.3.3 Blend homogeneity 
 
The USP recommends that blend uniformity analysis (BUA) be performed on a drug product 
that contains 50 mg of an API per dosage unit or if the API content is <50% w/w of content 
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of the dosage unit [242]. The acceptance criteria set by the USP for BUA is 100±10% of the 
expected quantity of the active ingredient with a RSD of no more than 5% [243]. 
 
The API content of powder blends prepared after blending between 3 and 15 min is shown in 
Figure 4.6 which shows that the optimal dry blending time was found to be 9 min, where the 
API content is within the USP tolerance limits for both RTD and MTZ.  
 
 
Figure 4.6 The variation in the content of MTZ and RTD in the sample aliquots of the blend as 
function of blending time  
 
HPLC analysis of the aliquots of powder collected following 9 min of dry blending revealed 
that the content of MTZ and RTD were 97.73±7.08% (RSD=7.24%) and 110.82±10.14% 
(RSD=9.15%) respectively as shown in Table 4.7 and Figure 4.6.   
 
Table 4.7 The actual content of MTZ and RTD determined in the powder blends of batches that 
underwent different dry blending time intervals 
Batch 
numbe
r* 
Blend 
time 
Actual amount (mg) per g 
n = 6 
Precision (% RSD) % Bias 
MTZ RTD MTZ RTD MTZ RTD 
RM 006 2 442.78 ± 83.39 108.79 ± 16.06 18.83 14.76 11.44 35.24 
RM 007 3 369.38 ± 19.63 178.74 ± 16.96 5.31 9.49 26.12 -6.39 
RM 003 5 312.50 ± 40.25 100.75 ± 14.34 14.23 12.88 37.49 40.02 
RM 008 7 298.18 ± 50.42 145.54 ± 77.97 53.57 16.91 40.36 13.36 
RM 009 9 488.66 ± 35.41 186.19 ± 17.04 7.24 9.15 2.26 -10.82 
RM 004 10 566.18 ± 30.54 247.79 ± 16.53 5.38 6.67 -13.23 -47.49 
RM 005 15 545.80 ± 530.82 198.51 ± 179.81 97.25 90.58 -9.16 -18.16 
* Indicates MTZ (500 mg per g) and RTD (168 mg per g) 
These results are in close agreement with the compendial specifications for these compounds 
despite the slight blend heterogeneity that may be attributed to differences in the particle size 
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and other properties of the blend constituents [244]. The properties of particles such as 
particle size and shape, adhesive and cohesive interactions, surface energy and electrostatics 
play a significant role in ensuring that there is a homogenous distribution of components in a 
powder mixture [245-248]. In addition material characteristics such as particle shape and size 
that tend to facilitate manufacturing processes are the same characteristics that compromise 
dose and content uniformity of powder blends and tablets [249,250]. Furthermore, the 
sampling techniques used to harvest powders for analysis may have also contributed to 
content heterogeneity. The use of a sample thief or any device may introduce sampling errors 
due to channelling and segregation as a consequence of perturbation of powder blends 
[251,252].    
 
4.3.4 Content uniformity of tablets 
 
Initially dose uniformity was a term used to describe weight uniformity of SODF. In 1970 the 
terminology gained a broader meaning and the definition was modified to include content 
uniformity as an additional parameter [253]. The USP and the International Pharmacopoeia 
(IP) require an assessment of the content uniformity of single-dose formulations and a limit 
of  ±15% w/w of the average amount of the API is expected to be present in the tablets 
[254,255]. 
 
HPLC analysis of 10 individual tablets of batches RM 010, RM 011 and RM012 revealed that 
a significant variation in the content of API was evident and the resultant data are 
summarized in Table 4.8.  
 
Table 4.8 Variation of tablet content uniformity and assay as function of blending time 
Batch 
number 
Blend time 
(min) 
Label claim (mg) Tablet content (%) n=10 Assay (%) %Bias 
MTZ RTD MTZ RTD MTZ RTD MTZ RTD 
RM 010 8 250.00 84.00 79.83±7.51 83.57±6.49 72.95±6.10 68.67±9.84 27.05 31.33 
RM 011 9 250.00 84.00 94.90±13.16 97.58±13.85 85.19±3.14 84.41±8.23 14.81 15.59 
RM 012 10 250.00 84.00 79.57±27.78 102.68±18.53 87.32± 6.1 77.06±6.67 20.43 22.94 
 
The use of a blending time of 9 min during the dry mixing of powders resulted in the 
production of tablets with better content uniformity (% bias MTZ = 14.81, RTD =15.59) and 
the results are in close agreement with compendial specifications when compared to the 
tablets produced when either 8 or 10 min of dry blending was used for manufacture. The 
uniformity of content of dose units is attributed to a variety of factors including  blending 
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time, load of blender and impeller and chopper speed as these factors can and do influence 
blend homogeneity [256]. In addition the design of equipment is also implicated [257]. The 
variation in content uniformity of tablets following the use of an optimal blending time may 
be attributed to segregation of material that is induced as a consequence of subsequent 
processing steps. The effect of air-induced segregation has been reported to be more 
pronounced in blends that exhibit variations in particle size of the constituents [258]. 
Furthermore variations in powder properties often affect the behaviour of a powder blend 
during handling and processing and usually leads to a variation in the final dose content of a 
finished product [259,260].   
 
4.4 CONCLUSIONS 
 
The formulation of a FDC of a clinically relevant drug combination is challenging when a 
low-dose API is to be incorporated into the dosage form. The variation of dose content in a 
final product is not an uncommon phenomenon in FDC, with a variety of factors, such as the 
characteristics and compatibility of formulation constituents, suitability of the equipment and 
processing methods used, contributing significantly to the final product dose content 
[257,258,260].  
 
Blending time is one of the critical parameters that determines dose homogeneity in a final 
product, nonetheless, subsequent processing and formulation constituents properties have 
also been reported as contributing factors [257-259]. The determination of a blending 
endpoint depends on the accurate determination of blend homogeneity which in turn is 
dependent on the sampling technique used. The blending time established for use in these 
studies has the necessary accuracy for the manufacture of suitable quality FDC tablets of 
RTD and MTZ.  
 
Direct compression is a convenient and cost effective method used for the manufacture of 
tablets, however the use of wet granulation method resulted in the production of tablets of 
better quality as can be seen from the data reported in Table 4.6. Therefore a wet granulation 
method of manufacture was adopted for the production of FDC tablets since the resultant 
powder characteristics of the batch manufactured by direct compression shown in Table 4.5 
did not favour the production of tablets of suitable quality.  
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 CHAPTER FIVE 
THE APPLICATION OF RESPONSE SURFACE METHODOLOGY AND IN-
VITRO RELEASE OF METRONIDAZOLE AND RANITIDINE   
 
5.1 INTRODUCTION 
 
5.1.1 Response surface methodology 
 
Statistical design of experiments (DOE) have been used in pharmaceutical industry for 
optimization of processes and formulations for over three decades [261,262]. DOE permit 
formulation scientists to study the effects of multiple factors that determine product quality 
during the optimization process simultaneously [263,264]. Furthermore DOE may be used to 
generate mathematical equations that can be modelled and used to produce graphical 
representations that describe the variability of responses of a system as a function of 
predetermined input factors [263]. The application of statistical design and mathematical 
equations in the development, improvement or optimization of pharmaceutical processes is 
defined as response surface methodology (RSM) [159,264-266]. 
 
The use of RSM in the optimization of pharmaceutical processes is usually performed in 
three steps, viz. performing a series of statistically designed experiments, development of 
mathematical models that describe the relationship between input and output variables 
through multiple linear regression, and finally identification of the experimental parameters 
that are critical for the production of a desired response(s) [267]. 
 
5.1.1.1 Statistically designed experiments in formulation development 
 
The optimization of formulations and manufacturing processes requires the identification of 
variables that can affect dosage form performance and the definition of an appropriate range 
in which the desired response can be expected to fall. There are two types of variables, viz. 
independent and dependent variables. Independent variables are those variables that affect the 
final characteristics of a product and that are easily manipulated by a formulation scientist, 
whereas dependent variables are the responses that may be observed following alteration of 
the independent variables [263,265]. 
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Classes of excipient such as diluents, binders and disintegrants and manufacturing parameters 
such as compression force are independent variables and their influence on dependent 
variables has been studied extensively and has been well documented [190,209]. However the 
appropriate ranges required to produce the desired response(s) are only determined from 
preliminary studies. In DOE the effect of input factors on response variables is assessed at 
three levels, viz. high, medium and low, with the levels coded +1, 0, and -1 respectively 
[263,265]. For immediate release formulations, typical independent variables may include but 
are not limited to disintegrant, lubricant, diluent, binder (type and composition) compression 
force, blending time, impeller and chopper speed. Response variables may include 
disintegration time, crushing strength, granule size distribution, and rate and extent of 
dissolution amongst others. 
 
In the pharmaceutical industry setbacks in the manufacture of products such as tablets include 
raw material shortages, equipment and facility breakdown that may well be inevitable, 
however the existence of an alternate validated method of manufacture may help to reduce 
disruption in production. The alternate manufacturing method may entail the use of different 
types of equipment and/or facility and raw materials. Due to these possible challenges the 
FDA have set guidelines that indicate permissible changes to a manufacturing process, 
formulation  and site of manufacture that can be made following regulatory approval for 
market authorization [268]. However the determination of an outcome following changes in a 
formulation composition or process variables requires that a series of experiments are 
performed and these in most cases are time and resource intensive. Therefore the use of RSM 
for the determination of an outcome following changes in the method of manufacture or 
formulation may be beneficial, since less time and resources may be consumed. Thus 
following the manufacture of an oral FDC of MTZ and RTD as described in § 4.2.4.2, the 
effect of varying the disintegrant, lubricant and binder content on tablet disintegration time 
and the rate and extent of in vitro release of MTZ and RTD were investigated. Furthermore, 
level two changes in component and compositions as described in Scale Up and Post 
Approval Changes for Immediate Release (SUPAC-IR) of solid oral dosage form guidelines 
[268] were used as the experimental domain.    
 
The DOE commonly used in the pharmaceutical industry for the optimization of formulations 
include factorial [269], central composite design (CCD) [270], Box-Behnken [271] and D-
optimal design [272] approaches. 
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5.1.1.2 Mathematical models 
 
The mathematical or polynomial equations that describe the relationship between 
independent and dependent variables may be first, second or third order in nature depending 
on how the output variables or responses react to changes in the input variables [273]. The 
relationship between the input and output variables exhibited in pharmaceutical systems is 
most often described by first and second order mathematical models [273]. 
 
Pharmaceutical systems with response variables that are significantly affected by a small 
change in the input factors and exhibit little or no interaction between the input variables are 
best described using first order mathematical models similar to that shown in Equation 5.1. 
Second order models are used to generate linear and quadratic equations in pharmaceutical 
systems that exhibit interactions between the input factors, and those that ultimately affect the 
response variable are best described using equations of the type shown in Equation 5.2. It has 
been reported that second order models are also applicable to input factors that exhibit 
extensive variation over an experimental domain and these relationships are best described by 
equations of the form shown in Equation 5.3 [265]. 
 
                                                                              Equation 5.1 
 
                                                                       Equation 5.2 
 
                               
        
           Equation 5.3 
Where, 
y = estimated response 
χi = input factors 
β0 = constant that represent the intercept 
βi = coefficient of first order term 
βii = coefficient of second order term 
βij = coefficient of second order interaction 
 
The values of the coefficients in the model are generated through multiple linear least squares 
regressions analysis of empirical data. A coefficient with a positive value is indicative of an 
agonistic effect of the factors on the measured response, whereas coefficients with a negative 
value indicate the opposite. The response variables that exhibit dependence on at least two 
independent variables can be illustrated in a three-dimensional manner that depicts the 
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variation of dependent factor(s) as a function of variation of the independent factors within an 
experimental domain [265]. The three-dimensional illustration of the variables is known as 
response surface plot. Alternatively a two-dimensional illustration of the independent 
variables plotted against one another produce contour plots that may also be used to describe 
the relationship between input factors and response variables [265]. 
 
5.1.1.3 Optimization 
 
The use of DOE in pharmaceutical systems is aimed at identification of the input variable 
levels within an experimental domain that would lead to the production of a single value or 
range of values for a response variable. The determination of levels or experimental domain 
that facilitates the production of the desired value of a measured response is usually achieved 
by the use of the response surface plots [265].The achievement of a successful optimization 
for a process is dependent on the properties of the variable(s) under investigation and the 
experimental design must be continuous and controllable in an experiment with negligible 
error [273]. 
 
5.1.1.4 Advantages of response surface methodology 
 
Statistical design of experiments that use RSM are time- and cost-effective techniques for the 
optimization of formulations or processes since precise information is generated from a small 
number of experiments that have been conducted in a systematic manner. Furthermore RSM 
provides the formulation scientist with insight into formulation development with respect to 
composition and product behaviour through the use of suitable mathematical models [263]. 
 
RSM is useful for the identification of input factors that are critical for the production of a 
high quality pharmaceutical product, and the detection of potential interactions and synergies 
between input variables that are critical for the optimization of a formulation [263]. In 
addition RSM provides a thorough understanding of the process factors that are significant 
for the successful scale up of batches to a manufacturing scale. 
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5.1.1.5 Limitations of response surface methodology 
 
A limitation of using RSM is that relationships between input factors and measured response 
variables in which complex interactions exist between the variables under investigation may 
not be adequately described. Therefore the usefulness of RSM in optimization of a system 
becomes limited since a thorough investigation of the complex interactions requires an 
immense amount of resources and time.  
 
The experimental design approach used for RSM, viz. Box-Behnken, full factorial and CCD, 
are useful for the evaluation of a small number of input variables, since the number of 
experiments increases dramatically as the number of variables required to be investigated 
increases. In addition, the resultant polynomial relationships estimated by linear regression 
analysis would also become too complex, as the number of factors investigated increases 
resulting in complication of the optimization procedure [263]. 
 
5.1.2 In vitro drug release testing 
 
Dissolution testing for the characterization of release rate profiles of compounds with low 
aqueous solubility has been reported [274,275]. Dissolution testing is used to assess the 
ability of a dosage form, viz. tablet or capsule, to release an API in a specific test medium and 
it plays a major role in drug-product development and manufacturing since an API must be in 
solution in order to be absorbed [222].  The test is primarily a quality control tool that is used 
to measure batch-to-batch consistency in drug release and to show the impact of inherent 
variability in formulation excipients or manufacturing procedures on the dissolution of an 
API from a SODF [222,276].  
 
The dissolution properties of a solid dosage form may be tested in an artificial physiological 
environment, which is termed in vitro release testing, or in a physiological environment, 
which is termed in vivo release testing. Samples are usually analyzed with an appropriately 
validated analytical method. The test media commonly used for in vitro drug release studies 
include water, buffered systems that are at a pH of 1.2 (0.1 M HCl), 4.6, 6.5 or 7.5 [268]. In 
vivo dissolution studies are complex and expensive to perform but are critical for the 
determination of bioavailability and formulation suitability. In general, in vivo studies involve 
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the analysis of an API and/or metabolite(s) in whole blood, serum or some other appropriate 
biological fluids after collection at specific times following oral administration [277,278]. 
 
The USP requires IR dosage forms to release 85% of  an API  from the dose unit into a 
medium at 37±0.5
°
C within 45 min using either USP Apparatus 1 or  Apparatus 2 operated at 
100 rpm and 50 rpm respectively [279]. This is a general requirement and provides guidance 
for the development of acceptance criteria for the dissolution of an API in an IR solid dosage 
form and does not constitute an approach to the testing of a product that is alternative to that 
required in the product monograph.  
 
The acceptance criterion for the dissolution of MTZ and RTD tablets differs from 
compendium to compendium. The USP requires that no less than 85% of the label claim of 
MTZ is released within one hour when tested in 0.1 M HCl using USP Apparatus 1 at 100 
rpm and at a medium temperature of 37± 0.5
º
C [280]. For RTD tablets the USP requires that 
no less than 90% of the label claim is released within 45 min in water using USP Apparatus 2 
operated at 50 rpm and at a medium temperature of 37± 0.5
º
C [281].   
 
The FDA suggests that for a rapidly dissolving drug substance no less than 85% of the label 
claim should dissolve within 30 min in solution of different pH made up across the pH range 
[282]. MTZ and RTD are considered to be Class I or highly soluble highly permeable and 
Class III or highly soluble and poorly permeable compounds respectively [282-284] and 
according to the Biopharmaceutics Classification System (BCS) they are classified as rapidly 
dissolving drugs. The high solubility of MTZ and RTD prevents the use of 30 min as a 
discriminatory sampling time point to determine the effect of formulation variables on drug 
release in any critical manner, therefore it was decided to adopt 10 min as the discriminatory 
sampling point for determination of the effect of formulation variables on drug release from 
tablets manufactured in laboratories that contained these compounds.  
 
5.1.2.1 Factors that influence dissolution of drugs 
 
There are several steps that a solid dosage form undergoes prior to dissolution of an API in 
that dosage form, viz. wetting, dissolution medium penetration, swelling, disintegration of 
components into granules, deaggregation of the granules to form fine particles, and ultimately 
dissolution of the API  [285]. Nonetheless the dissolution process is complex and is 
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dependent on a variety of factors of which the formulation, composition and intrinsic 
properties of the API play a critical role. 
 
5.1.2.1.1 Properties of the API 
 
The solubility of an API in the test medium plays a significant role in the control of 
dissolution rate of that API from a SODF. The factors that influence the solubility of an API 
include, but are not limited to, the particle size, crystalline nature, amorphic and/or hydration 
state, free acid or base, salt form, eutectic and polymorphic form of the API. These are factors 
that must be controlled in order to achieve an optimal dissolution rate of an API from a 
dosage form [285,286]. 
 
5.1.2.1.2 Formulation properties 
 
The dissolution rate of an API may be influenced by the type and amount of the excipients 
used in a formulation in addition to the manufacturing procedure used to produce the dosage 
form [286]. 
 
The type and amount of a disintegrant that is incorporated into a formulation controls the 
dissolution rate of an API from a SODF significantly [285]. In general the dissolution rate of 
an API from a dosage form is increased with an increase in the amount of disintegrant 
included in the formulation as a result of an increase in surface area of the API available for 
dissolution [286-288]. 
 
The effect of diluents on the dissolution rate of an API is dependent of the properties of the 
diluent and the API, viz. hydrophilicity and hydophobicity respectively. The use of a 
hydrophilic diluent in a formulation comprised of a hydrophobic API has been reported to 
facilitate the dissolution of that API due to increased wetting of the dosage form and 
improved hydrophilicity of the API [286,287]. The diluent facilitates the formation of a fine 
hydrophilic surface layer around the API that promotes solvation of the API [286,287]. 
 
The type and concentration of binder or granulating agent may also have a significant impact 
on the dissolution rate of an API from a SODF. The incorporation of high concentrations of a 
binder in a formulation may result into the production of hard and compact tablets that do not 
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disintegrate easily, resulting in slower dissolution due to the presence of low surface area for 
the dissolution [286,287].  A typical example of the effect of binder on API dissolution has 
been encountered in phenobarbital tablets that are comprised gelatine as a binding agent. The 
use of gelatine solution for the manufacture of phenobarbital tablets has been reported to 
facilitate the dissolution of phenobarbital compared to when a sodium 
carboxymethylcellulose solution was used [286,287,289]. 
 
The effect of lubricants on the dissolution rate of an API is dependent on the physical 
properties of the lubricant, viz. hydrophilicity and hydrophobicity and their respective 
concentrations. Most of the lubricants used in SODF formulations are hydrophobic and 
consequently decrease the dissolution rate of an API from the dosage form. Hydrophobic 
lubricants form a thin hydrophobic film around the dosage form that prevents the penetration 
of dissolution medium, thereby reducing the dissolution rate of the API [236,286,287]. 
Hydrophilic lubricants, on the other hand, facilitate the dissolution of an API from a dosage 
form. However the effect of hydrophilic lubricants on the dissolution rate are more apparent 
when incorporated in a formulation comprised of a hydrophobic API, whereby the lubricant 
facilitates the wetting of the API and consequently increases the dissolution rate of the API 
[286,287]. 
 
5.1.2.1.3 Manufacturing processes and conditions 
 
Manufacturing processes, viz. milling, granulation, drying and tableting, may affect the 
physicochemical properties of an API and consequently may affect the dissolution rate of the 
drug [290]. APIs that exhibit polymorphism may undergo polymorphic change in certain 
manufacturing processes such as milling and/or granulation that may lead to a change in the 
properties of the API that facilitate dissolution [290].  
 
During tablet compression the use of a high compression force often results in a decrease in 
the dissolution rate of the drug from that tablet. The use of high compression forces facilitates 
particle bonding that subsequently causes an increase in tablet hardness and the formation of 
a firmer and more effective sealing layer by the lubricant, consequently decreasing the 
penetration of dissolution medium into the tablet [286,291].  
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Another example of a process condition that affects the dissolution of drug from a SODF is 
that of extensive blending during lubrication following addition of lubricant to the 
formulation. The duration of lubrication of powder or granule blends using hydrophobic 
lubricants is critical to the dissolution performance of a dosage form. Over blending of 
powder or granule blends with magnesium stearate or hydrophobic lubricant may result in 
formation of a hydrophobic film on the surface of dosage form that acts as barrier to 
penetration of dissolution medium [164]. 
 
5.1.2.1.4 Dissolution apparatus 
 
There are seven official apparatus listed in the USP for use in dissolution testing, and these 
are USP apparatus 1 viz. rotating basket, USP apparatus 2 viz. paddle, USP apparatus 3 viz. 
reciprocating cylinder, USP apparatus 4 viz. flow-through cell, USP apparatus 5 viz. paddle 
over disk, USP apparatus 6 viz. rotating cylinder, and USP apparatus 7 viz. reciprocating 
holder [276]. The dissolution rate of an API from a SODF is also dependent on the type of 
dissolution apparatus used when conducting the dissolution test. However for SODF, USP 
apparatus 1 and USP apparatus 2 are the most commonly recommended apparatus in 
regulatory guidelines [292]. USP apparatus 3 has also been used for SODF in cases where 
dissolution results generated from USP apparatus 1 or  2 become unreliable due to shaft 
wobble, location, centring and coning [293]. Furthermore, due to the single container nature 
of USP apparatus 1 and 2, variations in medium parameters such as pH, change in sink 
conditions and saturation during an experiment are inevitable. Therefore the use of USP 
apparatus 3 may facilitate the generation of precise dissolution results in cases where the 
variation in medium parameters may exert a significant effect on the reliability of the 
dissolution results [292]. 
 
In addition the precise set-up of a dissolution apparatus contributes to the generation of 
accurate and reliable dissolution measurements since reproducibility of dissolution test results 
are dependent on the consistency of medium flow patterns and the hydrodynamic properties 
of a dissolution medium. It has been documented that most of the automated dissolution 
apparatus may produce erroneous dissolution data as result of disruption of system 
hydrodynamics due to continuous immersion of sample probes [285]. 
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5.1.2.1.5 Dissolution test parameters 
 
The reproducibility of dissolution rate testing results are affected by several test parameters 
including pH, the nature, composition, volume and viscosity of the dissolution medium in 
which the test is conducted [286]. Inconsistent production of dissolution media may lead to 
increases or decreases in the dissolution rate of an API, and dissolved air in the dissolution 
medium is another major source of error in dissolution rate testing. Temperature changes may 
result in the release of air that is dissolved in the dissolution medium and the bubbles could 
adhere to the surface of the dosage unit. As a consequence a barrier may be formed between 
the medium and the dosage unit under investigation, leading to a reduction in the dissolution 
rate of an API as a result of reduced surface area of tablet medium interface [285]. 
 
5.2 EXPERIMENTAL 
 
5.2.1 Proposed evaluation design 
 
The successful optimization of a formulation is dependent on the composition of the 
formulation whereby incorporation of suitable excipients in the formulation is of paramount 
importance in order to achieve optimal performance of the dosage form. The suitability of an 
excipient is usually determined through screening of potential excipients known to have the 
appropriate tableting characteristics. MCC and DCP, viz. diluents CCS and SSG, viz. 
disintegrants, are commonly used excipients that are usually included in formulation for the 
manufacture of tablets and their impact on a dosage form is well documented [182,288,294-
297]. Therefore to screen for a suitable diluent and disintegrant that may be used in the 
optimization process in these studies, batches RM 013, RM 014 and RM 015 were 
manufactured according to the method described in § 4.2.4.2.3 and the formulae described in 
Table 5.1, which is similar to the formula described in Table 4.2.  
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Table 5.1 Formulation composition of batches manufactured for preliminary studies  
Excipient RM 011  
(% w/w) 
RM 013  
(% w/w) 
RM 014  
(% w/w) 
RM 015  
(% w/w) 
API*     
MCC 27 27 - - 
DCP - - 27 27 
SSG 4 - - 4 
CCS - 4 4 - 
PVP-K30 1 1 1 1 
Colloidal silicon 
dioxide 
0.2 0.2 0.2 0.2 
Magnesium stearate 1 1 1 1 
*MTZ (50% w/w) and RTD (16.8% w/w) 
 
The selection of a suitable diluent and disintegrant for response surface studies was 
performed by evaluation of physicochemical characteristics such as weight, disintegration 
time, assay, dissolution,  friability, tensile strength and the crushing strength of the resultant 
tablets. Further, the physicochemical characteristics of  the tablets comprised of MCC and 
SSG were generated from batch RM 011 that had also been manufactured using the method 
described in § 4.2.4.2.3 and the formula described in Table 4.2 vide infra. 
 
Following the preliminary studies, the effect of  input variables, viz. binder, disintegrant and 
magnesium stearate composition, on the response variables  Dt and % drug released in 10 min 
(Q10) of MTZ and RTD were investigated using a Box-Behnken experimental design 
approach. 
 
5.2.2 Materials and equipment 
 
All the materials and equipment that were used were the same as those reported in § 4.2.2 and 
§ 4.2.3 respectively vide infra. 
 
5.2.3 Experimental design 
 
5.2.3.1 Box-Behnken design  
 
An evaluation of the main effects, interaction and quadratic effects of the input and response 
variables was performed using a Box-Behnken statistical screening design that had three 
centre points. The mathematical relationship between the input and output variables was 
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generated using Design Expert
®
 8.0.4 software (Stat-Ease Inc, Minneapolis, Minnesota, 
USA). The independent variable levels were established based on level two formulation and 
composition changes that have been described in SUPAC-IR [268] and were studied at three 
levels, viz. high, medium and low. The levels of the independent variables and the constraints 
of the responses used in optimization studies are described in Table 5.2. 
 
Table 5.2  Actual content of factors used and respective codes (independent variables) and constraints 
of response (dependent) variables used in Box-Behnken design 
Independent variables Levels used, Actual (Coded) 
Low (-1) Medium (0) High (+1) 
x1= CCS (% w/w) 15 20 25 
x2= PVP-K30 (% w/w) 0 5 10 
x3= Magnesium stearate (% w/w) 2.5 5 7.5 
Dependent variables Constraints 
y1= Dt Minimize 
y2= MTZ Q10 80 > y2 < 90 
y3= RTD Q10  80 > y3 < 90 
  
A summary of the composition of the independent variables used for the manufacture of 
tablets following the Box-Behnken design are listed in Table 5.3. 
 
Table 5.3 Combination sequence of independent variable levels generated using a Box-Behnken 
design of experiment 
Batch number 
a Independent variables 
x1 x2 x3 
RM 016 15.00 0.00 5.00 
RM 017 25.00 0.00 5.00 
RM 018 15.00 10.00 5.00 
RM 019 25.00 10.00 5.00 
RM 020 15.00 5.00 2.50 
RM 021 25.00 5.00 2.50 
RM 022 15.00 5.00 7.50 
RM 023 25.00 5.00 7.50 
RM 024 20.00 0.00 2.50 
RM 025 20.00 10.00 2.50 
RM 026 20.00 0.00 7.50 
RM 027 20.00 10.00 7.50 
RM 028 20.00 5.00 5.00 
RM 029 20.00 5.00 5.00 
RM 030 20.00 5.00 5.00 
a
 Indicates arrangement in standard order 
 
5.2.3.2 Statistical analysis of the data 
 
The significance of the model and model terms that were generated were analyzed using 
analysis of variance (ANOVA) type three (partial sum of squares) at a 5% level of 
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significance using  the statistical package, Design Expert
®
 8.0.4 (Stat-Ease Inc, Minneapolis, 
Minnesota, USA) . The predicted residual error sum of squares (PRESS) was used to assess 
which of the input factors had a significant impact on the measured response. A backward 
elimination procedure was used to fit data into the different predictor equations and the 
negligible effect of omission of non-significant factors was confirmed following comparison 
of the predicted and adjusted R
2
 values of the full and reduced model. Furthermore, predicted 
vs. actual data diagnostic plots were used to determine the goodness of fit of the proposed 
model to the experimental data and these results are shown in Appendix 2.  
 
5.2.4 Preparation and rheological studies of binder solutions 
 
Binder solutions were prepared using PVP-K30 at concentrations of 12.5% w/v and 25% w/v 
as described in § 4.2.4.2.1. Rheological studies of the resultant binder solutions were 
performed as described in § 4.2.4.2.2. 
 
5.2.5 Characterization of granules 
 
The impact of viscosity of the binder solution on granule particle size following granulation 
has been reported [227,260,298]. MCC exhibits properties of a binder in addition to its use as 
a diluent and its effect as a binder was investigated by comparing the particle size distribution 
of the granules that were produced using a binder solution comprised of PVP-K30 and 
purified water. 
 
The particle size distribution of the granules was established using a Model VT sieve shaker 
(Erweka, GmbH, Heussenstam, Germany) fitted to a Model UPE drive unit (Kraemer 
Elektronik GmbH,  Dramstadt, Germany) and a sieve stack comprised of sieves with 315, 
800, 1250 and 2000 µm apertures that conformed to DIN 4188 standards. A 100 g sample of 
the dried granulation was weighed and placed in the sieve stack that was then closed and set 
to shake for 10 min at an oscillation speed rpm of 200. The amount of granulation retained on 
the sieves was then weighed and the results were expressed as % w/w of the dry granules 
retained on the sieves. 
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5.2.6 Physical properties of tablets  
 
The tablets were subjected to dissolution, assay, disintegration, friability, crushing strength, 
tensile strength, thickness, diameter and weight testing and these procedures were performed 
as described in § 4.2.5.  
 
5.2.7 In vitro release 
 
In vitro release studies of the FDC were performed using USP Apparatus 2 (Hanson Research 
SR 8 PLUS, Chartsworth, California, USA) fitted with an Autoplus™ Multifill™ and 
Maximizer Syringe Fraction Collector. Six tablets were dropped into the dissolution vessels 
each containing 900 ml of degassed 0.1 M HCl (pH 1.2). The paddles were set to rotate at   
75 rpm since this speed represented a suitable compromise between the 50 and 100 rpm 
specifications described in the USP for RTD and MTZ respectively. The temperature of the 
dissolution media was maintained at 37±0.5
°
C and 5 ml aliquots were collected for analysis 
at intervals of 10, 20, 30 and 45 min with replacement of an equal volume of fresh medium 
after each sample collection. Aliquots of 0.1 ml of the samples were collected using an 
electronic pipette (Boeckel & Co. GmbH,  Hamburg, Germany) and transferred into a 5 ml 
A-grade volumetric flask followed by addition of 2 ml of IS that had been prepared as 
described in § 2.3.2.3. The resultant solution was made up to volume using MeOH:water 
(80:20) and filtered through 0.22 µm Acrodisc
®
 PSF syringe filter (Pall Corporation, Port 
Washington, New York, USA) prior to analysis using the HPLC method described in Chapter 
Two vide infra. 
 
5.3 RESULTS AND DISCUSSION 
 
5.3.1 Rheological studies 
 
The viscosities of the resultant PVP-K30 binder solutions in purified water listed in Table 5.4 
were in close agreement to the reported values [299].   
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Table 5.4 The viscosity of PVP-K30 binder solution 
PVP-K30 concentration in purified water 
 %w/v 
Viscosity (n=3) 
cP 
0   1.0 ± 0.01 
12.5   8.1 ± 0.01 
25.0 25.8 ± 0.01 
 
5.3.2 Physical properties of tablets  
 
The tablets that were produced were cream in colour and had a smooth surface without 
evidence of chipping or lamination. The resultant tablet weight, thickness, diameter, assay, 
crushing strength, tensile strength and friability data of all manufactured batches are 
summarized in Table 5.5. 
 
The weight of the tablets ranged between 494 and 510 mg with the average diameter ranging 
between 12.00 and 12.07 mm and thickness ranging between 3.31 and 3.40 mm.  
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Table 5.5 Physicochemical properties of the resultant tablets (preliminary and experimental design formulations) 
Batch number Weight (n=10) 
mg 
Thickness 
(n=10) mm 
Diameter 
(n=10) mm  
Crushing strength 
(n=10) N 
Tensile 
strength  MPa 
Friability 
(%) 
Dt (n=6) min Assay (n=3) % 
MTZ RTD 
RM 011 495.86±1.78 3.31±0.00 12.02±0.02    158±17.2 2.52 0.20 13.05±1.55   85.19 ± 3.14 84.41 ± 8.23 
RM 013 496.80±1.58 3.32±0.00 12.02±0.00    101±5.30 1.61 0.10 11.49±1.15   83.49 ± 4.13 81.30 ± 4.70 
RM 014 501.34±7.35 3.35±0.02 12.03±0.03   67.1±11.00 1.06 0.20   4.61±1.26   68.53 ± 2.53 78.92 ± 1.68 
RM 015 498.02±3.17 3.30±0.01 12.02±0.00   77.8±10.10 1.24 0.09   8.56±1.81   74.70 ± 4.43 73.69 ± 2.27 
RM 016 509.90±3.21 3.37±0.03 12.04±0.02   99.4±09.50 1.56 0.30   8.71±0.75   85.60 ± 1.60 86.09 ± 2.05 
RM 017 508.83±2.95 3.39±0.03 12.05±0.02   88.5±07.00 1.37 0.19   3.58±0.49   84.28 ± 2.01 81.89 ± 1.77 
RM 018 494.19±3.15 3.31±0.03 12.03±0.00   88.7±06.80 1.41 0.20 10.32±1.54   87.78 ± 6.41 85.34 ± 3.68 
RM 019 508.47±4.85 3.40±0.00 12.05±0.02 102.4±12.40 1.59 0.09   6.08±0.20 105.19 ± 1.85 81.51 ± 1.58 
RM 020 500.42±5.33 3.35±0.02 12.02±0.00   99.5±13.40 1.57 0.19   9.58±0.91   84.96 ± 2.67 89.05 ± 1.81 
RM 021 502.56±3.27 3.34±0.01 12.03±0.00   92.7±05.20 1.46 0.19   5.50±0.54 105.78 ± 4.42 99.79 ± 3.77 
RM 022 506.96±3.06 3.39±0.01 12.01±0.00 100.9±0.58 1.57 0.29 11.41±0.20   89.56 ± 3.36 91.32 ± 2.93 
RM 023 503.76±7.18 3.38±0.03 12.02±0.00   86.8±04.10 1.36 0.29   7.33±0.25   85.87 ± 1.49 88.74 ± 3.94 
RM 024 507.98±6.35 3.38±0.03 12.02±0.00 115.5±04.8 1.81 0.09   5.33±1.22 110.23 ± 2.11 86.81 ± 1.40 
RM 025 496.83±3.40 3.37±0.02 12.01±0.00 124.4±10.7 1.95 0.10   8.50±1.01   90.18 ± 2.25 86.06 ± 1.32 
RM 026 500.81±2.46 3.31±0.02 12.05±0.02   83.9±11.80 1.33 0.27   6.38±0.87   96.98 ± 2.70 94.56 ± 2.13 
RM 027 498.28±2.10 3.32±0.02 12.04±0.01   91.3±07.00 1.45 0.27   9.81±0.77   88.67 ± 1.18 84.71 ± 2.24 
RM 028 500.21±4.17 3.32±0.02 12.03±0.00   95.6±06.20 1.52 0.29   7.55±0.28   84.92 ± 5.87 85.01 ± 2.79 
RM 029 499.18±3.14 3.31±0.02 12.07±0.07   94.7±08.70 1.50 0.30   7.21±0.87   87.31 ± 3.84 90.47 ± 3.30 
RM 030 503.43±4.10 3.34±0.02 12.06±0.07   93.5±07.50 1.47 0.19   6.93±0.51   87.27 ± 7.20 86.93 ± 6.53 
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5.3.3 Preliminary screening formulations  
 
5.3.3.1 Physical properties of tablets  
 
The data summarized in Table 5.5 reveals that formulations that were manufactured using 
DCP, viz. batches RM 014 and 015, resulted in the production of soft tablets of between     
67-77 N compared to the formulation in which MCC, viz. batches RM 011 and RM 013, was 
used. These tablets exhibited crushing strength of between 101 and 158 N.  
 
All tablets were not friable as all the values for this parameter were ≤0.3% and all tablets had 
a Dt <15 min. Furthermore, formulations in which CCS was used produced tablets with 
shorter Dt compared to those which were manufactured using SSG. 
 
The content of MTZ:RTD  in tablets manufactured in these preliminary studies was low, with 
a drug content of < 80% for tablets in which DCP was used and >80%  for tablets in which 
the diluent was MCC. Therefore all subsequent batches were manufactured using MCC and 
the MTZ and RTD content for these was between 83-110% and 81-99% respectively. On this 
basis MCC and CCS were considered to be the most suitable diluent and disintegrant 
respectively for the response surface studies. 
 
5.3.3.2 In vitro release    
 
The dissolution profiles of MTZ and RTD from tablets that were manufactured in the 
preliminary studies, viz. batches RM 011, RM 013, RM 014 and RM 015, are shown in 
Figures 5.1 and 5.2 respectively. For ease of understanding the qualitative impact of the 
diluents, viz. MCC and DCP, on the Q10 for MTZ and RTD, the dissolution profiles of the 
tablets comprised of a similar disintegrant, viz. batches RM 011 and RM 015, RM 013 and 
RM 014, were compared. A similar approach was also used to evaluate the qualitative impact 
of the disintegrant, viz. CCS and SSG, on the Q10 for MTZ and RTD. 
 
5.3.3.2.1 In vitro release of metronidazole 
 
The dissolution profiles of batches RM 013 and RM 014 shown in Figure 5.1 indicate a burst 
release of MTZ with a Q10 value of 82% for tablets that are comprised of MCC and CCS, viz. 
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formulation RM 013, whereas those comprised of DCP and CCS, viz. formulation RM 014, 
exhibited a Q10 value of 55%. The high Q10 value for MTZ observed for the tablets in 
formulation RM 013 may be attributed to the hydrophilicity of MCC as it facilitates wetting 
of the tablet and consequently rapid dissolution of the drug from the tablet whereas DCP is 
hydrophobic and therefore may delay the wetting process [286,287].  
 
 
Figure 5.1 In vitro dissolution profiles of MTZ from preliminary batches 
 
The Q10 for MTZ observed for the tablets comprised of SSG and MCC, viz. formulation RM 
011, and CCS MCC, viz. formulation RM 013, revealed large variability in the rate of drug 
release. CCS appears to have a greater effect in facilitating the release of MTZ as evidenced 
by the Q10 value of 82% compared to the Q10 value of 24% exhibited in formulation RM 011. 
The release of MTZ in formulation RM 011 appears to be slow with only 32% released 
within the first 20 min of dissolution testing after which a burst release of MTZ occurs.  
 
In contrast to the effect of SSG on the Q10 value for MTZ in formulation RM 011 a relatively 
minor change was observed for the Q10 value of MTZ in formulations RM 014 and RM 015. 
Substitution of SSG for CCS in tablets comprised of DCP resulted in a change in the Q10 
value for MTZ from 66% to 55%. This observation suggests that the combination of SSG and 
DCP in a formulation may result in the production of tablets with better dissolution 
characteristics for MTZ compared to a formulation in which a combination of CCS and DCP 
are used. 
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5.3.3.2.2 Dissolution of ranitidine 
 
Drug release from formulation RM 013 exhibited a burst release of RTD with a Q10 value of 
89% and 95% observed for RTD within 30 min of the commencement of dissolution testing 
as shown in Figure 5.2.  
 
 
Figure 5.2 In vitro release profiles of RTD form preliminary formulations 
 
In contrast to the effect of CCS on the Q10 for RTD in formulation RM 013, tablets comprised 
of DCP, viz. formulation RM 014, exhibited a Q10 value of 59% for RTD followed by 83% 
release within 45 min of dissolution testing. These results suggest that MCC facilitates the 
dissolution of RTD to greater extent than DCP. 
 
The substitution of CCS for SSG in formulation RM 011 resulted in a drastic decline in the 
Q10 value for RTD with only 31% being released compared to the Q10 value of 89% observed 
when CCS was used in formulation RM 013. The dissolution of RTD from formulation RM 
011 appears to be slow, achieving ≥90% with 30 min of dissolution testing. Conversely a 
minor change was observed for the Q10 value for RTD following the substitution of CCS for 
SSG in formulations comprised of DCP, viz. formulations RM 014 and RM 015. Tablets in 
which SSG and DCP were used, viz. formulation RM 015, exhibited a Q10 of 59% for RTD 
whereas a Q10 of 61% was observed for the formulation comprised of CCS and DCP, viz. RM 
014. Therefore it may be concluded that a combination of MCC and CCS results in the 
production of tablets with better Q10 values compared to those produced with DCP. 
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5.3.4 Box-Behnken design formulations  
 
5.3.4.1 Micromeretic analysis of granules 
 
Granulation is a commonly used process to enlarge the particle size of a material [300] during 
the manufacture of tablets for the purposes of improving flowability, compressiblity and 
homogeneity of the powder blends and to reduce dust and possible cross-contamination 
[230,301].  
 
The particle size distribution of the granulation depicted in Figure 5.3 reveals some degree of 
similarity between the granule size distribution observed when using 12.5% w/v PVP-K30 
solution with a viscosity of 8.1±0.01 cP and those produced using water of 1.0±0.01 cP 
viscosity.  
 
 
Figure 5.3 Granulation size distribution of formulations comprised of 0.00%, 12.50% and 25.00% 
(w/v)  
of PVP-K30 
 
Approximately 66% w/w of the granulation in the formulations manufactured using 0% and 
12.5% w/v PVP-K30 were <315 µm in diameter, 27.5% w/w were sized ≥315≤800 µm and 
only 4.7% w/w were sized ≥800≤1250 µm. The granulation produced using a 25% w/v PVP-
K30 solution and viscosity of 25.8±0.01 cP was mostly comprised of two categories of 
granule size as shown in Figure 5.3. Approximately 45% w/w of the granulation was       
<315 µm in size and ≥315≤ 800 µm, whereas 7.3% w/w was sized ≥800≤1250 µm.  
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The difference in the size of the granules observed following granulation using the binder 
solution of 25% w/v PVP-K30 may well be due to the high viscosity of the binder solution. 
An increase in the viscosity of a binder solution is known to facilitate granule growth as a 
consequence of increased cohesivity of the binder solution and granule-break threshold 
[260,302]. Similar results were also reported by Becker et al. [298] following an investigation 
into the effect of use of different binding agents in wet granulation procedures. In contrast to 
the results observed when 25.8±0.01 cP PVP-K30 solution was used, the effect of viscosity 
on granule size distribution was not apparent for granules produced when water or 12.5% w/v 
PVP-K30 solution was used as the granulation fluid.  
 
5.3.4.2 Disintegration time (Dt)  
 
The impact of formulation variables on the Dt of the tablets was investigated using RSM to 
determine which of the input variables may have a significant impact on the Dt of the tablets. 
The quadratic model shown in Equation 5.4 describes the quantitative effect of CCS (x1), 
PVP-K30 (x2) and magnesium stearate (x3) on the Dt of the resultant tablet. 
 
y1=                                    
         
        
           Equation 5.4 
 
It is evident from Equation 5.4 that an increase in the amount of CCS used in the formulation 
resulted in a decrease in the Dt whereas an increase in the content of magnesium stearate and 
PVP-K30 leads to an increase in the Dt.   
 
The effect of the amount of CCS on the Dt of the tablets has been investigated and the 
decrease in Dt observed as function of an increase in the content of CCS is ascribed to 
increased wicking and the swelling capacity of the disintegrant [294,303]. An increase in the 
wicking and swelling capacity of CCS following exposure to water results in an increase in 
the rate of fragmentation of the tablet which is dependent on the concentration of CCS in the 
tablet [304]. Similar results were observed following the use of statistical optimization of an 
IR formulation of a water soluble drug [305]. 
 
In contrast magnesium stearate has been reported to delay the disintegration of tablets 
[306,307]. Magnesium stearate is hydrophobic in nature and is comprised of fine particles 
that easily abrade and adhere to the surfaces of other components of a formulation, leading to 
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the formation of a hydrophobic film on that surface [164]. The resultant hydrophobic film 
acts as a barrier and delays the penetration of water into the formulation, delaying wetting of 
the tablet and ultimately leading to a delay in disintegration. The concentration of magnesium 
stearate and the duration of lubrication blending have a profound effect on tablet 
disintegration [136]. However, since the blending time following the addition of the lubricant 
was constant for all the batches, the variation in Dt can be attributed to the amount of 
magnesium stearate in the formulation. Similar results were observed following formulation 
optimization studies of fast disintegrating tablets [306]. 
 
In general the quantity and type of binder used in wet granulation has an effect on the 
ultimate characteristics of a compressed tablet. The use of excess or a strong binder during 
granulation results in the production of tablets that are very hard and that do not disintegrate 
readily [286,299]. The increase in Dt observed as a result of an increase in binder content in 
the formulation may be attributed to an increase in the mechanical strength of the resultant 
tablets. Binders are cohesive in nature and facilitate the agglomeration of powder particles to 
form granules, resulting in improved compactability of the granules and improved 
mechanical strength of the tablets [308]. Although the evidence of a direct effect of PVP-K30 
on the disintegration of tablets has not been reported, the increase in Dt of these tablets may 
be attributed to a reduced permeability of the tablet to water, therefore the increase in 
mechanical strength of the tablets as a result of an increase in binder content confers 
resistance to penetration of water, consequently prolonging the disintegration time of the 
tablets. 
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Figure 5.4 A three-dimensional response surface plot showing the relationship between CCS, 
magnesium stearate and Dt with PVP-K30 maintained at medium level 
 
It is evident in Figure 5.4 that CCS has a profound effect on the Dt of the tablets compared to 
the effects of magnesium stearate. Tablets with the shortest Dt are produced when the content 
of CCS is at a high level, viz. ≥25 mg, and longer Dt are observed when the levels of CCS are 
low, viz. ≤15 mg. The effect of magnesium stearate and PVP-K30 on Dt are significantly 
dependent on the amount of CCS in the formulations. A significant decrease in Dt is observed 
when the content of magnesium stearate is decreased from 7.5 mg to 5.0 mg and a further 
decrease in content of this lubricant to <5.0 mg did not result in a further significant change 
in Dt.. 
 
The response surface plot in Figure 5.5 shows that the effect of PVP-K30 on Dt is also 
dependent on the CCS content. However, the effect of variation in levels of PVP-K30 on Dt 
is more pronounced when the content of CCS is ≥15≤21 mg and becomes less significant at 
high levels of CCS, viz. >21 mg of CCS, as shown in Figure 5.5. This may be due to 
increased wicking and swelling capacity of CCS as a consequence of an increase in 
concentration, as has been reported [294,303]. At low levels of CCS, viz. <20 mg per tablet, 
the mechanical strength of the tablet is determined by the content of PVP-K30 and resistance 
to fragmentation predominates whereas at high levels, viz. >20 mg of CCS, the mechanical 
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strength of the tablet is not sufficient to resist fragmentation induced as a result of wicking 
and swelling of the CCS irrespective of the levels of PVP-K30.  
  
 
Figure 5.5 A three-dimensional response surface plot showing the relationship between CCS,  
PVP-K30 and Dt with magnesium stearate maintained at medium level 
 
The contour plot depicted in Figure 5.6 visually describes the relationship between PVP-K30, 
CCS and the Dt with the content of magnesium stearate held constant at intermediate level. 
   
 
Figure 5.6 Contour plot showing the relationship between CCS, PVP-K30 and Dt at intermediate 
levels of magnesium stearate  
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A variation in the content levels of magnesium stearate and PVP-K30 has a relatively minor 
effect on the Dt when the concentration of CCS is held constant at intermediate levels, as 
shown in Figure 5.7.  
 
Figure 5.7 Contour plot showing the relationship between PVP-K30, magnesium stearate and 
disintegration time at intermediate levels of CCS 
   
Tablets with a long Dt, viz. 9 min, are produced when the content of magnesium stearate and 
PVP-K30 are at high levels, viz. 7.5 mg and 10.0 mg respectively. However a reduction in the 
content of both PVP-K30 and magnesium stearate to lower levels results in a relatively minor 
decrease in Dt to 6 min. The long Dt observed at high levels of magnesium stearate and PVP-
K30 may be attributed to increased hydrophobicity and formation of a viscous film that 
reduce wetability of the resultant tablets [136,286].  
 
5.3.4.3 In vitro release of tablets manufactured using a Box-Behnken design  
 
For ease of determination of the quantitative and qualitative effects of factor on drug release, 
the Q10 for MTZ and RTD from formulations manufactured with different levels of input 
factors were compared with those from formulations manufactured with intermediate levels 
of excipient composition, i.e. the centre formulations. The notation used to depict the 
formulations uses the ratios of CCS:PVP-K30:magnesium stearate and this convention has 
been adopted for the following discussion. By way of example, the centre point formulation 
is denoted 40:10:10. 
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5.3.4.4 In vitro release of formulations with low levels of factors  
 
The effect of low levels of CCS, PVP-K30 and magnesium stearate in different ratios on the 
dissolution of MTZ and RTD are depicted in Figure 5.8 and Figure 5.9 respectively.  
 
5.3.4.4.1  In vitro release of metronidazole 
 
The centre formulation exhibited 71% release within 10 min for MTZ and 100% of the 
compound is released within 20 min of the commencement of dissolution testing as shown in 
Figure 5.8.  
 
Figure 5.8 In vitro release profiles of MTZ for formulations that contain CCS, PVP-K30 and 
magnesium stearate at lower levels of composition compared to the centre formulation 
 
A reduction in the levels of CCS and the exclusion of PVP-K30 in formulation 30:00:10 
resulted in a significant effect on the Q10 for MTZ, viz. 40% released, however the total 
amount of MTZ released was unaffected. Formulation 40:00:05 exhibited a relatively minor 
decrease in Q10 for MTZ, viz. 65%, when PVP-K30 was excluded and magnesium stearate 
was included at low levels, however the overall amount of MTZ released was unaffected with 
84% MTZ released after 45 min of test. A reduction in CCS and magnesium stearate to 
minimum levels, viz. formulation 30:10:05 resulted in a dramatic reduction in the Q10 for 
MTZ to 36%, however approximately 100% MTZ was released within 20 min of 
commencing dissolution testing. It is evident that the Q10 for MTZ is dependent on the 
content of CCS. Furthermore the exclusion of PVP-K30 and the use of low levels of 
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magnesium stearate have a relatively minor effect on the release of MTZ as evidenced by the 
changes in Q10.  
 
5.3.4.4.2 In vitro release of ranitdine 
 
Similarly to the release of MTZ, the centre formulation exhibited a burst release of RTD with 
a Q10 for the drug of 67% and 89% drug release within 20 min of commencement of 
dissolution testing as shown in Figure 5.9. The exclusion of PVP-K30 and the reduction of 
CCS to a lower level in formulation 30:00:10 resulted in a decrease in Q10 for RTD to 50%. 
 
Figure 5.9 In vitro release profile of RTD for formulations that contain CCS, PVP-K30 and 
magnesium stearate at lower levels of composition compared with centre formulation 
 
However, the total drug released was unaffected since 92% RTD was released within 20 min. 
The reduction of magnesium stearate to 2.5 mg per tablet and the exclusion of PVP-K30 in 
formulation 40:00:05 had a relatively minor effect on the Q10 for RTD compared to that 
observed for the centre formulation. Formulations 40:00:05 exhibited a Q10 of 66% for RTD 
and 83% of RTD was released within 20 min of commencement of the test.  The reduction of 
both CCS and magnesium stearate to low levels, viz. 15 mg and 2.5 mg respectively, in 
formulation 30:10:05 resulted in a significant reduction in the initial amount of RTD released. 
Low levels of CCS and magnesium stearate in formulation 30:10:05 resulted in a Q10 of 40% 
for RTD and an almost two fold increase in the extent of drug released to a value of 77% 
after 20 min compared to the Q10, and 85% release was achieved with 30 min of 
commencement of the dissolution test. Therefore it is clear that the dissolution of RTD is 
dependent on the concentration of CCS in the formulation. Furthermore magnesium stearate 
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and PVP-K30 exhibited relatively minor effects on the dissolution of RTD compared to that 
observed for the centre formulation. However at low levels of CCS, viz. 15 mg, in 
formulations 30:00:10 and 30:10:05 the dissolution profiles suggest that PVP-K30 has a 
greater retardation effect on the dissolution of RTD compared to the effect observed for 
magnesium stearate when using this Q10 approach to evaluate the data.  
 
5.3.4.5 In vitro drug release of formulations with high levels of factors 
 
The effects of high levels of CCS, PVP-K30 and magnesium stearate on the release of MTZ 
and RTD are depicted in Figures 5.10 and Figure 5.11 respectively. 
 
5.3.4.5.1 In vitro release of metronidazole 
 
Formulation 50:20:10 in which high concentrations of CCS and PVP-K30 were used 
exhibited a burst release for MTZ with the resultant Q10 of 82% and 97% of MTZ released 
after 20 min as shown in Figure 5.10. High concentrations of CCS and magnesium stearate, 
viz. 50:10:15, had a relatively minor effect on the Q10 for MTZ compared to that observed for 
the centre formulation. In contrast, increasing the PVP-K30 and magnesium stearate content 
of the tablet to 10 mg and 7.5 mg respectively, viz. formulation 40:20:15, resulted in a 
decrease in Q10 for MTZ by a factor of 1.5 (46%) when compared to 71% for the centre 
formulation. 
 
Figure 5.10 In vitro release profile of MTZ for formulations that contain CCS, PVP-K30 and 
magnesium stearate at high levels of composition compared with centre formulation 
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It is apparent that the Q10 for MTZ is dependent on the amount of CCS used in the 
formulation. Moreover the effects of PVP-K30 and magnesium stearate on the Q10 of MTZ 
are also dependent on the CCS content. At high concentrations of CCS, viz. 25 mg per tablet, 
variations in the amount of PVP-K30, viz. formulation 50:20:10, and magnesium stearate, viz. 
formulation 50:10:15, exert relatively minor effects on the Q10 of MTZ. When the content of 
CCS is held constant at 20 mg per tablet, viz. formulation 40:20:15, an increase in the PVP-
K30 and magnesium stearate content results in a significant decrease for the Q10 of MTZ. The 
effect of varying the amount of binder on dissolution at constant levels of disintegrant has 
been reported [309]. The decrease in the value for Q10 observed following an increase in the 
content of PVP-K30 and magnesium stearate may be ascribed to the effect of a combination 
of factors, viz. formation of viscous film and hydrophobic film formation respectively. The 
inclusion of a high concentration of binder in a formulation may result in a formation of a 
viscous film on the surface of the tablet, with a consequent retardation in dissolution of the 
API [310]. 
 
5.3.4.5.2 In vitro release of ranitidine 
 
The in vitro dissolution profile of formulation 50:20:10 which is comprised of high amounts 
of CCS and PVP-K30, viz.25 and 10 mg per tablet respectively, is depicted in Figure 5.11 and 
reveals a Q10 of 62%  for  RTD  and a total of 86% release was observed within 20 min of 
commencement of dissolution testing. A similar profile was also observed for formulation 
50:10:15 in which an increase in the content of CCS and magnesium stearate resulted in a Q10 
of 72% and 90% of RTD was released within 20 min of commencement of the test. It is 
apparent that intermediate levels of PVP-K30, viz. 5 mg per tablet, and high levels of 
magnesium stearate and CCS facilitate the release of RTD. This observation indicates that a 
possible synergistic interaction between CCS and magnesium stearate exists which promotes 
the release of RTD. In contrast an increase in the content of magnesium stearate and PVP-
K30 and constant level of CCS, viz. formulation 40:20:15, results in the opposite effect being 
observed. The Q10 for RTD was reduced to 40% compared to that of 67% observed for the 
centre formulation. The low Q10 of 40% observed may be attributed to the high content of 
PVP-K30 and magnesium stearate as has been discussed [310,311]. 
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Figure 5.11 In vitro release profile of RTD for formulations that contain CCS, PVP-K30 and 
magnesium stearate at high levels of composition compared with centre formulation 
 
It is apparent that the overall Q10 for formulations that contain high and low amounts of CCS 
are similar, which suggests that CCS has a significant impact on the rate of drug release from 
these dosage forms. Further the impact of PVP-K30 and magnesium stearate on drug release 
is dependent on the content of CCS, which validates the fact that CCS is an important 
formulation factor that determines the rate of drug release. However the relationship between 
the factors and their levels in their impact on the rate of drug release is complex and involves 
some degree of interaction, as shown for formulation 50:10:15 depicted in Figure 5.11. The 
use of RSM may be valuable to investigate and explore the nature of this relationship and its 
potential impact on the release of MTZ and RTD. 
 
5.3.5 Response surface modelling 
 
The Q10 for MTZ and RTD are best described by use of a quadratic equation. The polynomial 
models used for the investigation of the relationship between the input factors and in vitro 
release profiles of MTZ and RTD are summarized in Equations 5.5 and 5.6. 
 
                                  
        
         
               Equation 5.5 
                                              
        
         Equation 5.6 
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Where, 
x1= CCS 
x2= PVP-K30 
x3= Magnesium stearate 
y2= Q10 of MTZ 
y3= Q10 of RTD 
 
Coefficients with more than one factor represent an interaction between factors and 
coefficients with second order terms are indicative of the quadratic nature of that relationship 
and are used to simulate the curvature of the design space of the sample. 
 
From Equation 5.5 it is evident that CCS has synergistic effect on the release of MTZ 
whereas PVP-K30 and magnesium stearate have an opposite effect. These results are 
supported by the in vitro release profiles depicted in Figures 5.8 and 5.10. Similar results 
were also observed following an investigation into the effect of disintegrant, filler ratio and 
lubricant levels on the in vitro release of propranolol hydrochloride [289]. 
 
Similarly CCS has a synergistic effect on the release of RTD whereas PVP-K30 and 
magnesium stearate have an antagonistic effect as described by Equation 5.6. Furthermore, 
CCS and magnesium stearate exhibit a synergistic interaction on the release of RTD, as can 
be seen from the positive value of the coefficient for this factor.  
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The impact of independent factors, viz. CCS, PVP-K30 and magnesium stearate, at different 
levels on the in vitro release rate of MTZ and RTD is shown on contour and three-
dimensional response surface plots in Figures 5.12-5.18 and 5.19-5.21 respectively. 
 
Figure 5.12 A three-dimensional response surface plot showing the impact of CCS and PVP-K30 on 
Q10 of MTZ at intermediate levels of magnesium stearate 
 
The three-dimensional response surface plot in Figure 5.12 reveals that the highest Q10 for 
MTZ ≥80% is achieved when the levels of CCS are high and those for PVP-K30 are between 
a low and intermediate level. In addition ≥80% of MTZ is released when the amount of CCS 
and PVP-K30 per tablet are >21 mg and <8 mg respectively. However, it is evident that the 
antagonistic effect of PVP-K30 in the attainment of a Q10 of ≥80% for MTZ is achieved when 
the content of PVP-K30 per tablet is >8 mg at which point an increase in the content of CCS 
to maximum levels of 25 mg per tablet resulted in <80% drug release. A similar antagonistic 
effect was also observed when the amount of CCS per tablet was >15<21 mg and a decrease 
in the Q10 for MTZ was exhibited when the content of PVP-K30 was >8 mg per tablet as seen 
in response surface plot in Figure 5.13. Therefore it may be concluded that the high Q10 of 
≥80% for MTZ may be achieved when the amount of CCS and PVP-K30 per tablet is >23 mg 
and <6 mg respectively and when an intermediate level of magnesium stearate is included in 
the formulation.   
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Figure 5.13 Contour response surface plot showing the impact of CCS and PVP-K30 on Q10 of MTZ 
at intermediate levels of magnesium stearate 
 
In general the impact of magnesium stearate and PVP-K30 on the Q10 for MTZ is minor in 
comparison to that of CCS, as can be seen in Figure 5.14.  It is clear that both factors have an 
antagonistic effect on drug release and an increase in the amount of either factor resulted in a 
decrease in the value of Q10 for MTZ. This effect is apparent when the amount of PVP-K30 is 
> 6 mg per tablet and may in part be attributed to the high hydrophilicity of MTZ which 
would require high concentrations of PVP-K30 to retard drug release by creating a viscous 
film on the tablet surface. A Q10 of ≥70% for MTZ is achieved when the content of 
magnesium stearate per tablet is >2.5<6.5 mg and that of PVP-K30 is <6 mg with CCS at an 
intermediate of 20 mg per tablet.  
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Figure 5.14 Contour response surface plot depicting the impact of magnesium stearate and PVP-K30 
on Q10 of MTZ at intermediate levels of CCS 
 
Figure 5.15  A three-dimensional response surface plot depicting the impact of magnesium stearate 
and PVP-K30 on Q10 of MTZ at intermediate levels of CCS 
 
It evident that magnesium stearate exhibits an antagonistic effect similar to the effects 
observed with PVP-K30 on the dissolution of MTZ as shown in Figures 5.14 and 5.15. 
However this effect is marked when the content of magnesium stearate per tablet is > 5.5 mg. 
These results are supported by the in vitro release profile of formulation 40:20:15 depicted in 
Figure 5.10. The decrease in drug release observed at concentrations of magnesium stearate  
> 5% w/w can be ascribed to the high degree of hydrophilicity of MTZ, whereby high  levels 
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of magnesium stearate are required to create an hydrophobic film that retards drug 
dissolution.  
 
It evident that an increase in the levels of CCS resulted in an increase in drug release, 
however a high Q10 of  ≥80 for MTZ was observed when the content of CCS and magnesium 
stearate per tablet was >22 mg and <6.5 mg respectively as shown in the response surface 
plots in Figures 5.16 and 5.17.  
 
Figure 5.16 Contour response surface plot of the impact of magnesium stearate and CCS on the Q10 
of MTZ at intermediate levels of PVP-K30 
 
Figure 5.17 A three-dimensional response surface plot showing the impact of magnesium stearate and 
CCS on Q10 of MTZ at intermediate levels of PVP-K30 
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The three-dimensional response surface plot for the Q10 for RTD depicted in Figure 5.18 is 
curvilinear in nature for the relationship of this parameter with the CCS input factor, whereas 
a linear relationship is observed for PVP-K30. As with the MTZ formulations it is clear that 
CCS has a profound effect on the release of RTD and it is clearly evident that an increase in 
the content of CCS results in an increase in the value of Q10 for RTD, and where there is a 
decrease in CCS concentration the converse is true. In contrast PVP-K30 appears to exert an 
antagonistic effect on the value for Q10 for RTD and the impact is greater when the amount of 
CCS per tablet is <17 mg per tablet. At low levels of CCS the Dt of the tablets is increased as 
a consequence of the low content of CCS [312]. The increase in Dt, of the tablets results in a 
lower Q10 value for RTD since the total surface area necessary for dissolution is smaller and 
therefore the impact of PVP-K30 on Dt is more apparent. The response surface plot depicted 
in Figure 5.19 shows that a high Q10 value of ≥78 is achieved when the amount of CCS is  
>23 mg per tablet and when PVP-K30 is omitted from the tablet formulation and 
intermediate levels of magnesium stearate are used. 
 
Figure 5.18 A three-dimensional response surface plot showing the impact of PVP-K30 and CCS on 
the Q10 of RTD at intermediate levels of magnesium stearate 
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Figure 5.19 Contour response surface plot showing the impact of PVP-K30 and CCS on the Q10 of 
RTD at intermediate levels of magnesium stearate 
 
In contrast to the effect of magnesium stearate on the value of Q10 for MTZ, different results 
are observed when evaluating the Q10 value for RTD. A curvilinear relationship is exhibited 
for the effect of CCS and magnesium stearate on the Q10 of RTD and a region corresponding 
to maximum value for Q10 ≥ 70% is located between intermediate levels of magnesium 
stearate and high levels of CCS, as depicted in Figure 5.20. These results suggest that a 
synergistic interaction exists between CCS and magnesium stearate at these levels, viz. ≥ 23 
mg per tablet and ≥ 4.5 ≤ 6.5 mg per tablet respectively, as shown in Figure 5.21. Although 
this synergistic interaction has not been reported, the results are in agreement with those 
reported by Wang et al. [236] after an investigation of drug and excipient interaction with 
lubricants. Close inspection of the in vitro release profile for formulation 50:10:15 as shown 
in Figure 5.11 and evaluation of the resultant model equation for parameter y3 shows that a 
synergistic interaction between CCS and magnesium stearate is clearly evident. 
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Figure 5.20 A three-dimensional response surface plots of the impact of magnesium stearate and CCS 
on the Q10 of RTD at intermediate levels of PVP-K30 
 
Figure 5.21 Contour response surface plot of the impact of magnesium stearate and CCS on the Q10 
of RTD at intermediate levels of PVP-K30 
 
The response surface plot depicted in Figure 5.22 reveals a linear antagonistic relationship 
between PVP-K30 and magnesium stearate on the Q10 value for RTD. It is clear that PVP-
K30 exerts a greater effect on the Q10 value than magnesium stearate and consequently the 
Q10 value is not affected with an increase in the levels of magnesium stearate in the 
formulation. The effect of magnesium stearate is more apparent at low levels of PVP-K30, 
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viz. < 2 mg per tablet, as indicated by a Q10 of < 70% for RTD when the amount of lubricant 
per tablet is ≥ 6.5 mg and where intermediate levels of CCS are used as shown in Figure 5.23.   
 
Figure 5.22 Athree-dimensional response surface plot depicting the impact of PVP-K30 and 
magnesium stearate on the Q10 for RTD at intermediate levels of CCS 
 
Figure 5.23 Contour response surface plot showing the impact of PVP-K30 and magnesium stearate 
on the Q10 for RTD at intermediate levels of CCS 
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5.3.6 Formulation optimization 
 
A numerical optimization technique using the desirability approach was used for the 
development of a new formulation that would ensure the desired responses were achieved. 
The constraints set for the designated responses are described in Table 5.2 in § 5.2.3.1 The 
predicted response values and respective factor compositions are summarized in Table 5.6. 
 
Table 5.6  Predicted values for input variables and the respective response variables 
Factor composition (mg) Response Desirability 
x1 x2 x3 y1 y2 y3 0.98 
25.0 0.0 5.70 3.96 min 84.85% 79.57% 
 
The physical characteristics of the tablets manufactured using the optimized formulation 
composition are summarized in Table 5.7.  
 
Table 5.7 Physical characteristics of the resultant tablets manufactured following numerical 
optimization 
Parameter Results  
Weight mg  505.25 ± 3.01 
Thickness mm  3.40 ± 0.01 
Diameter (mm)  12.00 ± 0.00 
Crushing strength (N) 92 ± 1.39 
Tensile strength (MPa) 1.43 
Friability (%) 0.3 
Disintegration (min) 3.82 ± 0.36 
 
 
The tablets that were produced were cream in colour and had a smooth appearance without 
any evidence of chipping or cracking. The physicochemical and mechanical parameters also 
comply with general compendial specifications for these variables. Furthermore the Q10 
values for MTZ and RTD observed in Figure 5.24 are in close agreement with the predicted 
values for this parameter. The percent error of the prediction (PE) observed for the optimum 
responses, viz. Dt, and the Q10 values for MTZ and RTD summarized in Table 5.8, indicate 
that the mathematical models generated have the necessary accuracy in the estimation of 
responses since the PE is < 5%. 
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Table 5.8 Experimental and predicted response values with percent error for prediction for the 
optimized formulation composition 
Response Experimental value Predicted value Percent prediction error 
y1 3.82 ± 0.46 3.96 -3.66 
y2 83.66 ± 5.23 84.85 -1.42 
y3 80.11 ± 4.10 79.57 0.67 
  
 
 
Figure 5.24 In vitro release profiles of the tablets manufactured following numerical optimization 
 
5.4 CONCLUSIONS 
 
The impact of viscosity on granulation particle size distribution has been revealed. The use of 
PVP-K30 at 25% w/v results in the production of granules with wide particle size distribution 
compared to the use of 12.5% w/v PVP-K30 solution. In addition purified water has a similar 
impact to the solution comprised of 12.5% w/v PVP-K30 on the granule particle size 
distribution. Therefore it can be concluded that purified water and PVP-K30 solution at 
12.5% w/v have a similar effect on granulation particle size distribution when the conditions 
described in § 4.2.4.2.3, and the formula in Table 5.1 that is comprised of MCC and CCS are 
used. 
 
Response surface methodology has many applications in the development and optimization 
of pharmaceutical systems, including the optimization of formulation, manufacturing 
processes and analytical methods. However, the application of RSM requires that accurate, 
precise and reproducible experimental conditions are used for the generation of reliable data. 
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50
P
er
ce
n
t 
re
le
a
se
 (
%
)
Time (min)
MTZ RTD
  
159 | P a g e  
 
Therefore the potential wide application of RSM is limited, due to the sensitivity of the 
technique to experimental variability.  
 
There are several statistical designs of experiment approaches that use RSM and these 
include but are not limited to Box-Behnken, CCD and D-Optimal designs. A Box-Behnken 
design was selected for this optimization since fewer experiments are required to generate 
data for the same number of factors compared to a CCD approach. Furthermore the Box-
Behnken approach has specific design points where factors are changed over three levels that 
facilitate the expansion of the experimental domain, whereas a D-Optimal approach 
establishes the design points algorithmically. The excipients that were selected as variables 
for evaluation and their impact on Dt and in vitro release of MTZ and RTD were CCS 
(disintegrant), PVP-K30 (binder) and magnesium stearate (lubricant). Furthermore the 
experimental domain was selected in accordance with level two formulation and composition 
changes described in the SUPAC-IR guideline, in order to determine the impact of these 
factors on the measured responses selected for monitoring. 
 
Three-dimensional and contour response surface plots clearly demonstrated the impact of the 
different levels of CCS, PVP-K30 and magnesium stearate on the Dt and the in vitro release 
of MTZ and RTD. It is clear from the response surface plots that CCS is the most significant 
factor that affects the measured responses and that the exclusion of PVP-K30 had no 
significant impact on tablet crushing strength or friability. Moreover it has been shown that 
magnesium stearate has a synergistic interaction with CCS, thereby promoting the in vitro 
release of RTD. The use of RSM has facilitated the determination of the impact of level two 
SUPAC for IR dosage forms on the Dt and Q10 values for MTZ and RTD. In addition this 
approach permitted the identification of significant factors in the formulations under 
investigation. Furthermore the development of a predicted optimal formulation which 
subsequently led to the production of tablets with the desired specifications summarized in 
Table 5.6 has been achieved by the use of RSM. 
 
Therefore the use of RSM has facilitated the assessment of the impact of level two SUPAC 
changes for IR formulations in a rapid and efficient manner with minimum waste of resources 
compared to the use of a change of single factor at a time (COST) approach.  
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CHAPTER SIX 
      CONCLUSIONS 
 
The oral route of administration is the most convenient route for drug delivery to the body. 
Although it is widely acceptable to patients, adherence to oral drug therapy becomes a 
challenge when prolonged use of multiple drug products is required to achieve an optimal 
therapeutic outcome. The use of FDC has the potential to improve adherence in the 
management of pathological conditions such as diabetes, hypertension, tuberculosis, heart 
failure and HIV/AIDS, amongst others, that require long-term therapy and that may use 
multiple drug products [7,313-316]. FDC have proved effective in reducing the risk of the 
emergence of drug-resistant strains of causative agents in infectious disease, and have also 
been shown to reduce the cost of treatment and risk of medication errors [315]. Thus, as with 
other pathological conditions that require multiple drug agents to achieve therapy, the use of 
FDC tablets for the management of ulcers may well reduce morbidity and mortality due to 
the disease and therefore FDC tablets of MTZ and RTD were manufactured for this purpose. 
 
An HPLC method was developed and validated in accordance to ICH guidelines for the 
simultaneous quantitation of MTZ and RTD [130]. The method was found to be sensitive, 
accurate, precise and linear over the concentration range 2.5-20 µg/ml and 1-8 µg/ml for 
MTZ and RTD respectively. The precision and accuracy of the HPLC method was confirmed 
by use of % RSD and % bias and the results of these parameters were < 5% for both 
compounds of interest. The HPLC method was also found to be stability-indicating and both 
MTZ and RTD were well resolved from degradants, using the same chromatographic 
conditions. 
 
Preformulation studies constitute an integral part of any formulation development process 
since they form the foundation of building quality into a product [317]. Preformulation 
studies require a wide scope of investigation of the compound(s) of interest and potential 
excipients that may be used in a formulation in order to ensure the development of a quality 
pharmaceutical product that will perform consistently following manufacture and in clinical 
use. The identification of the polymorphic nature of RTD was achieved by use of DSC and 
IR spectroscopy. These techniques are accurate and precise and have been used extensively 
for the identification of the polymorphic nature of many drug compounds. The melting 
temperature of RTD, determined using DSC, indicated that the raw material compound was 
  
161 | P a g e  
 
primarily comprised of polymorph 2 and this was confirmed by evaluation of the IR spectrum 
of this material. Thermal gravimetric analysis of MTZ and RTD indicated that both 
compounds exhibited thermal stability following heating to temperatures of approximately 
169
°
C and 143
°
C respectively.  
 
The use of MCC and/or DCP as diluents in tablet formulations is common, since their 
intrinsic physicochemical characteristics facilitate the tablet manufacturing process. There is 
a wealth of information with respect to the properties and application of MCC and DCP in the 
manufacture of SODF and therefore these materials were selected as potential diluents for the 
manufacture of FDC tablets containing MTZ and RTD. Both compounds, viz. MTZ and 
RTD, exhibited compatibility with MCC when assessed using DSC and IR spectroscopy 
whereas DCP revealed a potential interaction with MTZ at high temperature, however IR 
spectroscopy revealed that there was unlikely to be an interaction. Similarly MTZ and RTD 
exhibited a potential interaction at high temperatures but the interaction was not apparent 
following IR analysis which indicated that MTZ and RTD could be incorporated into a FDC 
formulation.  
 
SEM images of the materials revealed that MTZ and RTD exhibited particles that are larger 
in size when compared to the particle size of MCC and DCP. Therefore, for ease of 
processing, the materials of both compounds, viz. MTZ and RTD, were forced through a 
sieve of aperture size of 850 µm, in order to narrow the particle size distribution of the 
powders. 
 
Evaluation of the micromeretic results revealed that direct compression manufacture of the 
FDC was not feasible. The CI and HR values for both compounds indicated that MTZ and 
RTD exhibited poor flow and compressibility properties which further indicate that it was 
necessary to include a diluent in the formulation to facilitate the manufacturing process. MCC 
and DCP exhibit good flow properties and compressibility and were consequently used in the 
formulation of FDC tablets. MCC is frequently incorporated in tablet formulations since it 
confers suitable mechanical strength to tablets, whereas DCP is commonly used in the 
manufacture of tablets since it imparts suitable flow properties to a formulation. 
 
The suitability of a method of manufacture for a tablet formulation is dependent on the 
physicochemical properties of the formulation constituents which include thermal stability, 
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moisture sensitivity, particle size, shape and distribution amongst others. Furthermore the 
crystal properties of the solid system will also define the suitability of a method of 
manufacture. FDC tablets of MTZ and RTD were manufactured by direct compression and 
wet granulation. The tablets produced by direct compression exhibited physico-mechanical 
properties that did not meet compendial specifications for SODF. The tablets were friable, 
had a low crushing strength and exhibited capping, whereas those produced by wet 
granulation had a better appearance and met compendial specifications for SODF. Therefore, 
a wet granulation method of manufacture was adopted to produce a FDC of RTD and MTZ. 
In addition the blending process was optimized in order to ensure tablets that contained a 
uniform dose of both compounds were produced. 
 
Blend homogeneity is one of the critical parameters that ensures therapeutic efficiency of a 
dosage unit and is usually established through the analysis of multiple samples of a powder 
blend, sampled from different sites, in blending equipment, following mixing of the materials 
for different periods of time. The blend uniformity analyses revealed that blend homogeneity 
was achieved following 9 min of mixing and this was confirmed when the results of content 
uniformity testing were evaluated. 
 
Optimization of the manufacturing process by use of DOE required the selection of 
appropriate factors that are known to impart an optimal effect on selected measured 
response(s). The identification of factors and their combinations is usually achieved in two 
stages, viz. a review of literature and then undertaking screening studies. The information 
extracted from the literature is used to guide the formulation scientist in the screening process 
to identify suitable factors and their respective combinations that would be necessary to 
produce tablets that exhibit the desired response(s). The screening studies revealed that MCC 
and CCS produced tablets that appeared to have better physico-mechanical properties 
compared to those that were produced using DCP alone. The Q10 for MTZ and RTD from 
tablets comprised of MCC and CCS, viz. formulation RM 013, were 82% and 89% 
respectively, whereas for formulation RM 014 that was comprised of DCP and CCS the Q10 
for MTZ and RTD were 55% and 59% respectively. Although formulation RM 014 produced 
tablets that disintegrated in < 4 min, the Q10 values for MTZ and RTD from the tablets of 
batch RM 013 were used as the criterion for the selection of this formulation composition for 
the optimization, and evaluation of the impact of level two formulation and composition 
changes on product performance. 
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A Box-Behnken statistical design approach was selected to optimize the FDC formulation. 
The compositions of CCS, PVP-K30 and magnesium stearate were selected as the factors to 
be varied, in order to establish their impact on the Dt and in vitro release of MTZ and RTD 
from the tablet formulations that were manufactured. Level two formulation and composition 
changes, described in the SUPAC Guideline for IR, were used to establish the experimental 
domain. Contour and three-dimensional response surface plots were generated to examine the 
nature of the relationship between the levels of input factors on the measured responses. 
 
The results of the optimization studies revealed that the responses Dt, the Q10 for MTZ and 
RTD are strongly dependent on the levels of CCS in the formulation. The Dt exhibited an 
inverse linear relationship with variations in the concentration of CCS whereas the Q10 
showed a linear agonistic relationship for the same raw material. The effects of PVP-K30 and 
magnesium stearate on the measured responses were also dependent on the concentration of 
CCS in the formulation. An increase in the content of PVP-K30 and magnesium stearate 
resulted in an increase in the Dt when the content of CCS was maintained at low levels. A 
similar effect was observed for the Q10 for MTZ where an increase in the content of PVP-K30 
and magnesium stearate resulted in a decrease in the Q10 value at low concentrations of CCS, 
whereas increasing the concentration of CCS revealed that the converse is true. The effect of 
amount of PVP-K30 on the Q10 for RTD was also dependent on the content of CCS in the 
formulation, where increasing the content of PVP-K30 whilst using low levels of CCS 
resulted in a decrease in the Q10 value for RTD and decreasing the content of PVP-K30 in the 
formulation had the opposite effect. In contrast magnesium stearate exhibited a synergistic 
interaction with CCS on the Q10 value for RTD.  A high value for the Q10 for RTD, viz. > 
70%, was achieved when the amount of CCS and magnesium stearate in the formulation was 
at high and intermediate levels, respectively.  
 
The numerical optimization technique using the desirability approach was used to predict a 
formulation composition that would produce tablets that exhibit measured responses values 
within the predetermined constraints listed in Table 5.2. A formulation composition that 
included CCS, PVP-K30 and magnesium stearate at concentrations of 25.0, 0.0 and 5.7% 
w/w respectively was subsequently predicted. The predicted response values were in close 
agreement with the experimental values with a percent prediction error (PE) of 3.66, 1.42 and 
0.67 for the Dt, Q10 for MTZ and Q10 for RTD, respectively, indicating that the model was 
accurate for the prediction of the values of measured responses due to the small PE values, 
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viz. < 5%. In general, the accuracy of a model is usually expressed as the prediction error and 
a small PE value represents accurately estimated parameter(s) [318].  
 
A FDC of MTZ and RTD has been developed and manufactured by use of wet granulation. 
The manufacturing process was optimized and the impact of changes in formulation 
composition on dosage form performance has been evaluated using DOE. In addition RSM 
was used to optimize the tablet formulation with respect to disintegration and in vitro release 
of MTZ and RTD, and the formulation has the potential to be adapted to commercial 
manufacture.  
 
Future studies that are essential would include stability testing of the FDC tablets and the 
development of an alternative formulation that would permit the incorporation of MTZ and 
RTD in cases where potential incompatibilities between these compounds may exist. 
Furthermore, investigation of variation of process parameters such as impeller and chopper 
speed and the rate of binder addition by the use of RSM may be necessary in order to 
establish their impact on the disintegration and tensile strength of the tablets, and in vitro 
release of MTZ and RTD from the dosage form. Risk assessment studies would be necessary 
for the investigation of factors viz. qualitative and quantitative that may have detrimental 
effects on the product quality and to facilitate the establishment of a design space in which 
the quality of the product would be assured and maintained.     
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 APPENDIX 1 
BATCH MANUFACTURING RECORDS 
 
Templates of batch manufacturing records used in the manufacture of FDC tablets of MTZ 
and RTD indicating the quantities of excipients that were used and the procedure that were 
followed are included in the thesis. The records of all formulation batches that were 
manufactured are available on request. 
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BATCH MANUFACTURING RECORD 
DIRECT COMPRESSION 
 
Product 
 
Ranimetro 
Date of manufacture  
Temperature and humidity  
Formulator King’ori L D 
Batch number RM 001 
Batch size 500 g 
Target weight 500 mg 
Granulating fluid - 
 
FORMULA 
Material Unit Dose (mg) Batch (g) % w/w Raw Material number 
Ranitidine hydrochloride    84.0   84.0 16.8 RM 000244 
Metronidazole 250.0 250.0 50.0 RM 000247 
Microcrystalline cellulose pH 102 140.0 140.0 28.0 X061882 
Sodium starch glycolate   20.0    20.0   4.0 X070074 
Povidone K30     -      -   - X062448 
Colloidal silicone dioxide     1.0      1.0   0.2 X069339 
Magnesium Stearate     5.0      5.0   1.0 X052015 
TOTAL WEIGHT 500.0  500.0  100  
 
EQUIPMENT VERIFICATION 
Description Type Verified By Confirmed 
Balance Mettler Model PM 4600   
Sieves DIN 4418    
Blender Saral
®
 3.5 L   
Tablet Press Manesty
®
 B3B   
Tooling 12.00 mm flat faced 
punches 
  
Oven Memmert
®
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MANUFACTURING DIRECTIONS 
Step Procedure Equipment Settings Done by Checked by 
1 Separately weigh the material 
and screen through a 850 µm 
sieve 
Ranitidine hydrochloride 
Metronidazole 
Microcrystalline cellulose 
Sodium starch glycolate 
Mettler Model PM 
4600 
Sieve type DIN 4I88 
Unit (g)   
2 Place the material in (1) in a 
high-shear mixer granulator 
and blend for 9 min. 
Saral
®
 high-shear 
mixer granulator 
Impeller speed 
100 rpm 
Chopper speed 
0 rpm 
  
3 Weigh and screen the 
following material separately 
through a 315 µm sieve 
Colloidal silicone dioxide 
Magnesium stearate 
Sieve Type DIN 4188    
4 Mix blends (1) and (3) in the 
high-shear mixer granulator 
for3 min. 
Saral
®
 high shear 
mixer granulator 
Impeller speed 
100 rpm 
Chopper speed 
0 rpm 
  
5 Discharge the blend (4) in a 
tarred stainless steel bowl and 
weigh the blend 
Mettler Model PM 
4600 
Unit (g)   
6 Compress the blend in (5) 
into 500mg tablets. 
Sample 5 tablets every 90 s 
and record the weight, and 
hardness 
Mansety
®
B3B 
Mettler Model PM 
4600 
Pharmatest PTB 
311E 
Speed 25rpm  
Target hardness 
80-120 N 
Weight (mg) 
  
OBSERVATION AND DEVIATIONS 
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BATCH MANUFACTURING RECORD 
WET GRANULATION 
 
Product 
 
Ranimetro 
Date of manufacture  
Temperature and humidity  
Formulator King’ori L D 
Batch number RM 002 
Batch size 500 g 
Target weight 500 mg 
Granulating fluid 12.5% w/v Povidone K30 solution 
 
FORMULA 
Material Unit Dose (mg) Batch (g) % w/w Raw Material number 
Ranitidine hydrochloride    84.0   84.0 16.8 RM 000244 
Metronidazole 250.0 250.0 50.0 RM 000247 
Microcrystalline cellulose pH 102 135.0 135.0 27.0 X061882 
Sodium starch glycolate   20.0    20.0   4.0 X070074 
Povidone K30     5.0      5.0   1.0 X062448 
Colloidal silicone dioxide     1.0      1.0   0.2 X069339 
Magnesium Stearate     5.0      5.0   1.0 X052015 
TOTAL WEIGHT 500.0  500.0  100  
 
EQUIPMENT VERIFICATION 
Description Type Verified By Confirmed 
Balance Mettler Model PM 4600   
Sieves DIN 4418    
Blender Saral
®
 3.5 L   
Tablet Press Manesty
®
 B3B   
Tooling 12.00 mm flat faced punches   
Oven Memmert
®
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MANUFACTURING DIRECTIONS 
Step Procedure Equipment Settings Done by Checked by 
1 Separately weigh the  material and 
screen through a 850 µm sieve 
Ranitidine hydrochloride 
Metronidazole 
Microcrystalline cellulose 
Sodium starch glycolate 
Mettler Model 
PM 4600 
Sieve type DIN 
4I88 
Unit (g)   
2 Place the material in (1) and 50% 
of the disintegrant in a high-shear 
mixer granulator and blend for 9 
min. 
Saral
®
 high-shear 
mixer granulator 
Impeller speed 
100 rpm 
Chopper speed 
0 rpm 
  
3 Weigh and screen the following 
material separately through a 315 
µm sieve 
Colloidal silicone dioxide 
Magnesium stearate 
Sieve Type DIN 
4188 
   
4 Granulate the blend in (2) with a 
Povidone K30 binder solution  
Saral
®
 high shear 
mixer granulator 
 
 
Cole- Palmer
®
 
Peristaltic pump 
Impeller speed 
100 rpm 
Chopper speed 
1000 rpm 
Pump speed 
25 rpm 
Air pressure 
52 PSI 
  
5 After the addition of the binder 
solution continue mixing the wet 
granules in (4) for an additional 
minute 
Saral
®
 high shear 
mixer granulator 
 
 
 
Impeller speed 
100 rpm 
Chopper speed 
1000 rpm 
  
6 Dry the wet granules in (5) in a dry 
heat oven 
Memmert
®
 Temperature 
50°C 
Time 24 h 
  
7 Pass the dry granules through a 
350 µm sieve and add the granules 
in the blender and mix for 3 min 
with the balance of the disintegrant 
and the lubricants in (3) 
Sieve Type DIN 
4188 
Saral 
® 
high shear 
mixer granulator 
 
 
Impeller speed 
100 rpm 
Chopper speed 
0 rpm 
  
8 Compress the blend in (9) into 500 
mg tablets. 
Sample 5 tablets every 90 s and 
record the weight, and hardness 
Mansety
®
B3B 
Mettler Model 
PM 4600 
Pharmatest PTB 
311E 
Speed 25 rpm, 
Target 
hardness 80-
120 N 
Weight (mg) 
  
OBSERVATION AND DEVIATIONS 
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 APPENDIX 2 
RESPONSE SURFACE METHODOLOGY STATISTICS 
 
DISINTEGRATION 
  
Table 7.1Model fit comparison for disintegration of tablets 
Model PRESS 
Linear 12.99 
Quadratic   6.5 
 
Table 7.2 Backwards elimination results quadratic model for tablet disintegration 
Factor Coefficient Standard deviation p value Significance 
Intercept 7.21 0.29 0.0013 Significant 
x1- CCS -2.15 0.18 < 0.0001 Significant 
x2- PVP-K30 1.21 0.18 0.0011 Significant 
x3- Magnesium stearate 0.66 0.18 0.0144 Significant 
x1x2 0.30 0.20 0.2900 Not significant 
x1x3              0.25 0.9850 Not significant 
x2x3 -0.11 0.25 0.6759 Not significant 
x1
2 0.5 0.26 0.1174 Not significant 
x2
2 -0.62 0.26 0.0660 Not significant 
x3
2 
0.74 0.26 0.0385 Significant 
 
 
 
Figure 7.1 Predicted vs. Actual diagnostic plot for Dt. 
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Q10 FOR MTZ 
 
Table 7.3 Model fit comparison for in-vitro release of MTZ 
Model PRESS 
Linear 1463.31 
Quadratic 682.17 
 
 
Table 7.4 Backward elimination results quadratic model for the Q10 value for MTZ 
Factor Coefficient Standard deviation p value Significance 
Intercept 72.35 2.73 < 0.0001 Significant 
x1- CCS 22.94 1.67 < 0.0001 Significant 
x2- PVP-K30 -5.98 1.67 0.0073 Significant 
x3- Magnesium stearate -3.88 1.67 0.0491 Significant 
x1x2 3.62 2.18 0.1579 Not significant 
x1x3 1.58 2.18 0.5014 Not significant 
x2x3 -2.37 2.18 0.3271 Not significant 
x1
2 -9.72 2.46 0.0043 Significant 
x2
2 -4.76 2.27 0.0894 Not significant 
x3
2 
-10.83 2.46 0.0023 Significant 
 
 
 
Figure 7.2 Predicted vs. Actual diagnostic plot for the Q10 value of MTZ. 
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Q10 FOR RTD 
 
Table 7.5 Model fit comparison for in vitro release for RTD 
Model PRESS 
Linear 1000.83 
Quadratic 367.24 
 
Table 7.6 Backward elimination results quadratic model for the Q10 value for RTD 
Factor Coefficient Standard deviation p value Significance 
Intercept 65.16 1.56 < 0.0001 Significant 
x1- CCS 14.78 1.15 < 0.0001 Significant 
x2- PVP-K30 -7.64 1.15 0.0002 Significant 
x3- Magnesium stearate -1.17 1.15 0.3381 Not significant 
x1x2 0.66 1.72 0.7195 Not significant 
x1x3 5.16 1.62 0.0131 Significant 
x2x3 -1.98 1.72 0.3020 Not significant 
x1
2 -8.65 1.69 0.0009 Significant 
x2
2 -4.76 2.27 0.4609 Not significant 
x3
2 
-6.19 1.69 0.0063 Significant 
 
 
 
Figure 7.3 Predicted vs. Actual diagnostic plot for the Q10 value of RTD. 
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 APPENDIX 3 
BATCH RECORD SUMMARY 
 
Only four batch record summaries indicating the quantities of excipients used and the 
physical tests that were conducted are included in the thesis. The records for all the 
formulation that were manufactured are available on request.  
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BATCH SUMMARY RECORD 
Product Ranimetro 
Date of manufacture 9
th
  June 2010 
Formulator King’ori LD 
Batch number RM 011 
Batch size 1000 tablets 
Target weight 500 mg 
Granulating fluid 12.5% w/v Povidone K30 solution 
Temperature 19±0.5°C 
Humidity 50±3% 
FORMULA 
Material Unit Dose (mg) Batch (g) % w/w Raw Material number 
Ranitidine hydrochloride    84.0   84.0 16.8 RM 000244 
Metronidazole 250.0 250.0 50.0 RM 000247 
Microcrystalline cellulose pH 102 140.0 140.0 28.0 X061882 
Sodium starch glycolate   20.0    20.0   4.0 X070074 
Povidone K30     -      -   - X062448 
Colloidal silicone dioxide     1.0      1.0   0.2 X069339 
Magnesium Stearate     5.0      5.0   1.0 X052015 
TOTAL WEIGHT 500.0  500.0  100  
TABLET PARAMETER 
 Mean±SD 
Weight                  (mg)    496±1.78 
Diameter               (mm) 12.02±0.02 
Thickness              (mm)    3.31±0.00 
Crushing strength   (N)     158±17.2 
Disintegration time (min)  13.05±1.55 
 
IN VITRO RELEASE 
                                                                                            
 
Figure 8.1 In vitro release of MTZ and RTD of formulation RM 011 
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BATCH SUMMARY RECORD 
Product Ranimetro 
Date of manufacture 10
th
  June 2010 
Formulator King’ori LD 
Batch number RM 013 
Batch size 1000 tablets 
Target weight 500 mg 
Granulating fluid 12.5% w/v Povidone K30 solution 
Temperature 20.±0.5°C 
Humidity 51±3% 
FORMULA 
Material Unit Dose (mg) Batch (g) % w/w Raw Material number 
Ranitidine hydrochloride    84.0   84.0 16.8 RM 000244 
Metronidazole 250.0 250.0 50.0 RM 000247 
Microcrystalline cellulose pH 102 135.0 135.0 27.0 X061882 
Croscarmellose sodium   20.0    20.0   4.0 X070074 
Povidone K30     5.0      5.0   1.0 X062448 
Colloidal silicone dioxide     1.0      1.0   0.2 X069339 
Magnesium Stearate     5.0      5.0   1.0 X052015 
TOTAL WEIGHT 500.0  500.0  100  
TABLET PARAMETER 
 Mean±SD 
Weight                  (mg) 496.80±1.58 
Diameter               (mm)   12.00±0.00 
Thickness              (mm)     3.32±0.00 
Crushing strength   (N)      101±5.3 
Disintegration time (min)   11.49±1.15 
 
IN VITRO RELEASE 
                                                                                       
 
Figure 8.2 In vitro release of MTZ and RTD of formulation RM 013 
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BATCH SUMMARY RECORD 
 
Product Ranimetro 
Date of manufacture 11
th
 June 2010 
Formulator King’ori LD 
Batch number RM 014 
Batch size 1000 tablets 
Target weight 500 mg 
Granulating fluid 12.5% w/v Povidone K30 solution 
Temperature 19±0.5°C 
Humidity 50±3% 
FORMULA 
Material Unit Dose (mg) Batch (g) % w/w Raw Material number 
Ranitidine hydrochloride    84.0   84.0 16.8 RM 000244 
Metronidazole 250.0 250.0 50.0 RM 000247 
Dibasic calcium Phosphate 135.0 135.0 27.0 X061882 
Croscarmellose sodium   20.0    20.0   4.0 X070074 
Povidone K30     1.0      1.0   1.0 X062448 
Colloidal silicone dioxide     1.0      1.0   0.2 X069339 
Magnesium Stearate     5.0      5.0   1.0 X052015 
TOTAL WEIGHT 500.0  500.0  100  
TABLET PARAMETER 
 Mean±SD 
Weight                  (mg) 501.34±7.35 
Diameter               (mm)   12.03±0.03 
Thickness              (mm)     3.35±0.02 
Crushing strength   (N)     67.1±11.00 
Disintegration time (min)     4.61±1.26 
 
IN VITRO RELEASE 
 
 
Figure 8.3 In vitro release of MTZ and RTD of formulation RM 014 
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BATCH SUMMARY RECORD 
 
Product Ranimetro 
Date of manufacture 12
th
 June 2010 
Formulator King’ori LD 
Batch number RM 015 
Batch size 1000 tablets 
Target weight 500 mg 
Granulating fluid 12.5% w/v Povidone K30 solution 
Temperature 19±0.5°C 
Humidity 50±3% 
FORMULA 
Material Unit Dose (mg) Batch (g) % w/w Raw Material number 
Ranitidine hydrochloride    84.0   84.0 16.8 RM 000244 
Metronidazole 250.0 250.0 50.0 RM 000247 
Dibasic calcium phosphate 135.0 135.0 27.0 X061882 
Sodium starch glycolate   20.0    20.0   4.0 X070074 
Povidone K30     1.0      1.0   1.0 X062448 
Colloidal silicone dioxide     1.0      1.0   0.2 X069339 
Magnesium Stearate     5.0      5.0   1.0 X052015 
TOTAL WEIGHT 500.0  500.0  100  
TABLET PARAMETER 
 Mean±SD 
Weight                  (mg) 498.02±3.17 
Diameter               (mm)   12.02±0.00 
Thickness              (mm)     3.30±0.01 
Crushing strength   (N)     77.8±10.10 
Disintegration time (min)     8.56±1.81 
 
IN VITRO RELEASE 
                                                                                  
 
Figure 8.4 In vitro release of MTZ and RTD of formulation RM 015 
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